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Summary 
 
Rheumatoid arthritis (RA) patients have an increased prevalence of cardiovascular disease 
(CVD). Traditional cardiovascular risk factors do not fully explain this increased incidence. 
Cardio-respiratory fitness and obesity are acknowledged CVD risk factors; however these are 
generally excluded when assessing CVD risk in RA patients. This PhD thesis aims to 
investigate the association between cardio-respiratory fitness and traditional CVD risk factors 
in RA patients and establish whether exercise can improve these CVD risk factors.  
To determine cardio-respiratory fitness of RA patients a simple submaximal step test was 
validated (n=24). A cross sectional study was then carried out with 100 RA patients who 
underwent assessments of fitness (step test), RA disease, CVD risk factors and body 
composition. RA patient fitness level was poor (22 ± 6 ml·kg-1·min-1). Traditional CVD risk 
factors were not obviously elevated but poor fitness was strongly associated with poor body 
composition. Thirty-five patients were unable to complete the step test. These patients rated 
their arthritis as worse, more painful, disabling and had a greater prevalence of obesity. This 
study highlighted two important modifiable CVD risk factors (poor fitness and obesity) that 
are not routinely measured. An 8 week exercise intervention (n=10) designed to increase 
cardio-respiratory fitness was then implemented and improved cardiovascular health (systolic 
blood pressure), body composition (body fat, waist and hip circumference) and RA disease (p 
< 0.05).  
RA patients are suffering from the effects of being unfit and overweight. Not only are they 
independent CVD risk factors, they impact considerably on patients disease perception and 
functional ability. These risk factors should be considered as part of RA care and information 
should be provided to help patients improve their cardiovascular health and general 
wellbeing. Regular exercise can help improve the above CVD risk factors as shown in this 
thesis.  
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1 Chapter 1: Introduction  
 
It is well documented that patients with rheumatoid arthritis (RA) have an increased risk of 
developing cardiovascular disease (CVD) (Avina-Zubieta et al., 2012, Wallberg-Jonsson et 
al., 1997). It is also believed that mortality from CVD is 50% higher in patients with RA 
when compared to the general population (Avina-Zubieta et al., 2008, Maradit-Kremers et al., 
2005). However, the mechanisms underlying this increased risk of CVD in RA are not fully 
understood (Mutru et al., 1989, Symmons et al., 1998, Cavagna et al., 2012). Early research 
suggests that traditional CVD risk factors do not fully explain this increased incidence (Del 
Rincon et al., 2001, Solomon et al., 2003). The National Institutes of Health (NIH) define 
cardiovascular risk factors as conditions or habits that raise an individual’s risk of developing 
heart disease (NIH, 2006). Hypertension, dyslipidemia, diabetes mellitus, smoking and 
obesity are very powerful predictors of CVD risk in the general population (Wilson et al., 
1998). However, some studies suggest that the cardiovascular risk profile is no different in 
people with or without RA (Solomon et al., 2004). A study by del Rincon et al. (2005) 
suggested that established CVD risk factors needed to be present for systemic inflammation 
to promote atherosclerosis in RA (del Rincon et al., 2005).  
 
As well as the traditional CVD risk factors listed above, poor cardio-respiratory fitness, 
defined as the body’s ability to sustain physical activity, is an independent risk factor for 
CVD in the general population (Carnethon et al., 2003). RA patients have a significantly 
reduced cardio-respiratory fitness when compared to their age matched controls (Beals et al., 
1985, Cimen et al., 2001, Ekdahl and Broman, 1992, Minor et al., 1988, Sokka and 
Hakkinen, 2008). However, despite evidence that RA patients have poor cardio-respiratory 
fitness and that poor fitness is a CVD risk factor in its own right, the measurement of cardio-
respiratory fitness in clinical practice is generally nonexistent. This introduction will review 
the literature regarding cardio-respiratory fitness and CVD risk factors in RA and will aim to 
highlight the present deficiencies in the literature, which has led to the thesis’ experimental 
studies. 
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1.1 Rheumatoid Arthritis  
 
1.1.1 Rheumatoid Arthritis Definition and Classification 
 
Arthritis (meaning inflammation of the joints) describes a group of conditions that cause joint 
damage. One of the most common inflammatory forms of arthritis is rheumatoid arthritis 
(RA) (Reginster, 2002). Given the presence of autoantibodies, such as rheumatoid factor (RF) 
and anti–citrullinated protein antibody (tested as anti–cyclic citrullinated peptide [anti-CCP]), 
RA is considered an autoimmune disease (Firestein, 2003). Autoimmunity and the overall 
systemic and articular inflammatory load drive the destructive progression of the disease. To 
date, the exact cause of RA remains unknown. However, various factors including genetic 
factors, environmental factors and infectious agents have been suggested as potential triggers 
of this disease (Feldmann et al., 1996). RA mainly affects the synovial joints, often in a 
symmetrical fashion and is characterised by pain, swelling and stiffness of the joints. RA is 
typically cyclical in nature, whereby an individual experiences periods of increased disease 
activity (known as flares) and periods of remission. The diagnosis of RA is based on a pattern 
of clinical and laboratory abnormalities. The American College of Rheumatology (ACR) 
outlined specific criteria for the classification of RA in 1987 (Arnett et al., 1988). The criteria 
for the classification of RA were formulated from a computerized analysis of 262 
contemporary, consecutively studied patients with RA and 262 control subjects with 
rheumatic diseases other than RA (non-RA). The criteria were as follows:  
 
1) Morning stiffness in and around joints lasting at least one hour before maximal 
improvement.  
2) Soft tissue swelling of three or more joint areas observed by a physician.  
3) Swelling of the proximal interphalangeal, metacarpophalangeal, or wrist joints. 
4) Symmetric swelling.  
5) Rheumatoid nodules as observed by a physician. 
6) The presence of rheumatoid factor.  
7) Radiographic erosions and/or periarticular osteopenia in hand and/or wrist joints.  
 
A diagnosis of RA is made when at least four of the seven above criteria are present. The 
1987 ACR criteria are the standard means of defining RA and are in widespread international 
use. However, more recently it has been suggested that this criteria is not without limitation. 
15 
 
It is believed that the 1987 ACR criteria fail to identify patients in the earlier stages of their 
disease. Because of this discrepancy, a new classification criterion has been developed; the 
2010 ACR/EULAR criteria (Aletaha et al., 2010).  
 
1.1.2 The Clinical Dilemmas in Rheumatoid Arthritis 
 
RA is the most common form of chronic joint inflammation affecting 0.5-1% of the UK 
population (Symmons et al., 2002). It is most prevalent in individuals aged 40-60 years and 
the risk of developing RA is approximately 5 times higher in women (Panel, 2004). If left 
untreated, RA would lead to irreversible joint damage causing deformity and ultimately 
disability (Akil and Amos, 1995, Emery, 2002). As a consequence of their disease RA 
patients suffer severe joint pain, reduced mobility and reduced muscle strength (Akil and 
Amos, 1995, Ekdahl and Broman, 1992). Most RA patients also suffer from an accelerated 
loss of muscle mass; a condition known as “rheumatoid cachexia” (Roubenoff, 2008). This 
causes severe disability and has a significant impact on an individuals’ quality of life. It has 
been suggested that less than half of patients with RA are still working after 10 years of 
disease (Sokka et al., 1999, Young et al., 2002). Thus, this disease has considerable social 
and economic consequences for both the individual and society (Reisine et al., 2007).   
 
1.1.3 Treatment of Rheumatoid Arthritis  
 
To date there is no known cure for RA. However, over the last decade the treatment of RA 
has changed dramatically (Grazio, 2008). Treatment of RA patients focuses on decreasing 
inflammation, limiting joint destruction, reducing pain and improving overall quality of life 
(QoL). This treatment comes in the form of medication, surgery and rehabilitation. The most 
common medications used are listed in Table 1.1 (Gaffo et al., 2006).  
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Table 1.1 Summary of the main drug treatment in RA 
TYPE MEDICATION AIM 
 
NSAID 
 
Diclofenac 
Naproxen 
Ibuprofen 
Reduce pain & inflammation 
Steroid Prednisone 
Reduce pain & inflammation 
Slow disease progression 
Decrease joint damage 
 
DMARD 
 
Methotrexate 
Sulphsalazine, 
Hydroxychloroquine 
Leflunomide 
Reduce pain & inflammation 
Slow disease progression 
Decrease joint damage 
Biologic 
Infliximab 
Etanercept 
Adalimumab 
Tociluzimab 
Rituximab 
Decrease TNF 
Decrease B-cell 
Decrease IL-6 
Slow disease progression 
Decrease joint damage 
NSAID; Non steroidal anti inflammatory drug, DMARD; Disease modifying anti rheumatic drug, TNF; Tumor 
necrosis factor, IL-6; Interleukin-6.  
 
1.2 Extra-articular Disease Manifestations  
 
Although RA is primarily a ‘joint’ disease, the systemic nature of RA means that it is also 
associated with a number of extra-articular organ manifestations. The prevalence of systemic 
manifestations in RA is approximately 8-12%; however this figure does not include 
cardiovascular disease (CVD) (Turesson and Jacobsson, 2004, Turesson et al., 2002). These 
extra-articular manifestations are strongly associated with increased disease activity and with 
markers of inflammation, such as higher levels of C-reactive protein (CRP) (Baecklund et al., 
2006, Hannawi et al., 2007, Van Doornum et al., 2002). The most common extra-articular 
manifestations include rheumatoid nodules, cardiopulmonary disease (pleural effusion, 
nodules, and interstitial lung disease), Sjogrens syndrome (dry eyes and mouth), rheumatoid 
vasculitis, peripheral neuropathy, rheumatoid cachexia and cardiovascular disease (Turesson 
et al., 2003). For the purpose of this thesis only cardiovascular disease will be discussed in 
more detail.   
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1.2.1 Cardiovascular Disease (CVD) 
 
The World Health Organisation (WHO) defines CVD as a general term used to describe 
conditions that affect the heart and blood vessels. These include atherosclerosis, coronary 
heart disease (angina, myocardial infarction), stroke, heart failure and peripheral arterial 
disease. Statistics from the British Heart Foundation (BHF) show that CVD causes one in 
three deaths in the general UK population, making it the most common cause of death in the 
UK (BHF, 2009). The development of CVD is strongly associated with CVD risk factors. A 
risk factor is simply a condition or habit that increases an individual’s risk of developing 
CVD. These risk factors can be modifiable (e.g. hypertension) or non modifiable (Pyorala et 
al., 1994).  
 
1.2.1.1 Modifiable CVD Risk Factors  
 
Modifiable CVD risk factors include: 
 
1) Hypertension: defined as a blood pressure greater than 140 mmHg systolic or 90 
mmHg diastolic or receiving antihypertensive medication. Hypertension is the 
strongest risk factor for stroke and plays a significant role in the development of heart 
attacks. The positive association between systolic blood pressure or diastolic blood 
pressure and risk of developing CVD disease is well established (Frohlich, 1997).  
2) Dyslipidemia: defined as high total cholesterol (> 5.2 mmol·l-1), high triglycerides (> 
1.8 mmol·l-1), high low density lipoprotein cholesterol (LDL-c) (> 3.4 mmol·l-1) or on 
lipid lowering therapy. Elevated lipid levels in serum are associated with an increased 
risk in the development of CVD (Cullen, 2000).  
3) Smoking: cigarette smoking substantially increases an individual’s CVD risk. Current 
cigarette smokers have a 70% increased risk of fatal coronary heart disease (CHD). 
The overall incidence of nonfatal CHD as well as sudden death is two to fourfold 
higher in cigarette smokers (Jonas et al., 1992, Willett et al., 1987).  
4) Diabetes mellitus: defined as a high fasting glucose (> 7.0 mmol·l-1) or receiving 
treatment for diabetes. Diabetes mellitus increases the risk of developing CHD by 
three to sevenfold in women and by two to threefold in men (Grundy et al., 1999). 
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5) Obesity: defined as a high body mass index (BMI) (> 30 kg.m-2). Over the last 20 
years the prevalence of obesity has escalated worldwide (Engeland et al., 2003) and is 
strongly associated with an increased risk of developing CVD (Poirier and Eckel, 
2002). This is discussed in further detail in section 1.3.2. 
6) Physical Inactivity: being physically inactive/unfit has been shown to significantly 
increase the risk of developing CHD (Hasselstrom et al., 2002, LaMonte et al., 2000). 
However, when determining the CVD risk of an individual, the assessment of their 
cardio-respiratory fitness is often ignored. This is discussed in further detail in section 
1.4.    
 
1.2.1.2 Non Modifiable CVD risk factors 
 
It is accepted that modifiable CVD risk factors can be improved either by a change in 
lifestyle or by medication. However, there are some other risk factors which an individual 
cannot change. These are known as non-modifiable risk factors and they include: 
 
1) Age: over the age of 55 years, the risk of developing CVD increases significantly 
(Smith et al., 2004).  
2) Gender: males have a greater CVD risk when compared to pre-menopausal females.  
However, after the menopause a females risk is believed to be similar to that of males 
(Mercuro et al., 2010).  
3) Family history: a person is considered to have a family history of heart disease if they 
have a first-degree blood relative that has had CHD or stroke before the age of 55 
years (for a male relative) or 65 years (for a female relative) (Assimes, 2010, 
Bachmann et al., 2010).  
4) Ethnicity: individuals from African or Asian descent have a higher risk of developing 
CVD than other racial groups (Chaturvedi, 2003). 
 
CVD is partially attributed to traditional CVD risk factors and global CVD risk can be 
estimated using a number of risk stratification algorithms. One of the most widely used CVD 
risk scores is the Framingham risk score (Eichler et al., 2007). The Framingham risk score 
was originally developed for use in the North American population and has since been shown 
to be less accurate when used in other populations, e.g. the UK (Brindle et al., 2003). Because 
of this, other CVD risk scores have been developed. These include the QRISK2 and the Joint 
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British Society (JBS) risk scores (Crowson et al., 2012). These are explained in further detail 
in Chapter 2.  
 
Another method for assessing the CVD risk of an individual is the clustering of CVD risk 
factors. This concept originally described as ‘Syndrome X’ is now known as Metabolic 
Syndrome (MetS) (Kahn, 2008). MetS is a cluster of 3 or more of the following 
abnormalities: increased waist circumference, elevated triglycerides, reduced high density 
lipoprotein, elevated blood pressure and elevated fasting glucose. It is considered a 
significant and independent risk factor for CVD (Galassi et al., 2006). Fulfilment of the 
criteria for MetS is thought to increase CVD risk by two to threefold (Bray and Bellanger, 
2006).  
 
1.3 Rheumatoid Arthritis and Cardiovascular Disease (CVD) 
1.3.1 Cardiovascular Disease Risk in Rheumatoid Arthritis 
 
It has already been established that CVD is an extra-articular feature of RA disease. RA is 
associated with increased morbidity and mortality from atherosclerosis (Bacon and Townend, 
2001).  It is believed that up to 50% of deaths in RA patients are attributable to CVD, whilst 
cerebrovascular disease accounts for the second greatest cause of excess mortality in RA 
patients (Wolfe et al., 1994). Thus the majority of the CVD observed in this population may 
result from premature atherosclerosis (Salmon and Roman, 2008). It has been reported that 
the average lifespan of an RA patient is shortened by 3 – 18 years (Van Doornum et al., 
2002) and that the CVD risk of an RA patient is equivalent to the CVD risk of someone 
without RA who is 10 years older (Kremers et al., 2008). The exact cause for this increased 
incidence of CVD in RA remains unclear.  
 
Research to date has focused on fatal cardiovascular events in RA (Kremers et al., 2005, 
Nurmohamed, 2009, Solomon et al., 2003) and traditional risk factors often using CVD risk 
stratification algorithms like the Framingham risk score (Chung et al., 2006, Dessein et al., 
2005). However, some researchers believe that traditional risk factors of CVD like smoking, 
obesity, diabetes mellitus and physical inactivity do not fully explain the increased incidence 
of CVD in the RA population. An early investigation suggested that RA patients had a higher 
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rate of cardiovascular events compared to healthy people even after adjustments for 
traditional risk factors (Del Rincon et al., 2001). Their observations have subsequently led 
other researchers to believe that additional mechanisms other than traditional risk factors are 
responsible for the significant cardiovascular risk in RA patients. It has been hypothesised 
that inflammation may be a primary contributor to CVD in RA (Kremers et al., 2005) with 
other traditional risk factors such as smoking, hypertension, obesity, and diabetes mellitus 
having a less significant role than that observed in the general population (Gonzalez et al., 
2008, Quyyumi, 2006).  
 
RA is characterised by severe inflammation of the synovium where there is a 3-100 times 
elevation of pro inflammatory cytokines (interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor 
necrosis factor α (TNF-α) and markers of inflammation (e.g. CRP) (Feldmann et al., 2001). It 
has been suggested that these circulating cytokines may play a significant role in vascular 
disease (Sattar et al., 2003) by promoting the development of premature atherosclerosis. The 
exact cause of this increased atherosclerosis in RA is unclear but studies investigating the 
effects of inflammation on the promotion of atherogenesis suggest that IL-6 and TNF-α are 
particularly important in this process (Rho et al., 2009). This notion is supported by the 
observations that anti-TNF-α agents improve endothelial dysfunction (Hurlimann et al., 
2002) and reduce carotid intima-media thickness (Del Porto et al., 2007). These observations 
suggest that specific inflammatory markers promote endothelial dysfunction, the first step in 
the pathogenesis of atherosclerosis (Yasmin et al., 2004), see Figure 1.1. 
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Figure 1.1 Inflammatory pathways linked to the development of atherosclerosis in patients with 
rheumatoid arthritis (Ozbalkan et al., 2010). EPC; endothelial progenitor cells. 
 
 
Since RA is a chronic inflammatory disorder, the control of inflammation with medication is 
essential. However, some medications like corticosteroids and non-steroidal anti-
inflammatory drugs (NSAIDs) may also cause hypertension, insulin resistance and 
dyslipidemia (Johnson, 1997, Kalback, 1972, Quyyumi, 2006). A recent meta-analysis 
suggested that NSAIDs like naproxen, diclofenac and ibuprofen are not well tolerated in 
terms of cardiovascular risk (Trelle et al., 2011). Suggestions have been made that prolonged 
administration of NSAIDs have been shown to increase the risk of non fatal myocardial 
infarction (García Rodríguez and Gozalez-Perez, 2005). However, not all medications used in 
the treatment of RA have adverse effects on CVD risk. Disease modifying anti rheumatic 
drugs (DMARDs) like methotrexate have been shown to reduce CVD risk (Westlake et al., 
2010).  
 
Despite earlier research suggesting that traditional CVD risk factors do not explain the 
increased incidence of CVD in RA, many studies continue to investigate the potential role of 
traditional risk factors in the development of CVD in RA. However, their findings are 
somewhat conflicting. Some studies suggest that RA patients have a higher systolic blood 
pressure (Alkaabi et al., 2003), dyslipidemia (Metsios et al., 2009), increased incidence of 
diabetes, and greater BMI (Del Rincon et al., 2001) than those without RA. While other 
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studies have reported the opposite and found that the prevalence of hypertension in RA is no 
different to that of the general population (Boyer et al., 2011) and that dyslipidemia actually 
has a paradoxical effect on CVD risk in patients with RA, with lower lipid levels resulting in 
a greater CVD risk (Semb et al., 2010). As in the general population, CVD risk scores have 
been used to estimate CVD risk in RA patients; Chung et al. (2006) investigated the 
Framingham risk score of a group of RA patients and healthy matched controls. RA patients 
with long standing RA had a significantly higher Framingham CVD risk score when 
compared to healthy controls (Chung et al., 2006). However, despite its widespread use the 
Framingham risk score often underestimates risk in certain populations, especially women 
(Mahoney et al., 2001). Since women are most commonly affected by RA, and the 
knowledge that traditional risk factors often behave differently in RA, the Framingham risk 
score may not be such an accurate estimation of CVD risk in this population. It has even been 
suggested that risk scores like the Framingham underestimate CVD risk by fivefold in some 
RA patients. Other studies have investigated the prevalence of the MetS to estimate the CVD 
risk of RA patients. However, their results have also been somewhat questionable due to the 
differences in the definitions used to classify MetS (Pereira et al., 2009). Some studies show 
that RA patients have a higher prevalence of MetS compared to individuals without RA 
(Chung et al., 2008, Crowson et al., 2011) and that those patients with long standing RA have 
an even greater prevalence of MetS compared to patients with early RA (Chung et al., 2008).  
 
It is evident from the literature that RA related systemic inflammation contributes to the 
accelerated atherogenesis observed in RA, even when other traditional risk factors are taken 
into consideration (Ozbalkan et al., 2010). However, with modern drug treatment, tight 
control of RA is possible; in fact, CVD event rates are reported to be lower in patients treated 
with methotrexate (Micha et al., 2011). Despite these advances in medical treatment, the rate 
of CVD morbidity and mortality still remain high when compared to the general population. 
The European League against Rheumatism (EULAR) has highlighted the need for RA 
specific methods to identify patients with a high CVD risk (Peters et al., 2010). Two 
independent CVD risk factors that have been mentioned previously in this current chapter but 
have not received much attention in the study of RA patients are obesity and cardio-
respiratory fitness. The impact of obesity and poor cardio-respiratory fitness in relation to 
CVD risk factors in patients with RA is unknown.   
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1.3.2 Obesity  
 
Obesity is a well established risk factor for the development of CVD (Sowers, 2003). It is the 
excessive accumulation of body fat that fundamentally occurs from an energy imbalance 
between calories consumed and calories expended (Bray and Bellanger, 2006). The World 
Health Organisation (WHO) defines obesity as a body mass index (BMI) (weight divided by 
height squared) of greater than 30 kg·m-2. A BMI of 25 – 30 kg·m-2 represents the overweight 
category. Data from the Health Survey for England (HSE) showed that in 2009, 61% of 
adults (aged 16 or over) in England were overweight or obese, of these 23% were obese (i.e. 
1 in 4 adults in England are obese). This is similar to statistics reported by the Welsh Health 
Survey (2010) - 3 in 5 adults were classified as overweight or obese, with 1 in 5 adults 
classified as obese. This level of obesity is a significant burden on the National Health 
Service (NHS). Direct costs caused by obesity are estimated to be £4.2 billion per year and 
forecast to more than double by 2050 if this trend continues (Weiler and Stamatakis, 2010).  
 
Obesity has a severe impact on an individual’s health. It is an independent risk factor of many 
chronic diseases such as diabetes mellitus, CVD and some cancers; endometrial, breast and 
colon cancer (Bergstrom et al., 2001). WHO reported that being overweight and obesity are 
the fifth leading risks for global death (WHO, 2009). It is suggested that individuals who are 
overweight or obese have a decreased life expectancy of 3 - 7 years (Peeters et al., 2003). 
Adults who are overweight or obese have elevated serum levels of C-reactive protein, IL-6, 
TNF-α, and leptin, which are all known markers of inflammation (Das, 2001). This suggests 
that obesity may be a low-grade systemic inflammatory disease (Bullo et al., 2003). Not only 
is obesity a problem in the general population, it is also a significant problem in patients with 
RA and is likely a result of genetic and lifestyle influences (Marti et al., 2004).  
 
1.3.3 Obesity in RA 
 
RA is a chronic inflammatory disease that is associated with altered body composition (Giles 
et al., 2008). The chronic inflammation of the disease, particularly activation of the nuclear 
factor kappa-beta (NF- κβ) pathway, triggers metabolic alterations leading to the degradation 
of lean tissue, especially muscle mass (Marcora et al., 2006). If this is combined with an 
inactive lifestyle, a reduction in muscle mass with an increased accumulation of fat mass may 
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result. This process is well known as rheumatoid cachexia (Roubenoff et al., 1994). It is 
believed that approximately two thirds of RA patients suffer from rheumatoid cachexia 
(Elkan et al., 2009, Walsmith et al., 2004). Not only do these detrimental alterations in body 
composition cause increased muscle weakness and disability; it can also contribute to feelings 
of fatigue and increased risk of CVD (Metsios et al., 2009, Roubenoff et al., 1994).   
 
Despite the fact that obesity is an independent risk factor for CVD in the general population 
and that RA patients have an increased risk of CVD, very few studies have directed their 
focus on obesity in the RA population. Most RA patients have their weight routinely assessed 
when they attend rheumatology clinics. However, this is mainly used as a demographic 
characteristic reported in medical notes and is generally excluded from further interpretation 
(Stavropoulos-Kalinoglou et al., 2011).  
 
The WHO definition for obesity using BMI is valid for the general population. However, it 
has been proven inaccurate for some populations with altered body composition (Evans et al., 
2006, Goh et al., 2004). As patients with RA can often have increased fat mass with little or 
no change in total body weight, the standard BMI cut off value may not be useful in RA 
patients. Stavropoulos-Kalinoglou et al. (2007) compared the BMI of patients with RA to that 
of the general population. For a given body fat content measured by bioelectrical impedance 
analysis patients with RA had a significantly lower BMI by almost 2 kg.m-2. Consequently it 
is proposed that the BMI cut offs for RA patients should be reduced to 23 and 28 kg.m-2 to 
define overweight and obesity respectively (Stavropoulos-Kalinoglou et al., 2007). A recent 
review of the literature on obesity in RA reported that the BMI of RA patients ranged from 
26.5 – 28.2 kg.m-2 which is similar to that of the general population (Stavropoulos-
Kalinoglou et al., 2011). A UK based study found that 68% of RA patients were overweight 
(BMI > 25 kg.m-2) and 31% were obese (BMI > 30 kg.m-2) (Armstrong et al., 2006). These 
values are marginally higher than that reported by the HSE in 2009 for the general population 
– 61% and 23% for overweight and obese, respectively. However, if RA specific cutoffs were 
used then an even higher prevalence of obesity (37%) would be observed (Stavropoulos-
Kalinoglou et al., 2007).  
 
It is clear from the literature to date that more research is needed to identify the optimal 
method for assessing obesity in RA patients. Although the suggestions made by 
Stavropoulos-Kalinoglou et al. (2007) to lower BMI cut offs seem promising, further research 
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is needed on the validity of these revised criteria. Perhaps the best solution is to examine 
several measures of body composition to determine obesity.  
 
1.3.4 Measures of Obesity  
 
The assessment of body composition is quite challenging as direct measurement of adipose 
tissue in vivo is virtually impossible. Because of this several alternative indirect and easy to 
use methods have been developed. The main tests of body composition are discussed below.  
1.3.4.1 Body Mass Index (BMI) 
 
BMI is the most common method of measuring obesity (Burkhauser and Cawley, 2008). 
However, it may not be the most suitable measure of obesity in RA patients (Stavropoulos-
Kalinoglou et al., 2007) (see section 1.3.3). BMI is an index that assesses obesity on a whole 
body level; it takes into account total weight but it does not distinguish between the different 
tissues that make up the human body. Total body weight = fat mass + lean mass (muscle, 
organs, bone). Thus, individuals of similar height and weight can have significantly different 
levels of lean mass. Their BMI would be equal but body fat could differ significantly. This is 
one of the major limitations of using BMI as a measure of obesity.  
1.3.4.2 Waist Circumference and Waist Hip Ratio (Waist:Hip) 
 
Waist circumference is an indirect measure of central adiposity (Lean et al., 1995). In adults 
central adiposity is known to be associated with increased risk of obesity-related conditions 
including type 2 diabetes, hypertension and heart disease (Seidell, 2010). Although indices of 
central adiposity are closely correlated with BMI, they have been shown to predict future ill 
health independently of BMI (Yusuf et al., 2005). The WHO (WHO, 2008) has advised that 
an individual’s relative risk of obesity-related ill health can be more accurately classified 
using both BMI and waist circumference than by either alone (Huxley et al., 2010). The 
WHO has developed a set of thresholds to categorise an individual’s risk of obesity-related 
illness based on waist circumference. For European men and women the cut‐off points for 
waist circumference are 94 cm and 80 cm, respectively. However, NICE guidelines state that 
if waist circumference exceeds 102 cm for men and 88 cm for women, there is an even 
greater risk of ill health (NICE, 2006). Abdominal obesity is further defined by waist hip 
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ratio (Waist:Hip). A Waist:Hip above 0.90 for males and above 0.85 for females indicates a 
substantially increased risk of metabolic complications (WHO, 1995).   
1.3.4.3 Body Fat Percentage 
 
A proportion of body fat is vital for normal physiological functioning; this is referred to as 
essential fat. For men essential fat is approximately 2-5% and naturally higher for women at 
10-13% (Gallagher et al., 2000). The rest of the total body fat is called storage fat, this is the 
excess fat stored in adipose tissue. Storage fat can accumulate around internal organs 
(visceral fat) or under the skin (subcutaneous fat). Optimal levels of body fat for females and 
males are outlined below in Figure 1. 2.  
 
 
Figure 1.2 Percent body fat norms based on NIH and WHO guidelines (WHO, 2000).   
 
Body fat percentage can be assessed using several methods including skinfold thickness, 
bioelectrical impedance analysis (BIA), hydrostatic weighing and dual x-ray absorptiometry 
(DEXA). Below is a brief description of each method. 
 
Skinfold Thickness  
This method simply involves the measurement of skinfolds of the body at various sites. The 4 
spot formula is considered to be relatively accurate (Durnin and Womersley, 1974). This 
method determines body fat based on the sum of 4 skinfolds (biceps, triceps, subscapular and 
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iliac crest). Although this method is quick and requires minimal equipment, the accuracy of 
this technique is observer dependent.  
 
Bioelectrical Impedance Analysis (BIA) 
BIA is relatively simple, quick and a non-invasive measure of body composition with 
minimal intra- and inter-observer variability (Diaz et al., 1989). The benefit of BIA is that 
results are available immediately and reproducible with < 1% error on repeated measurement 
(Segal et al., 1991). This technique became commercially available for the first time in the 
mid-1980s (Buchholz et al., 2004), and requires inexpensive, portable equipment, making it 
an appealing alternative to assess body composition in epidemiological studies.  
 
Hydrostatic weighing  
Hydrostatic or underwater weighing is based on Archimedes Principle of displacement which 
states that the buoyant force on a submerged object is equal to the weight of the fluid that is 
displaced by the object. Until recently this method of assessing body composition was 
considered to be the gold standard. Hydrostatic weighing involves the measurement of body 
weight in and out of the water. After the correction for residual volume, percent fat can be 
calculated based on the underwater weight using standard equations (Brozek et al., 1963).  
 
Dual x- ray absorptiometry (DEXA)  
Whilst the above techniques assume two body compartments, DEXA can estimate three body 
compartments consisting of fat mass, lean body mass, and bone mass. DEXA systems use a 
source that generates X-rays at two energies. The differential attenuation of the two energies 
is used to estimate the bone mineral content and the soft tissue composition. When two X-ray 
energies are used, only two tissue compartments can be measured; therefore, soft tissue 
measurements (i.e., fat and lean body mass) can only be measured in areas where no bone is 
present. DEXA measurements are based in part on the assumption that the hydration of fat-
free mass remains constant at 73%. Hydration, however, can vary from 67%–85%. DEXA is 
considered by many to be the new reference method (Van Der Ploeg et al., 2003). Despite 
this, a long assessment time and exposure to radiation makes this method unsuitable for use 
in large studies.  
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1.4 Cardio-respiratory Fitness  
 
Another acknowledged independent risk factor for CVD is reduced cardio-respiratory fitness 
(Blair et al., 1989, Carnethon et al., 2003, Sandvik et al., 1993). Cardio-respiratory fitness is a 
measure of the body’s ability to uptake, transport and utilize oxygen during sustained 
physical activity (ACSM, 2000, Hartung et al., 1993). The criterion measure of cardio-
respiratory fitness is maximal oxygen uptake (VO2 max) (Armstrong et al., 1991). Cardio-
respiratory fitness is typically expressed in litres of O2 consumed per minute or in millilitres 
of O2 consumed per kilogram of body mass per minute. Factors influencing cardio-
respiratory fitness include non-modifiable factors like gender, age and genotype (Buskirk and 
Hodgson, 1987) and modifiable factors such as physical activity, obesity and medical 
condition (Lee et al., 2010). Typically males have a VO2 max 40-60% higher than females 
(McArdle et al., 2005). This difference is most notably due to the variance in muscle mass 
and stroke volume between males and females (Fletcher et al., 2001). Age is also a major 
influencing factor; maximal oxygen intake declines by approximately 5 ml·kg-1·min-1 per 
decade from 25 to 65 years of age, with some possible acceleration thereafter (Shephard, 
1987, Weiss et al., 2006). Potential causes of this age-related loss in cardio-respiratory fitness 
include decreases in maximal heart rate, stroke volume and arterio-venous oxygen difference 
(Weiss et al., 2006). Refer to Tables 1 and 2 in Appendix 1 for normative fitness data 
between gender and age groups taken from Heywood (1998).  
 
Cardio-respiratory fitness is a sensitive and reliable measure of habitual physical activity 
(ACSM, 1998, Church et al., 2007), but it is also a very useful health indicator for both 
symptomatic and asymptomatic patients in clinical practice (Myers et al., 2002). An 
association between cardio-respiratory fitness and all cause mortality was first identified by 
Blair and colleagues (Blair et al., 1989). Data from numerous subsequent epidemiological 
studies indicate that low cardio-respiratory fitness is a strong independent risk factor for all-
cause and cardiovascular disease (CVD) mortality in asymptomatic individuals, persons with 
co-morbid conditions (hypertension, obesity, type 2 diabetes mellitus), and those with 
established coronary artery disease (Franklin and McCullough, 2009). It is reported that the 
strength of association between low cardio-respiratory fitness and mortality is comparable to 
that between mortality and traditional CVD risk factors such as obesity, hypertension, 
dyslipidemia and smoking (Blair et al., 1989, Laukkanen et al., 2004, Wei et al., 1999). It has 
also been suggested that the measure of cardio-respiratory fitness (VO2 max) is the only 
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variable other than age and co-morbidity to be predictive of future dependence in the elderly 
(Paterson et al., 2004). 
 
Despite the convincing evidence that fitness is associated with morbidity and mortality 
independently of other CVD risk factors (Carnethon et al., 2003, Kodama et al., 2009), the 
importance of cardio-respiratory fitness is still often overlooked from a clinical perspective 
compared with other more ‘traditional’ risk factors like high blood pressure, abnormal lipids, 
or smoking (Lee et al., 2010). The same is true for patients with RA.  
 
1.5 Cardio-respiratory Fitness in RA 
 
Research has shown that patients with RA have poor cardio-respiratory fitness in comparison 
to healthy age matched controls with some studies reporting a cardio-respiratory fitness level 
20-30% lower in comparison to individuals without RA (Cimen et al., 2001, Ekdahl and 
Broman, 1992). This discrepancy in cardio-respiratory fitness level may be due to physical 
inactivity during inflammatory stages of the disease and continued physical inactivity during 
stages of disease remission (Mancuso et al., 2007).  
 
Taking into consideration the established association between cardio-respiratory fitness and 
CVD risk, it seems reasonable to believe that the poor cardio-respiratory observed in RA 
patients may exacerbate, or even contribute to, some individuals heightened CVD risk. 
However, this potential link has not been tested.  
 
1.6 Measures of Cardio-respiratory Fitness    
There are two ways cardio-respiratory fitness can be measured, directly using a maximal 
exercise test or indirectly using a submaximal exercise test. The gold standard for assessing 
cardio-respiratory fitness is a VO2 max test (Shephard et al., 1968); this is a maximal exercise 
test which is typically performed using a treadmill or a cycle ergometer. Although this is the 
more accurate measure of cardio-respiratory fitness this test is not without limitations. A VO2 
max test requires expensive equipment, trained personnel, maximal effort from the participant 
and an element of risk when performing such a test. Major complications like myocardial 
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infarction or serious arrhythmias can occur and have been reported at a rate of up to 5 per 
10,000 tests, with sudden cardiac death occurring in up to 0.5 per 10,000 tests (Arena et al., 
2007). Maximal exercise testing in clinical patients can often be limited by cardiopulmonary, 
musculoskeletal, and neuromuscular impairments and complaints such as exertion, dyspnea, 
fatigue, weakness, and pain (Noonan and Dean, 2000). Due to these limitations submaximal 
exercise tests are often used to predict cardio-respiratory fitness.  
 
Submaximal exercise tests estimate cardio-respiratory fitness from exercise heart rate, 
oxygen consumption or exercise time to exhaustion. This estimation is based on the linear 
relationship between exercise heart rate and oxygen consumption (VO2) (Astrand and 
Ryhming, 1954). Typically submaximal exercise tests are less difficult to perform, less time 
consuming and more importantly provide an adequate estimate of cardio-respiratory fitness. 
A review by Noonan and Dean (2000) reported a high correlation between maximal and 
submaximal exercise testing (r = 0.7–0.9) in various submaximal tests such as submaximal 
treadmill and cycle ergometer tests, 12-minute run test, and 1-mile walk test (Noonan and 
Dean, 2000). 
 
To date, various submaximal exercise tests have been developed. These include tests 
designed to meet the needs of people with various functional limitations and disabilities and 
the needs of older adults (Brown et al., 1985, Bruce et al., 1973, Hagberg, 1994, Marciniuk 
and Gallagher, 1994). Bruce et al. (1973) developed the Modified Bruce Treadmill Test 
which is widely used to estimate VO2 max especially in individuals with coronary heart 
disease (Bruce et al., 1973). Astrand and Rhyming (1954) developed a submaximal cycle 
ergometer test (A-R cycle ergometer test) which is based on the linear relationship between 
oxygen consumption and heart rate. It is one of the most widely used cycle ergometer tests 
that is often used to assess fitness and develop training programmes (Astrand and Ryhming, 
1954). However, some studies using this test have reported that the protocol can elicit lower-
extremity discomfort in some people, which may invalidate the results (Wisen and Wohlfart, 
1995). Other submaximal exercise tests include the single stage treadmill walking test 
(Ebbeling et al., 1991). This walking test is reported to be suitable for individuals of all ages 
and fitness levels and in particular for those who suffer from fatigue. The above submaximal 
exercise tests have been previously validated in healthy populations and some clinical 
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populations. The walking test has also been validated in individuals with rheumatic disease 
(Minor and Johnson, 1996).  
 
Despite various submaximal exercise tests being valid and reliable predictors of cardio-
respiratory fitness in healthy individuals and various other clinical populations it is not 
unreasonable to suggest that these tests are not suitable for use in a clinical setting. The 
equipment needed (motorised treadmills or cycle ergometers) to perform these tests are 
expensive and require a lot of space. Some of the tests are even time consuming and often 
require trained personnel. In contrast, step tests that require limited equipment (i.e. step, 
metronome, heart rate monitor and stop watch), represent an attractive modality for assessing 
cardio-respiratory fitness in a clinical setting. Since the earliest reported step test, now known 
as the Harvard step test (Brouha et al., 1943), numerous submaximal step test protocols have 
been developed. These include the Queens College step test (McArdle et al., 1972), the 
Canadian home fitness test (Shephard, 1976), the Chester step test (Sykes and Roberts, 2004) 
and the Siconolfi step test (Siconolfi et al., 1985). Siconolfi et al. (1985) developed a simple 
step test to predict cardio-respiratory fitness in a healthy population. It was shown to be a 
valid predictor of directly measured VO2 max (r = 0.92) and very reproducible. An advantage 
of the Siconolfi test over the others is that it may be completed at relatively low levels of 
exercise. This is very important in low active, clinical groups like patients with RA where 
exercise intolerance is a feature of their disease. The benefits of this step test are that it 
requires minimal time, effort, space and equipment, which is ideal for use in a clinical setting. 
Because of this, Marcora and colleagues used this step test with a group of systemic lupus 
erythematosus (SLE) patients and found it to be a valid and reliable measure of cardio-
respiratory fitness in this clinical population (Marcora et al., 2007). As predictive exercise 
tests are population specific this test would need to be validated in a group of RA patients 
before it could be used in a clinical setting as a measure of cardio-respiratory fitness. This is 
discussed in further detail in Chapter 3.  
 
1.7 Exercise and Rheumatoid Arthritis  
 
In addition to the drug treatment described in section 1.1.3, there is growing scientific 
evidence that exercise is both safe and very beneficial for RA patients (Bearne et al., 2002, de 
Jong and Vliet Vlieland, 2005, Minor, 1996, Minor et al., 1989, Munneke et al., 2005). 
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Unfortunately, research has also shown that RA patients often fear disease aggravation and 
the traditional approach of rheumatology health professionals to recommend exercise 
restriction may explain the inactive lifestyle of this population (de Jong et al., 2003, Scott and 
Wolman, 1992). However, recently it has been well documented that properly designed 
physical exercise programmes can have very beneficial effects on cardio-respiratory fitness, 
strength and physical functioning without increasing disease activity or joint damage 
(Hakkinen, 2004, Westby, 2001).  
 
An early meta-analysis of six randomised controlled trials suggested that dynamic exercise 
therapy was effective in improving aerobic capacity, muscle strength and joint mobility 
without any deleterious effects on disease activity (Van den Ende et al., 1998). Subsequently 
a large number of studies that have been subject to systematic review (Baillet et al., 2010, 
Hurkmans et al., 2009, Roubenoff et al., 1992, Stenstrom and Minor, 2003) indicate that 
exercise is effective in the management of patients with RA, and does not induce adverse 
effects. In fact exercise has been shown to improve functional ability (de Jong et al., 2003) 
and significantly reduce pain (Van den Ende et al., 2000).  
 
Whilst the exercise benefits for RA patients are widely recognized and suggested to be 
beneficial for most RA patients (NICE, 2009). The conclusion of many exercise programmes 
is that more research is required to investigate the most effective exercise prescription 
(intensity, frequency, duration, and mode), the optimum modes of exercise delivery, and how 
adherence to training can be facilitated. A summary of exercise types and recommendations 
for individuals with RA based on current evidence is depicted in Table 1.2 (Cooney et al., 
2011).  
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Table 1.2 Summary of general exercise guidelines for RA. This information is derived from 
ACSM exercise management guidelines (Durstine et al., 2003) and the research literature 
(Cooney et al., 2011). 
 
Benefit Type of Exercise How Best to Achieve 
 
Improve CV health 
Cycling 60–80% HR max 
Walking 30–60 mins/session 
Swimming 3–5 days/week 
Dance 
Increase duration, then intensity 
over time 
 
Increase muscle mass & strength 
 
60–80% 1RM 
Free weights 
8–10 exercises (large muscle 
groups) 
Weight machines 8–12 reps/exercise 
Therabands 2-3 sets 
 
2-3 days/week 
 
Increase intensity over time 
 
Increase ROM & flexibility for enhanced 
joint health 
Stretching 
 
Tai Chi exercises 
10–15 minutes 
2 days/week 
Yoga/Pilates 
 
 
Improve balance* 
One leg stance 
On a regular basis 
Stability ball 
Strengthening core 
muscles 
 
*The effects of balance training alone in RA patients to enhance functional capacity through increased 
proprioception and coordination and to reduce the risk of falls have yet to be conducted (Silva et al., 2010). 
Thus the effectiveness and safety of balance training are unclear. HR; heart rate, RM; repetition maximum, 
ROM; range of motion.  
 
 
Typically exercise interventions in RA have focused on the effects of aerobic training, 
progressive resistance training (PRT) and a combination of both types. Aerobic activities 
most often included in exercise interventions are walking, running, cycling, exercise in water, 
and aerobic dance. Walking is a good mode of exercise as it is inexpensive, requires no 
special skills, is safe, and can be performed both indoors and outdoors. Regular brisk 
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walking, even in short bouts, improves aerobic fitness and reduces aspects of CVD risk in 
healthy adults (Forestier et al., 2009). Cycling is also an excellent mode of aerobic activity 
that works the large muscle groups of the lower extremity. Cycling, in line with the 
guidelines in Table 1.2, improves aerobic capacity, muscle strength, and joint mobility with 
no exacerbation of disease activity (Van den Ende et al., 1996). Water-based exercise has 
also been studied in RA. Hydrotherapy has been shown to be very effective for RA sufferers. 
As little as two 30-minute sessions for 4 weeks have been shown to significantly reduce joint 
tenderness, improve knee range of movement, and improve emotional and psychological 
well-being (Hall et al., 1996). Dancing is another form of aerobic exercise which has reported 
improvements in aerobic power and resulted in positive changes in depression, anxiety, and 
fatigue, with no deterioration in disease activity in RA patients (Noreau et al., 1995). 
However, despite the large number of studies demonstrating the beneficial effects of exercise 
in RA, no study to date has investigated the beneficial effects of aerobic exercise on RA 
patients’ cardiovascular risk factors.  
 
With a loss in muscle mass, and subsequent functional limitation and burgeoning disability a 
characteristic of the disease, RA patients should be encouraged to perform exercises which 
elicit muscle hypertrophy and strengthening. Several studies have demonstrated the beneficial 
effects for RA patients of performing muscle strengthening exercises, in particular 
progressive resistance training (PRT). These improvements include increases in muscle mass, 
reduction in fat mass, and substantial improvements in physical function (Hakkinen et al., 
2005, Lemmey et al., 2009, Marcora et al., 2005). A two-year dynamic strength training 
programme in early RA patients found significant improvements in muscle strength (19–
59%) along with impressive reductions in systemic inflammation, pain, morning stiffness, 
and disease activity (Häkkinen et al., 2001). These findings suggest that long-term dynamic 
strength training can significantly improve the physical well-being of RA patients without 
exacerbating disease activity. Muscle strength gains from PRT programmes can also be 
maintained over several years of continued training at sufficient intensity (de Jong et al., 
2009, Hakkinen, 2004).  
 
It is very clear from the literature detailed above that exercise is beneficial for patients with 
RA. However, despite this knowledge RA patients remain physically inactive. 68% of RA 
patients in the UK do not take part in any regular physical activity (Sokka and Hakkinen, 
2008). It was also reported that only 13.8% of all RA patients studied reported exercising 
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three or more times per week, which is the amount of exercise shown to provide health 
benefits in this population (Andersen et al., 2000, Gregg et al., 2003).  
 
Considering cardiovascular co-morbidity and mortality are increased in patients with RA 
(Pincus et al., 1984) and the very low levels of cardio-respiratory fitness and physical activity 
in this population; it is conceivable that poor fitness and physical inactivity may contribute to 
the cardiovascular morbidity and mortality observed in this population. The existing evidence 
does not allow an estimate of the relative impact of poor fitness and physical inactivity on 
CVD in these patients (This is discussed in greater detail in Chapter 6). With a clear gap in 
the literature the need for research investigating CVD risk factors, cardio-respiratory fitness 
and the effect of exercise training on CVD health in RA patients is paramount. 
 
1.8 Aims and Objectives  
1.8.1 Broad Aim  
 
The broad aim of this thesis is to investigate the association between cardio-respiratory 
fitness and traditional cardiovascular disease (CVD) risk factors in patients with rheumatoid 
arthritis (RA).    
 
1.8.2 Specific Objectives  
 
1. To assess the validity and reliability of the Siconolfi step test for estimating cardio-
respiratory fitness in patients with RA. In order to investigate the association between cardio-
respiratory fitness and traditional CVD risk factors, a valid test to measure cardio-respiratory 
fitness in RA patients is firstly required (Chapter 3).  
 
2. To determine the association between cardio-respiratory fitness (step test) and traditional 
cardiovascular disease risk factors in rheumatoid arthritis patients attending a routine 
rheumatology clinic appointment (Chapter 4).  
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3. Like poor cardio-respiratory fitness, obesity is also an independent risk for CVD and is 
often under investigated in RA. The aim of this study was to determine the impact of obesity 
on RA disease, CVD risk factors and fitness and function (Chapter 5). 
 
 4. To investigate whether a short term supervised exercise intervention can improve RA 
patients overall cardiovascular health and general wellbeing. It is the first study of its kind to 
assess the effects of exercise on CVD risk factors in a sample of RA patients (Chapter 6).  
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2 Chapter 2: Methodology  
 
2.1 Participants  
 
A total of 135 RA patients were recruited as participants for the studies presented in this 
thesis. In the first study 30 RA patients took part in the validation study and acted as their 
own controls to determine the reliability of the step test. In the second study, data was 
collected from 100 RA patients who attended a routine rheumatology clinic appointment. Ten 
RA patients (5 of which also took part in the second study) were recruited and took part in an 
8 week supervised exercise programme that formed the basis of study three. All patients had 
a diagnosis of RA according to the American College of Rheumatology 1987 Criteria for the 
Classification of Rheumatoid Arthritis (Arnett et al., 1988). All studies included in this PhD 
thesis received ethical approval by the local research ethics committee. Participants were 
given verbal and written information about each project and were given a minimum of 48 
hours to decide whether or not they wished to take part. Patients who were interested in 
taking part signed an informed consent on the first day of their assessment according to the 
declaration of Helsinki (WMA, 2000). Due to the varying nature of each individual study, 
further details regarding participants are given in the methods section of each respective 
study.  
 
2.2 Assessments  
 
Full descriptions of assessments common to all studies are given in this section. Where 
necessary they are presented again to allow the reader to understand the methodology for 
each independent study. Assessments are categorised into relevant sub headings which 
include Aspects of Rheumatoid Arthritis, Cardiovascular Risk Factors, Body Composition 
and Fitness and Function.  
 
 
 
 
 
 
38 
 
2.2.1 Measuring Aspects of Rheumatoid Arthritis   
 
2.2.1.1 Erythrocyte Sedimentation Rate (ESR) & C - reactive protein (CRP) 
 
ESR and CRP are levels used to monitor disease activity and to monitor how well a patient is 
responding to treatment. ESR is one of the most common laboratory assessments performed 
on persons with rheumatic diseases. ESR is determined by the rate at which the red blood 
cells fall in one hour and is reported in mm·hr-1. The principle of measurement is the study of 
the aggregation capacity of red blood cells by telemetry using the TEST1 method (Alifax, 
Padova, Italy). CRP is an acute phase protein produced by the liver and is elevated when 
inflammation is present in the body. Like ESR, it is a non-specific test and so does not 
indicate where in the body inflammation exists. CRP is expressed in mg·l-1 and CRP levels > 
3 mg·l-1 are associated with an increased cardiac risk (Ridker et al., 2002). CRP was 
measured using an OLYMPUS AU2700 analyzer (Beckman Coulter, Nyon, Switzerland). 
The test principle is based on the CRP reaction with anti-human CRP antibodies to yield 
insoluble aggregates. The absorbance of these aggregates is proportional to the CRP 
concentration in the sample. All blood samples were collected by qualified phlebotomists and 
analysed by the staff in the clinical biochemistry laboratory at Ysbyty Gwynedd. At this 
laboratory CRP levels below 5 mg·l-1 are expressed as CRP < 5, CRP values above 5 mg·l-1 
are given a specific number.  
 
2.2.1.2 Disease Activity Score 28 (DAS 28) 
 
The DAS 28 is a measure of disease activity in RA. It includes the joints of the hand, wrist, 
elbow, shoulder and knee whereby the number of tender and swollen joints are reported 
(Fransen and van Riel, 2005). Using a 10 cm visual analogue scale (VAS) the patient rated 
their arthritis during the last week from zero (best ever) to 100 (worst ever). This is known as 
the patients global health score. These results along with either a score for ESR or CRP were 
included in a mathematical formula to produce the overall disease activity score (Hensor et 
al., 2010):  
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DAS 28 ESR = 0.56*sqrt(t28) + 0.28*sqrt(sw28) + 0.70*Ln(ESR) + 0.014*GH     
DAS 28 CRP = 0.56*sqrt(t28) + 0.28*sqrt(sw28) + 0.36*Ln(CRP+1) + 0.014*GH + 0.96 
 
Where: 
t = number of tender joints  
sw = number of swollen joints  
GH = patients global health rated on the 10 cm VAS  
 
A DAS 28 of > 5.1 implies high disease activity;  > 3.2 - < 5.1 indicates moderate disease 
activity; < 3.2 low disease activity, and < 2.6 remission (Fransen and van Riel, 2005). See 
Appendix 2 for a copy of the DAS 28 used. Assessments of patient’s joints were made by the 
rheumatologist, rheumatology nurse specialist or the PhD student.  
 
2.2.1.3 Rheumatoid Factor (RF) & Anti Cyclic Citrullinated peptide (anti –CCP)  
 
RF: Rheumatoid factors (RF) are antibodies directed against the fragment crystallizable (Fc) 
portion of immunoglobulin G and are present in 70% to 90% of people with RA (Nell et al., 
2005). However, RF can be found in people without RA or with other autoimmune disorders. 
The RF is not diagnostic for RA but can be predictive of a more aggressive and erosive 
disease when compared to RF negative patients (Smolen, 1996).  
 
CCP: In recent years a new test for RA has been developed, the anti-CCP (Schellekens et al., 
2000). It measures levels of antibodies that bind citrulline modified proteins. This test is more 
specific for RA when compared to the RF. The presence of anti-CCP antibodies can be used 
to predict which patients will develop more severe RA (Schellekens et al., 2000, van Gaalen 
et al., 2005). Information regarding RA patients RF and CCP was obtained from patients’ 
medical notes. The clinical biochemistry laboratory at Ysbyty Gwynedd uses an 
aagglutination test to measure RF and an Axis-Shield anti-CCP ELISA to determine CCP. 
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2.2.1.4 Health Assessment Questionnaire (HAQ) 
 
The HAQ is an international, validated, self reported measure of physical function or 
functional disability (Fries et al., 1980) that is used in patients with a wide variety of 
rheumatic diseases, including RA, osteoarthritis, SLE, ankylosing spondylitis and psoriatic 
arthritis (Bruce and Fries, 2003). HAQ scores less than 1 indicate none or mild disability, a 
score of 1-2 indicates moderate disability and a score of greater than 2 represents severe 
disability. The short version of the HAQ was used in this thesis. A copy of this questionnaire 
can be seen in Appendix 3.  
 
2.2.2 Cardiovascular (CVD) Risk Factors and Global CVD Risk  
 
2.2.2.1 Blood Pressure 
 
Blood pressure was measured twice on the brachial artery using the standard auscultatory 
technique (3M Littmann Select Stethoscope, S.E., USA; Gold series DS66 
Sphygmomanometer, Welch Allyn GmbH and Co, Jungingen, Germany) whilst the patient 
had been resting in a seated position for approximately 10 minutes. The average of the two 
measurements is reported throughout.  
 
2.2.2.2 Fasting lipids & Glucose 
 
Patients were required to visit their GP surgery or Ysbyty Gwynedd to have a fasting lipid 
and glucose blood test within 4 weeks of their study date in study 2 and 1 week of their 
assessment in study 3. Patients were instructed not to eat or drink anything except water for 
10-12 hours before their blood test. Dyslipidemia was classed as a total cholesterol > 5.2 
mmol·l-1, triglycerides > 1.8 mmol·l-1, LDL-c > 3.4 mmol·l-1 or if a patient was receiving 
lipid lowering therapy. Guidelines were taken from the Third Report of the National 
Cholesterol Education Programme (2002). Blood samples were analyzed in the clinical 
biochemistry laboratory at Ysbyty Gwynedd using an OLYMPUS AU2700 analyzer 
(Beckman Coulter, Nyon, Switzerland). 
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2.2.2.3 Framingham Risk Score 
 
The Framingham Risk Score is a risk assessment tool developed by the Framingham Heart 
Study that predicts an individual’s risk of having a heart attack in the next 10 years 
(Anderson et al., 1991). A calculation is made using the following information: age, gender, 
total cholesterol, HDL-c, systolic blood pressure, smoking status and presence of diabetes. A 
Framingham Risk Score of < 10% represents low risk, 10-20% indicates moderate risk and > 
20% represents a high CVD risk. The Framingham risk score was obtained by using the 
following online Framingham calculator: http://cvrisk.mvm.ed.ac.uk/calculator/calc.asp 
 
2.2.2.4 QRISK2 
 
The QRISK2 CVD score is another tool used to estimate CVD risk (Hippisley-Cox et al., 
2008). This is a more recent tool than the Framingham and has been specifically developed 
for use in the United Kingdom. However, to date the number of publications using the 
QRISK2 is limited and so both tools are used in this thesis. The advantages of using the 
QRISK2 is that it contains many of the traditional risk factors included in Framingham (such 
as age, gender, cholesterol/HDL ratio, blood pressure, diabetes and smoking status) as well as 
important additional risk factors: 
 
 Self assigned ethnicity 
 Family History of premature CVD in a first degree relative under the age of 60 
 Deprivation (measured using the Townsend deprivation score) (Woodward et al., 
2007) 
 Blood pressure treatment 
 BMI 
 Rheumatoid Arthritis 
 Chronic Kidney Disease 
 Atrial Fibrillation 
 
The QRISK2 score was obtained by using the following online calculator: 
http://www.qrisk.org/index.php.  
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2.2.2.5 Metabolic Syndrome 
 
The metabolic syndrome consists of a constellation of risk factors, primarily abdominal 
obesity, hyperglycemia, low HDL-c, high triglycerides, and hypertension. The Third Report 
of the NCEP Adult Treatment Panel (ATP Ш), published in 2001, is the most widely used 
definition for metabolic syndrome. A diagnosis of ‘metabolic syndrome’ requires three of the 
five criteria listed above. 
 
2.2.3 Body Composition 
 
2.2.3.1 Body Mass Index (BMI) 
 
BMI was calculated by dividing a person’s weight measurement (in kilograms) by the square 
of their height (in meters): BMI = weight (kg) ÷ height2 (m). WHO guidelines categorise 
individuals based on their BMI. Adults with a BMI of < 18 kg·m-2 are considered 
underweight, a BMI of 18.5 – 24.9 kg·m-2 represents normal weight, whilst a BMI of 25 to 
29.9 kg·m-2 and > 30 kg·m-2 represents overweight and obese individuals respectively 
(WHO, 2000).  
 
2.2.3.2 Body Fat Percent 
 
Body fat percent was assessed by bioelectrical impedance analysis (BIA) using a Tanita TBF 
– 305 Body Composition Analyzer (Tanita Corporation, Tokyo, Japan). The procedure for 
measuring body fat percent involved participants being instructed to remove their shoes and 
socks and to stand on the scales with each foot placed on the metal plate. BIA then calculated 
body composition by sending a low, safe electrical signal through the body. BIA operates on 
the principle that fat mass exhibits greater resistance to the flow of electrical current than fat 
free mass due to differences in water content (Baumgartner et al., 1990) and has been shown 
to be a valid measure of percent body fat when compared to the gold standard dual x-ray 
absorptiometry (DEXA) (Goldfield et al., 2006, Hsieh et al., 2011). Hsieh and colleagues 
reported a correlation of 0.93 between BIA and DEXA. Optimal values for body fat 
percentage were given in Figure 1.2.  
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2.2.3.3 Waist and Hip circumference and Waist hip ratio (Waist:Hip)  
 
Waist circumference was measured midway between the uppermost border of the iliac crest 
and the lower border of the costal margin (rib cage). Hip circumference was measured around 
the widest portion of the buttocks. Measurements were taken when the tape was snug but did 
not compress the skin (WHO, 2008). The waist hip ratio was calculated using the following 
equation: 
 
Waist:Hip = waist circumference (cm) ÷ hip circumference (cm) 
 
2.2.4 Fitness and Physical Activity  
 
2.2.4.1 Step Test  
 
The Siconolfi Step test was originally developed as a valid and reliable measure of fitness in 
a healthy population aged 19-70 years (Siconolfi et al., 1985). The step test involves stepping 
up and down a 10 inch step for three minutes per stage for a maximum of three stages. 
Stepping rate is kept constant using a metronome. The stepping rates for stages 1-3 are 17, 
26, and 34 steps per minute, respectively. Heart rate, measured by telemetry (Model RS400, 
Polar Electro OY, Finland), is recorded at the end of each three minute stage. If heart rate 
does not equal or exceed 65% of the age predicted maximum heart rate (220 – age), then the 
participant is instructed to complete another stage. If the target heart rate (65% of maximum 
heart rate) is met then the participant continues stepping until the end of that stage. Each 
stage is separated by a one minute seated rest. The heart rate at the end of the final stage is 
used to estimate cardio-respiratory fitness (VO2 max) using equations developed by Siconolfi 
et al. (1985). See Appendix 4.  
 
2.2.4.2 Physical Activity – IPAQ 
 
The purpose of the International Physical Activity Questionnaire (IPAQ) is to provide a set of 
well-developed instruments that can be used internationally to obtain comparable estimates of 
physical activity (Craig et al., 2003). The IPAQ assesses physical activity undertaken across a 
comprehensive set of domains including: 
 
1. Leisure time physical activity 
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2. Domestic and gardening (yard) activities 
3. Work-related physical activity 
4. Transport-related physical activity  
 
The IPAQ short form asks about three specific types of activity undertaken in the four 
domains above. The specific types of activity that are assessed are walking, moderate-
intensity activities and vigorous-intensity activities (Hagstromer et al., 2006). Data collected 
from the IPAQ can be reported as a continuous measure in the form of MET minutes per 
week or categorical in the form of low, moderate and high levels of physical activity. For a 
copy of the questionnaire used in this thesis see Appendix 5.  
 
2.3 Data Analysis  
 
For all studies data was inserted into The Statistical Package for Social Sciences version 19.0 
(SPSS Inc. Chicago, IL, USA). The Kolmogorov-Smirnov test of normality was used to 
assess the dispersion of variables. Specific information regarding the statistical analysis 
performed is explained in greater detail in each respective study.  
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3 Chapter 3:  
 
Validity and reliability of the Siconolfi Step Test for estimating cardio-respiratory 
fitness in rheumatoid arthritis patients 
 
3.1 Introduction  
 
Despite cardio-respiratory fitness being widely recognised as an important health indicator, 
the assessment of cardio-respiratory fitness is often overlooked from a clinical perspective 
compared with other CVD risk factors (Lee et al., 2010). The criterion measure of cardio-
respiratory fitness is maximal oxygen uptake (VO2 max) and its accurate measurement usually 
requires: expensive testing systems; treadmills or cycle ergometers; suitably trained 
personnel; and maximal effort from the participant (Davis, 1995). It could be argued, 
therefore, that the requisites for measuring VO2 max might preclude routine assessment of 
cardio-respiratory fitness in patients ‘at risk’ or incapable of maximal exercise. On the other 
hand, VO2 max can be estimated relatively easily from a short bout of submaximal exercise 
lasting approximately 3 to 9 minutes (Noonan and Dean, 2000).  
 
A wide variety of predictive submaximal exercise protocols are available for use; these 
include treadmill walking (Bruce et al., 1973, Ebbeling et al., 1991) and cycle ergometry 
(Astrand and Ryhming, 1954) tests. However, motorised treadmills and cycle ergometers are 
not always available in a clinical setting. In contrast, step tests that require limited equipment 
(i.e. step, metronome, heart rate monitor and stop watch), represent an attractive modality for 
assessing cardio-respiratory fitness in a clinical setting. An advantage of the Siconolfi test 
over the other step tests is that it may be completed at relatively low levels of exercise. This 
is very important in low active, clinical groups like patients with RA where exercise 
intolerance is a feature of their disease. Since predictive exercise tests are population specific 
the aim of this study was to validate the Siconolfi step test as a measure of cardio-respiratory 
fitness in patients with RA. 
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3.2 Methods  
 
3.2.1 Participant Recruitment  
 
With ethical approval (REC reference: 08/WNo01/68), a prospective validation study was 
conducted in adults attending rheumatology out-patient services of the Betsi Cadwaladr 
University Health Board (West). Exclusion criteria specific to this study were: a current RA 
flare; joint surgery in the preceding two months; patients taking beta blockers; established 
cardiovascular disease; recent upper respiratory tract infection; pregnancy and, history of 
substance abuse. Consequently, 30 RA individuals (24 females) provided written informed 
consent and entered the study (Figure 3.1). 
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Figure 3.1 Flow chart displaying number of RA patients approached, recruited and completed. 
 
 
 
Approached 
 
n = 110 
 
 
Step tested in clinic 
n = 33 
 
 
Recruited via letters 
n = 77 
 
Informed consent 
 
n = 30 
 
Completed Study 
 
n = 22 
Failed to complete study 
 
n = 8 
2 = dropout 
1 = cardiac condition 
5 = failure to complete a test 
 
Declined 
 
n = 52 
 
 
 
Declined 
 
8 = failed to complete 
20 = declined 
 
48 
 
3.2.2 Protocol  
 
Participants were required to attend Llandudno General Hospital on two occasions. The visits 
were separated by 1 to 3 weeks and scheduled for the same time of day. Participants were 
instructed to avoid performing strenuous exercise 24 hours prior to testing and not to 
consume any food, caffeine, alcohol or tobacco in the 3 hours before being assessed. 
 
Visit one: Height and body mass were measured by standard procedures and body mass index 
(BMI) was calculated (kg·m-2). The systolic and diastolic blood pressures were taken by the 
standard auscultatory technique. Functional status (disability) measures were determined 
using the Stanford Health Assessment Questionnaire (HAQ) (Fries et al., 1980). Disease 
activity was assessed using the Disease Activity Score based on 28 joint assessments (DAS 
28). Then, each participant undertook the Siconolfi step test which has been described in full 
detail in chapter 2 (see section 2.2.4.1). Upon completion of the step test, each participant 
was familiarized with the equipment and procedures for a graded exercise test to volitional 
exhaustion using a cycle ergometer (Ergomedic 828E, Monark Exercise AB, Sweden); this 
included familiarization with the Borg categorical scale for rating perceived exertion (RPE) 
(Borg, 1982). An example of the Borg RPE scale used can be seen in Appendix 6. 
 
Visit two: At the next testing session, each participant repeated the step test. Then, after a 30 
minute rest period, a 12 lead ECG was performed at rest. If the ECG trace was normal, 
participants performed a VO2 max test. This test is a direct measurement of maximal oxygen 
uptake (cardio-respiratory fitness). Typically VO2 max tests can be performed on a treadmill or 
cycle ergometer. For this project a cycle ergometer was chosen. The test involved pedalling at 
a constant rate of 50 revolutions per minute (rpm) for two minutes with no resistance added 
to the flywheel. Thereafter, resistance increased in increments of 25 watts every two minutes, 
until volitional exhaustion (McArdle et al., 2005). Expired gases and air flow were monitored 
breath-by-breath using an automated system (800Ergo test, ZAN GmBH, Germany). Heart 
rate and ratings of perceived exertion (RPE) were measured at the end of every two minute 
stage (Borg, 1982). It was anticipated that many of these de-conditioned patients would not 
be able to obtain a true maximal aerobic capacity, defined as a plateau in oxygen 
consumption during the final stage, maximal heart rate > 85% of age-adjusted predicted 
maximal heart rate (220–age), respiratory exchange ratio (RER) > 1.10 and ratings of 
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perceived exertion (RPE) > 17 (Howley et al., 1995, Issekutz and Rodahl, 1961). Therefore, 
the highest VO2 recorded during the maximal cycling exercise test was considered to be the 
VO2 peak value (Lindstedt et al., 1988).  
 
3.2.3 Data analysis 
 
The primary outcome measure obtained during each of the step tests was estimated VO2 max 
(expressed as ml·kg-1·min-1), determined using the equations developed by Siconolfi et al. 
(1985). Outcome measures obtained during the cycling test to volitional exhaustion included; 
VO2 peak, peak heart rate, RER and ratings of perceived exertion (RPE).  
 
3.2.4 Statistical Analysis 
 
Data was entered into a database and statistical analyses were performed (SPSS, version 19 
for Windows, SPSS, Chicago, IL).The mean and standard deviation (SD) were calculated for 
normally distributed data. The paired t-test was used to establish whether there was a 
significant systematic bias between test measurements; a two-tailed p < 0.05 was considered 
significant. The concurrent validity of VO2 max estimated from the Siconolfi step test was 
assessed using the Bland and Altman technique (Bland and Altman, 1986). The standard 
error of the estimate (SEE) and the Pearson correlation coefficient (r) was also calculated. 
The inter-day reproducibility of estimated VO2 max was assessed using the test-retest within 
subject coefficient of variation, the Bland and Altman technique, the intraclass correlation 
coefficient (ICC) and the Pearson correlation coefficient. 
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3.3 Results 
 
One hundred and ten consecutive patients were contacted over 13 months (July 2009 to 
August 2010) regarding potential participation in the study. Of these, 80 were unwilling to 
participate; thus, 30 (24 female) patients were recruited to the study; however 5 recruits (5 
female) failed to complete all of the tests and 1 male withdrew due to a previously 
undiagnosed cardiac complaint (Figure 3.1). The demographic data, disease characteristics 
and disability scores of the remaining 24 patients are given in Table 3.1.  
 
 
Table 3.1 Characteristics of 24 patients (19 females and 5 males) with RA participating in the 
study 
  Females Males Total Group 
Age (years) 54.5 ± 10.5 49.4 ± 9.5 53.4 ± 10.4 
Weight (kg) 69.5 ± 15.3 90.0 ± 17.0 73.8 ± 17.5 
Height (cm) 164.0 ± 5.6 178.6 ± 6.3 167.1 ± 8.6 
BMI (kg·m-2) 25.8 ± 5.1 28.3 ± 5.1 26.3 ± 5.1 
Resting SBP (mmHg) 125.0 ± 2.0 139.0 ± 7.0 128.0 ± 11.0 
Resting DBP (mmHg) 79.0 ± 1.0 86.0 ± 2.0 81.0 ± 6.0 
Disease Duration (years) 13.0 ± 1.9 12.8 ± 1.8 13.0 ± 7.3 
DAS 28 ESR 2.9 ± 0.3 2.0 ± 0.3 2.7 ± 1.1 
HAQ (0-3) 0.6 (range 0 to 1.6) 0.2 (range 0 to 0.4) 0.5 (range 0 to 1.6) 
Values are mean ± SD or range. BMI; body mass index; SBP; systolic blood pressure; DBP; diastolic blood 
pressure; DAS; disease activity score; ESR; erythrocyte sedimentation rate, HAQ; health assessment 
questionnaire.  
 
 
The step test was well tolerated, with no adverse events. All of the 24 patients completed both 
step tests in a single stage. Data for submaximal tests are summarized in Table 3.2. The mean 
value for VO2 max estimated at Visit 1 (22.5 ± 4.7 ml·kg
-1·min-1) was marginally, albeit 
significantly higher than that at Visit 2 (22.0 ± 4.5 ml·kg-1·min-1, p = 0.049). The within-
subject coefficient of variation for estimated VO2 max was 5.4%. The Bland-Altman plot 
(Figure 3.2) of the within subject change for estimated VO2 max versus the mean for both step 
tests (i.e. Visit 1 and Visit 2) indicate a small systematic bias (- 0.5 ml·kg-1·min-1) between 
the first and second tests. The 95% limits of agreement (LoA) was ± 2.2 ml·kg-1·min-1. The 
intraclass correlation coefficient (ICC) was 0.97 (95% CI of 0.94 to 0.99) and the Pearson 
correlation coefficient (r) was 0.97 (95% CI 0.93 to 0.99). 
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Table 3.2 Heart rate (bpm & % age predicted maximum) and corresponding estimated VO2 max 
for 24 patients (19 females and 5 males) that performed the Siconolfi step test. 
 Visit 1 Visit 2 
  HR Peak % Age 
predicted 
Max 
Estimated 
VO2 max 
HR Peak % Age 
predicted 
Max 
Estimated 
VO2 max 
Females 122 ± 12 74 ± 9 21.2 ± 0.9 125 ± 14 75 ± 9 20.8 ± 0.9 
Males 120 ± 10 70 ± 4 27.6 ± 1.9 127 ± 14 74 ± 6 26.7 ± 1.8 
Total Group 122 ± 11 73 ± 8 22.5 ± 4.7 125 ± 14 75 ± 8 22.0 ± 4.5 
Values are mean ± SD. VO2; oxygen consumption; HR; heart rate, BPM; beats per minute.   
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Figure 3.2 Bland-Altman plot of VO2 max predicted by the Siconolfi step test on visit 1 and visit 2. 
The mean bias is represented by the solid line and the 95% limits of agreement are represented 
by the dashed lines. 
 
 
Two female patients did not complete the graded exercise test for the determination of VO2 
peak. Mean peak values for HR, VO2, RER and RPE of the remaining 22 patients are presented 
in Table 3.3. 
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Table 3.3 Physiological variables from the maximal cycling ergometry test in 22 patients (17 
females and 2 males). 
  Females Males Total Group 
HR peak 158 ± 13 159 ± 22 158 ± 15 
Age predicted max (%) 95 ± 6 93 ± 8 95 ± 7 
VO2 peak (ml·kg
-1·min-1) 19.2 ± 4.1 22.3 ± 4.0 19.9 ± 4.2 
RERpeak (VO2/VCO2) 1.18 ± 0.12 1.14 ± 0.04 1.18 ± 0.11 
RPE (15 point scale) 19 ± 2 18 ± 2 19 ± 2 
Values are mean ± SD. RER; respiratory exchange ratio; RPE; ratings of perceived exertion; VO2; oxygen 
consumption; VCO2; carbon dioxide production.  
 
 
The mean values for VO2 max estimated from the second step test (Visit 2) and directly 
measured VO2 peak were (22.0 ± 4.5) and (19.9 ± 4.2) ml·kg
-1·min-1, respectively (p = 0.003). 
The Bland-Altman plot of within-subject differences between estimated VO2 max and directly 
measured VO2 peak versus the mean of the two tests is presented in Figure 3.3. The systematic 
bias between estimated VO2 max and directly measured VO2 peak was 2.1 ml·kg
-1·min-1, the 
95% limits of agreement (LoA) was ± 5.7 ml·kg-1·min-1, and the SEE was 2.6 ml·kg-1·min-1 
(95% CI 2.0 to 3.8 ml·kg-1·min-1). The Pearson correlation coefficient (r) was 0.79 (95% CI 
0.55 to 0.91). When VO2 max estimated from the first step test (Visit 1) was used for the same 
analyses, the findings were found to be very similar (r = 0.77; 95% CI 0.52 to 0.90). 
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Figure 3.3 Bland-Altman plot of VO2 peak measured during the cycle test and VO2 max predicted 
by the Siconolfi step test (visit 2). The mean bias is represented by the solid line and the 95% 
limits of agreement are represented by the dashed lines. 
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3.4 Discussion 
 
The findings presented here demonstrate that administration of the Siconolfi step test 
provides a valid and reproducible estimation of cardio-respiratory fitness (VO2 max) in routine 
clinical practice. These findings are important; VO2 max, the measure of an individual’s 
cardio-respiratory fitness, is a strong independent predictor of mortality in asymptomatic 
individuals as well as in clinical patients. Low cardio-respiratory fitness carries the same or 
higher strength of association or risk for mortality as routinely measured clinical risk factors 
such as hypertension, dyslipidemia, diabetes, family history of CVD and smoking (Lee et al., 
2010). Furthermore, meta-analysis indicates that a cardio-respiratory fitness below ~ 28 
ml·kg-1·min-1 results in substantially higher rates of all-cause mortality and CHD/CVD events 
in healthy persons (Kodama et al., 2009). This is alarming considering the average cardio-
respiratory fitness level of the RA patients in this investigation was 19.9 ± 4.2 ml·kg-1·min-1. 
Despite all the evidence to support the use of cardio-respiratory fitness as an additional 
clinical measure for identifying CVD risk, the assessment of VO2 max is usually not performed 
in most, if not all, clinical practices.   
 
Direct measurement of VO2 max may place certain patient groups like RA patients at risk and 
is not always practical in many healthcare settings. In contrast, estimation of VO2 max from 
submaximal testing appears to have greater applicability, particularly for assessment of 
cardio-respiratory fitness in a clinical setting. Submaximal predictive tests like the Siconolfi 
step test provide a simple, safe and valid estimate of VO2 max. Originally developed to 
estimate VO2 max in apparently healthy individuals (Siconolfi et al., 1985), the purpose of the 
present study was to determine if administration of the Siconolfi step test provided a valid 
and reliable estimate of VO2 max in patients with RA, a population with increased CVD risk 
and low exercise tolerance.   
 
The findings presented in this chapter indicate that VO2 max estimation from the Siconolfi step 
test was in reasonable agreement with the criterion measure, i.e. directly measured VO2 peak. 
However, there was a small significant positive bias in the estimated versus the actual VO2 
max. The bias ± 95% LoA indicated that the Siconolfi step test could potentially overestimate 
VO2 max by 3.6 ml·kg
-1·min-1 in RA patients. Furthermore, the overall standard error of 
estimate of ± 2.6 ml·kg-1·min-1 means that the accuracy of the VO2 max estimation in RA 
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patients with an actual VO2 max ranging from 12.9 to 27.0 ml·kg
-1·min-1 was approximately 10 
to 20%.  
 
An estimated value for VO2 max that is higher than the directly measured VO2 peak may reflect 
differences between stepping and cycling exercise. It is possible that local muscle fatigue 
experienced by those unaccustomed to cycling exercise may have resulted in some of the 
maximal exercise tests being terminated before attainment of ‘true’ VO2 max (Midgley et al., 
2009). However, other indicators of maximal effort concomitant with VO2 max (Howley et al., 
1995), such as attaining a heart rate within 15 bpm of the age-predicted maximal value, a 
respiratory exchange ratio of greater than 1.10, and RPE greater than 17, were achieved in 
RA patients. This suggests that the current patients did exercise at or close to their maximal 
effort (Poole et al., 2008). Another possible explanation for overestimation of cardio-
respiratory fitness by the step test may be related to the timing of tests performed on visit 2. 
However, the short duration of the step test (i.e. 3 minutes) and the longer rest period (i.e. 30 
minutes minimum) between tests argue against this.  
 
The test-retest repeatability of the estimated VO2 max via the step test in the current study was 
excellent. The Pearson correlation coefficient and ICC indicated a very high correlation 
between the two step tests. However, there was a small but significant inter-trial bias (- 0.5 
ml·kg-1·min-1). The 95% LoA (± 2.2 ml·kg-1·min-1) is considered acceptable. Thus, an 
increase in estimated VO2 max of approximately 2.5 ml·kg
-1·min-1 or above following an 
exercise training intervention could be considered a change that is due to factors other than 
chance. In RA patients, this would equate to an increase in cardio-respiratory fitness of 
around 20% for the individual with the lowest VO2 max whereas the person with the highest 
VO2 max would experience a 10% increase. 
 
We know of only one other study that has investigated the validity and test-retest 
reproducibility of the Siconolfi step test in a patient group. Marcora and colleagues (Marcora 
et al., 2007) found that the Siconolfi step test was reasonably valid and highly reliable in 
patients with well controlled systemic lupus erythematosus (SLE). Compared to the patients 
in the present study, the SLE patients in that study were younger, weighed slightly less, had 
similar BMI, and had a higher directly measured VO2 max relative to body mass. The validity 
and reliability analyses for our study compare well to those of Marcora et al. (2007). 
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The most concerning, but unsurprising finding, of the present study was the very low value 
for the directly measured VO2 max in the RA patients. Previous reports indicated that VO2 max 
may be 20 to 30% lower in RA patients compared with age matched healthy controls (Chang 
et al., 2009, Ekdahl and Broman, 1992, Harkcom et al., 1985, Minor et al., 1989). A major 
determinant of VO2 max is the degree of physical activity over recent weeks and months. 
Evidence suggests that approximately 68% of RA patients in the UK are physically inactive 
(Sokka and Hakkinen, 2008); therefore, compromised cardio-respiratory fitness in patients 
with RA is hardly surprising. Despite knowing that increased incidence of CVD-related 
morbidity and mortality is a common feature of RA (Avina-Zubieta et al., 2008, Pincus et al., 
2001), the relative contributions of physical inactivity, traditional risk factors, and high grade 
systemic inflammation to the exacerbated CVD risk in this population remains unclear 
(Metsios et al., 2009, Sattar et al., 2003, Solomon et al., 2010, Stevens et al., 2005). However, 
exercise is recognized as useful adjunct treatment for RA (Cooney et al., 2011), although the 
relationships between cardio-respiratory fitness, exercise training and CVD risk factors in RA 
patients requires more research (Metsios et al., 2009).   
 
The strengths and weaknesses of this study warrant comment. The Siconolfi step test is easy 
to administer, requires minimal equipment, and is relatively quick since it can be completed 
at low levels of exercise. Thus, there is considerable potential for its use as a clinical tool for 
routine assessment of cardio-respiratory fitness in patients with RA and other clinical 
populations who are at risk of developing CVD. All of the patients studied here completed 
the test after the first stage. Although fatigue, pain, limited joint mobility and impaired 
muscle strength are all common features of RA (Arnett et al., 1988, Ekdahl and Broman, 
1992) the step test was reasonably well tolerated by patients in this study. Potential sources of 
error in the current study included: prediction of maximum heart rate from the 220-age 
formula; assumption of a linear relationship between heart rate and VO2; and, the individual’s 
ability to maintain the correct stepping tempo; all of which are common to submaximal 
exercise testing (Howley et al., 1995). Potential fatigue resulting from the VO2 max test taking 
place after the step test was minimised by ensuring that at least 30 minutes rest was provided 
and that resting ECG was normal after the 3 minutes of the step test exercise. Due to RA 
being primarily a joint disease we specifically chose to compare the step test to a cycling-
based VO2 max test. Even though cycling is not a weight-bearing activity, it may put the knee 
joint under a similar strain/range of movement than a walking-based test. A treadmill-based 
VO2 max test may have resulted in a higher VO2 max than what was obtained in this study 
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(Shephard, 1984). Another limitation is the modest sample size; however, it was sufficient to 
meet the study objectives, with suitable measures of validity and test-retest reliability being 
observed.  
 
3.5 Conclusion 
 
The present study is the first to demonstrate that the Siconolfi step test is a reliable method 
for assessing cardio-respiratory fitness in an RA population. In light of considerable 
epidemiological evidence that supports the cardio protective effects of regular physical 
activity and cardio-respiratory fitness; the current findings indicate a role for simple, 
clinically available physiological estimation of VO2 max. Another important finding is the very 
low cardio-respiratory fitness in patients with RA. It is well known that this group is twice as 
likely to die from a CVD related event when compared to the general population (Avina-
Zubieta et al., 2008). Therefore, following on from the current study it is believed that 
patients with RA and other chronic diseases with increased risk of CVD should have their 
cardio-respiratory fitness measured as part of their cardiovascular screening and advised to 
maximise as part of any long term management plan. This is achievable using the step test in 
RA.   
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4 Chapter 4:  
 
Association between cardio-respiratory fitness (step test) and traditional cardiovascular 
disease risk factors in rheumatoid arthritis 
4.1 Introduction  
 
The measurement of cardio-respiratory fitness as part of routine clinical care is generally 
nonexistent in rheumatology. One reason for this may be that a simple method to assess 
fitness in a clinical setting did not exist. Now that the step test was shown to be a very simple 
tool to assess cardio-respiratory fitness in this population, this next chapter aims to highlight 
the potential importance of such a measure in routine clinical practice.  
 
Rheumatoid arthritis (RA) is a chronic systemic immune and inflammatory disease that is 
associated with a 50-60% increased risk of mortality from CVD compared to the general 
population (Avina-Zubieta et al., 2008). It is believed that both traditional CVD risk factors 
and novel risk factors such as inflammation contribute to the increased risk of atherosclerotic 
CVD in patients with RA. Furthermore, other precipitating factors, such as persistent low 
levels of physical activity (Lee et al., 2000, Metsios et al., 2009, Warren et al., 2010) and 
poor cardio-respiratory fitness (Blair et al., 1989, Myers et al., 2002) likely contribute.   
 
Studies involving RA patients have revealed significantly reduced cardio-respiratory fitness 
levels with reductions of 20-30% being reported in research by Stenstrom and Minor (2003). 
Average VO2 max values obtained from a group of female RA patients equalled 22 ml·kg
-
1·min-1 (Minor and Hewett, 1995). The same poor level of cardio-respiratory fitness was also 
observed in our cohort in the previous chapter. Comparing these poor values to healthy adults 
of similar age confirms that RA patients have a significantly reduced cardio-respiratory 
fitness level (Stenstrom and Minor, 2003, Mitros et al., 2011, McKenzie et al., 2011, 
Schulman et al., 1996).   
 
To our knowledge only one study exists that has examined the associations between physical 
activity and traditional CVD risk factors in patients with RA (Metsios et al., 2009). Reduced 
physical activity was associated with increased systolic blood pressure, total cholesterol, and 
low density lipoprotein. There are no studies that have examined the association between 
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classical CVD risk factors such as hypertension and dyslipidemia and cardio-respiratory 
fitness. Therefore, the aim of the present study was to determine whether poor cardio-
respiratory fitness is in fact associated with a worse CVD risk factor profile and whether this 
also associates with worse RA disease in a typical RA population.  
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4.2 Methods 
 
4.2.1 Participant Recruitment 
 
With ethical approval (REC reference: 10/WNo01/11) 100 consecutive adults attending 
rheumatology out-patient services of the Betsi Cadwaladr University Health Board (West) 
were recruited. Patients diagnosed with RA and who attended the rheumatology clinic, were 
considered as potential participants for this study. Exclusion criteria were: patients pregnant 
or breastfeeding, taking a beta blocker, suffering from dementia, neurological impairment, 
cancer, or if they had a musculoskeletal impairment that prevented them from being able to 
do the step test. Patients with unstable chronic and terminal illness were also excluded.  
 
4.2.2 Protocol   
 
Patients attending their routine rheumatology appointment were invited to take part in this 
testing session. Interested patients were assessed in parallel to their rheumatology medical or 
nurse practitioner clinic appointment. On the day of this appointment the following measures 
were assessed in this approximate order:  
1. RA Related Factors 
Patients were required to have a recent blood test (< 4 weeks) for the assessment of 
inflammation (ESR and CRP). Functional status (disability) was determined using the 
Stanford Health Assessment Questionnaire (HAQ). Disease activity was assessed using the 
Disease Activity Score 28 (DAS 28) and patients rated their arthritis over the last week 
(global health) and their current level of pain using a 10 cm visual analogue scale.  
2. CVD risk Factors 
Whilst patients were rested systolic and diastolic blood pressures were taken by the standard 
auscultatory technique. Patients were required to give a fasting blood sample within four 
weeks of the testing session to assess fasting lipids and fasting glucose. Detailed information 
regarding patients smoking status, family history of heart disease and current medication was 
obtained using a cardiovascular questionnaire. 
3. Body Composition 
Height and body mass were measured by standard procedures and body mass index (BMI) 
was calculated (kg·m-2). Bioelectrical impedance analysis was used to assess body fat 
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percentage (Tanita corp., Tokyo, Japan) and waist and hip circumference was also measured 
to determine waist hip ratio (Waist:Hip). 
4. Fitness and physical activity 
Patients completed the International Physical Activity Questionnaire (IPAQ) – short form to 
assess their level of physical activity in the last 7 days. Once completed, each participant 
undertook the Siconolfi step test, which has been described in length in chapter 2 (see section 
2.2.4.1). Each individual’s VO2 max was estimated from the exercise heart rate at the end of 
the test according to established equations (see Appendix 4).  
 
4.2.3 Statistical Analysis 
 
All data analysis was performed using the Statistical Package for Social Sciences version 
19.0 (SPSS Inc. Chicago, Illinois, USA). The Kolmogorov – Smirnov test of normality was 
used to assess the distribution of the variables. Non parametric tests were performed on data 
that was not normally distributed (CRP, HAQ, glucose).  
 
Pearson’s correlation coefficient (parametric), Spearman’s correlation coefficient (non 
parametric), logistic regression analysis and ANCOVA were performed to assess the 
association between fitness and RA disease related factors, body composition, CVD risk 
factors and global CVD risk scores. Hierarchical multiple regression was performed to 
determine what factors best predict fitness.  
 
Participants were categorised according to their performance on the step test (able to do step 
test ‘ABLE’ and unable to do the step test ‘UNABLE’). MANOVA was used to assess the 
differences between the step ability groups for RA disease, body composition and CVD risk 
factors. If MANOVA revealed a significant difference, the dependent variables were 
considered separately using a Boneferroni adjusted alpha level (0.05/number of dependent 
variables). Binary logistic regression analysis was used to determine the impact of certain 
factors on step ability. Chi squared analysis was used to assess the association between step 
ability groups and all other categorical variables – RA disease, body composition, CVD risk 
and physical activity. Discriminant function analysis was performed to determine the best 
predictor of step ability. Statistical significance was set at p < 0.05 for all analyses unless 
stated otherwise.   
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4.3 Results   
 
100 RA patients (69% female) were included in this investigation (mean ± SD; age 59.6 ± 
10.2 years; disease duration 10.4 ± 9.1 years). RA patients had well controlled disease with 
low levels of inflammation (ESR = 16.1 mm·hr-1; CRP = 12.7 mg·l-1), disease activity (DAS 
28 ESR = 2.7) and disability (HAQ = 0.87). Detailed information regarding RA patients’ 
disease related factors is given in Table 4.1.   
 
Table 4.1 Description of RA patient’s disease related factors.  
Patient Characteristic             Mean or % SD 
Age (years) 59.6 10.2 
Female (%) 69  
   
RA variables   
RA duration (years) 10.4 9.1 
RA ≤ 2 yrs (%) 15  
RA 2-5 yrs (%) 18  
RA 5-10 yrs (%) 31  
RA >10 yrs (%) 36  
ESR (mm·hr-1) 16.1 12.7 
CRP (mg·l-1) 12.7+ 17.5 
CRP < 5 mg·l-1 (%) 49  
CRP > 5 (mg·l-1) 21.2* 21.5 
Rheumatoid factor positive (%) 72  
CCP positive (%) 79  
DAS 28 ESR 2.7 1.4 
DAS 28 CRP 2.8 1.1 
VAS arthritis (0-100) 31.9 23.8 
Pain (0-100) 22.9 27.6 
HAQ (0-3) 0.87 0.76 
Values are mean ± SD or percentage of patients (%), N = 100. ESR; erythrocyte sedimentation rate, CRP; C-
reactive protein, CCP; cyclic citrullinated peptide, DAS; disease activity score, VAS; visual analogue scale, 
HAQ; health assessment questionnaire. *mean CRP of patients with a CRP > 5 mg·l-1, +CRP = 4 was used for 
CRP values < 5.  
 
The majority of patients were being treated with DMARDs such as Methotrexate (66%), 
Leflunomide (16%), Sulphasalazine (13%) and Hydroxychloroquine (7%) with only 19% of 
patients receiving biologic therapy. 60% of patients were receiving monotherapy and 32% of 
patients were receiving combination therapy (28% of patients receiving a combination of 
two, 4% of patients receiving a combination of three). Eight percent of patients were not 
being treated with DMARDs. In terms of steroid exposure, 43% had never taken any steroids, 
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44% had taken steroids in the past and 13% of patients were currently taking steroids. The 
average (range) current steroid daily dose was 7.9 (2.5 – 20) mg. Of the steroid users 63%, 
15% and 23% were taking average daily doses of ≤ 7.5 mg, 10 mg and ≥ 15 mg, respectively.  
 
Based on their mean BMI, both females and males were categorised as overweight (BMI > 
25), with a full breakdown of body composition of the RA patients shown in Table 4.2. In 
fact, 68% of the RA patients were over fat or obese according to their body fat percent and 
the prevalence of being overweight or obese was much higher in female RA patients (75%) 
than in males (52%).   
 
  
Table 4.2 Body composition of RA patients.  
Patient characteristic Total (n = 100) Females (n = 69) Males (n = 31) 
Weight (kg) 74.5 ± 15.9 71.50 ± 15.0 79.8 ± 15.8 
BMI (kg·m-2) 
BMI < 25 (%) 
BMI 25-< 30 (%) 
BMI > 30 (%) 
27.9 ± 5.7 
39 
34 
27 
28.2 ± 6.0 
39 
30.5 
30.5 
27.1 ± 5.1 
39 
42 
19 
Body Fat (%) 
Body fat normal (%) 
Body fat overfat (%) 
Body fat obese (%) 
37.5 ± 14.5 
32 
22 
46 
43.6 ± 12.9 
25 
17 
58 
24.2 ± 7.2 
48 
32 
20 
Waist (cm) 91.2 ± 13.2 87.5 ± 11.8 97.6 ± 11.6 
Hip (cm) 100.7 ± 11.3 100.9 ± 12.4 100.1 ± 8.6 
Waist:Hip .90 ±  .07 .87 ± .05 .97 ± .05 
Values are mean ± SD or percentage of patients (%), N = 100. BMI; body mass index.   
 
 
Overall the traditional cardiovascular risk factors and associated physiological variables were 
found to be within normal ranges (described in section 1.2.1.1). However, on the day of the 
assessment 66% of patients were found to be hypertensive and 69% of patients had 
dyslipidemia (Table 4.3).   
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Table 4.3 Cardiovascular risk factors (CVD) of RA patients.  
Patient Characteristic  Mean or % SD 
Hypertensive (%)* 66  
SBP (mmHg) 139.6 20.8 
DBP (mmHg) 80.9 11.6 
Anti hypertensive medication (%) 32†  
Dyslipidemia (%)* 69  
TC (mmol·l-1) 5.2 1.1 
TG (mmol·l-1) 1.5 0.8 
LDL-c (mmol·l-1) 3.1 1.0 
HDL-c (mmol·l-1) 1.5 0.5 
TC/HDL ratio 3.8 1.8 
Anti hyperlipidemia medication (%) 28#  
Diabetics (%) 8  
Glucose (mmol·l-1) 5.2 1.0 
Smoking status   
Current smoker (%) 23  
Ex Smoker (%) 46  
Family history CVD (%) 27  
Values are mean ± SD or percentage of patients (%), N = 100. SBP; systolic blood pressure, DBP; diastolic 
blood pressure, TC; total cholesterol, TG; triglycerides, LDL-c; low density lipoprotein, HDL-c; high density 
lipoprotein, MetS; metabolic syndrome.*Hypertensive; SBP > 140 mmHg, DBP > 90 mmHg or on medication, 
Dyslipidemia; High TC > 5.2, LDL-c > 3.4, TG > 1.8 or on medication. † Central alpha agonist (n=1), Diuretic 
(n=5), Calcium antagonist (n=8), Ace inhibitor (n=18). #Statin (n=27), Fibrate (n=1).  
 
 
Using some of the above physiological measures (e.g. blood pressure, TC, BMI), global CVD 
risk scores were calculated. The Framingham 10 year CVD risk was moderate for females (> 
10%) and high for males (> 20%). The QRISK2 reported an even higher average 10 year 
CVD risk (19.8%) which was also moderate for females and high for males. Forty-one 
percent of RA patients were classified as having MetS based on the clustering of risk factors 
(see section 2.2.2.5). See Table 4.4 for global CVD risk score data.  
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Table 4.4 Global CVD risk scores in patients with RA.  
Patient Characteristic  Mean or % SD 
Framingham 10 year risk (percent) 15.9 10.4 
Framingham risk – females (percent) 11.8 7.1 
Framingham risk – males (percent) 26.1 10.0 
QRISK2 (percent) 19.8 13.5 
QRISK2 – females (percent) 14.9 10.2 
QRISK2 – males (percent) 30.9 13.7 
Metabolic syndrome (NCEP) (%) 41  
Values are mean ± SD, N = 100. NCEP; national cholesterol education programme.  
 
4.3.1 Fitness  
 
Of the 100 RA patients, 65% were able to complete the step test. Their cardio-respiratory 
fitness was predicted using age, gender, weight and their exercise heart rate. Further details of 
the patients unable to complete the step test are provided in section 4.3.2. Total predicted 
fitness (n=65) was 22.0 ± 5.9 ml·kg-1·min-1 and was 20.3 ± 4.8 ml·kg-1·min-1 and 26.3 ± 6.2  
ml·kg-1·min-1 for females and males, respectively (Figure 4.1). Results from the International 
Physical Activity Questionnaire (IPAQ) showed that 55% of patients were classed as 
inactive, 35% were moderately active with only 10% of patients self reporting a high level of 
physical activity.   
 
 
Figure 4.1 Predicted VO2 max (ml·kg-1·min-1) for female and male RA patients (N = 65). Values 
are mean ± SD.  
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The association between cardio-respiratory fitness and the other variables measured; RA 
related factors, body composition and CVD risk factors are analysed below (see Tables 4.5-
4.7).  
 
4.3.1.1 RA Factors 
 
In relation to the RA disease related factors cardio-respiratory fitness correlated significantly 
with HAQ scores, with better cardio-respiratory fitness associated with less reported 
disability. Cardio-respiratory fitness did not correlate with the other RA disease related 
factors when controlling for age and gender (see Table 4.5).  
 
Table 4.5 Associations between cardio-respiratory fitness and RA disease related factors.  
RA Characteristic Correlation P 
Disease Duration (years) 0.027 0.909 
ESR (mm·hr-1) -0.039 0.871 
CRP (mg·l-1) -0.065 0.609 
Tender Joints (n) 0.017 0.892 
Swollen Joints (n) 0.091 0.473 
DAS 28 ESR -0.072 0.763 
DAS 28 CRP -0.100 0.674 
VAS arthritis (0-100) 0.112 0.640 
Pain (0-100) 0.006 0.981 
HAQ (0-3) -0.255 0.040* 
Values are Pearson’s or Spearman’s correlations controlling for age and gender, N = 65. 
ESR; erythrocyte sedimentation rate, CRP; C-reactive protein, CCP; cyclic citrullinated peptide, DAS; disease 
activity score, VAS; visual analogue scale, HAQ; health assessment questionnaire.  
 
 
 
4.3.1.2 Body Composition  
 
Cardio-respiratory fitness correlated significantly with all measures of body composition 
(weight, BMI, body fat percent, waist circumference, hip circumference and waist:hip) when 
adjusting for age and gender (see Table 4.6). Waist circumference was strongly associated 
with level of cardio-respiratory fitness, whilst wasit:hip was poorly associated with level of 
cardio-respiratory fitness.  
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Table 4.6 Associations between cardio-respiratory fitness and body composition.  
Body Composition Correlation P 
Weight (kg) -0.641 0.000* 
BMI (kg·m-2) -0.614 0.000* 
Body fat percent (%) -0.481 0.000* 
Waist (cm) -0.651 0.000* 
Hip (cm) -0.584 0.000* 
Waist: Hip -0.254 0.045* 
Values are Pearson’s correlations controlling for age and gender, N = 65. BMI; body mass index  
 
 
Cardio-respiratory fitness was 24% lower in patients who were obese (using percent body fat) 
compared to patients who were not obese (19.1 ± 4.9 ml·kg-1·min-1 versus 23.7 ± 5.8 ml·kg-
1·min-1, p = 0.002). Using ANCOVA, with age, gender and disease duration as covariates, 
obesity remained a significant and independent predictor of cardio-respiratory fitness (F 1, 60 = 
8.3; p < 0.01).  
 
4.3.1.3 CVD Risk Factors  
 
Cardio-respiratory fitness correlated significantly with diastolic blood pressure and 
triglycerides but did not correlate with the other CVD risk factors or Global CVD risk scores 
(see Table 4.7).  
 
Table 4.7 Associations between cardio-respiratory fitness and CVD risk factors.  
CVD Risk Factors  Correlation P 
SBP (mmHg) -0.054 0.675 
DBP (mmHg) -0.344 0.006* 
TC (mmol·l-1) -0.163 0.285 
TG (mmol·l-1) -0.270 0.043* 
LDL-c (mmol·l-1) -0.045 0.747 
HDL-c (mmol·l-1) 0.024 0.874 
Glucose (mmol·l-1) -0.228 0.115 
Global CVD Risk Score 
  
Framingham risk (%) -0.067 0.662 
QRISK2 (%) -0.165 0.278 
Values are Pearson’s or Spearman’s correlations controlling for age and gender, N = 65. SBP; systolic blood 
pressure, DBP; diastolic blood pressure, TC; total cholesterol, TG; triglycerides, LDL-c; low density 
lipoprotein, HDL-c; high density lipoprotein. 
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There was also no significant association between cardio-respiratory fitness and family 
history of heart disease (OR = 1.06, 95% CI = 0.96-1.17; p = 0.275), diabetes (OR = 1.07, 
95% CI = 0.93-1.24; p = 0.321), hypertension (medication or high blood pressure) (OR = 
1.08, 95% CI = 0.98-1.18; p = 0.112), dyslipidemia (medication or high cholesterol) (OR = 
1.08, 95% CI = 0.98-1.19;  p = 0.105), smoking status (OR = 0.94, 95% CI = 0.86-1.04; p = 
0.212), metabolic syndrome (OR = 1.07, 95% CI = 0.97-1.18; p = 0.172) or number of CVD 
risk factors (OR = 0.96, 95% CI = 0.87-1.07; p = 0.479). 
 
Based on the above associations hierarchical multiple regression was used to assess the 
ability of two measures (body fat percent, HAQ) to predict level of cardio-respiratory fitness. 
HAQ was entered at step 1, explaining 3.7% of the variance in fitness levels (R square 
change 0.037). After entry of body fat percent at step 2 the total variance explained by the 
model as a whole was 30.2% (F (2,62) = 13.43, p < 0.001). Body fat percent explained an 
additional 26.6% of the variance in fitness, after controlling for HAQ, R square change 0.266, 
(F (1,62) = 23.59, p < 0.001). In the final model, only body fat percent was a significant 
predictor of cardio-respiratory fitness (beta -0.53, p < 0.001). 
 
4.3.2 “Step Ability” 
 
Of the 35 RA patients that were unable to complete the step test, 66% were female and 34% 
were male. The reasons given by the participants that were unable to complete the step test 
were 88% pain (in the hip, knee, ankle/foot), 31% unbalanced/weakness and 23% 
breathlessness. In order to analyse this population in more detail a comparison of the ‘Unable 
group’ was made with those patients who were ‘able’ to complete the step test. Differences 
between females and males were also analysed (full description of gender specific results are 
detailed in Appendix 7). The pertinent findings are outlined below.  
 
4.3.2.1 RA factors 
 
Differences in RA disease variables between the two step ability groups were analysed. 
Patients unable to complete the step test rated their arthritis as worse, more painful and 
disabling than those that were able to complete the step test. VAS arthritis (F (1, 96) = 23.4, 
p = 0.000, partial eta squared = 0.19), pain (F (1, 96) = 10.4, p = 0.002, partial eta squared = 
0.10) and HAQ (F (1, 96) = 36.4, p = 0.000, partial eta squared = 0.28) were the only 
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variables to reach significance, using a Bonferroni adjusted alpha level of 0.005 between the 
two groups (see Table 4.8). Similar results were observed for the female RA patients. 
However, no differences in RA disease related factors were observed between males who 
were able or unable to complete the step test (see Appendix 7).  
 
 
Table 4.8 RA characteristics of unable and able patients.  
 RA Characteristic  
Unable                   
(n = 35) 
Able                   
(n = 65) 
P 
  
Age (years) 62.2 ± 8.4 58.2 ± 10.9 0.062 
 Disease duration (years) 11.0 ± 10.5 10.1 ± 8.4 0.665 
 ESR (mm·hr-1) 19.9 ± 13.4 14.1 ± 11.9 0.017 
 CRP (mg·l-1) 17.9 ± 21.6 8.8 ± 14.8 0.010 
 Tender joints (n) 1.8 ± 3.1 2.1 ± 4.5 0.823 
 Swollen joints (n) 0.6 ± 1.6 0.8 ± 2.3 0.792 
 VAS arthritis (0-100) 46.4 ± 24.1 24.3 ± 19.9 0.000* 
 Pain (0-100) 34.9 ± 31.5 16.8 ± 23.4 0.002* 
 DAS 28 ESR 3.1 ± 1.2 2.5 ± 1.5 0.022 
 DAS 28 CRP 3.0 ± 1.1 2.6 ± 1.2 0.041 
 HAQ (0-3) 1.5 ± 0.7 0.6 ± 0.6 0.000* 
 *Significant at Bonferroni adjusted alpha level of P < 0.005, Values are mean ± SD, N = 100. ESR; erythrocyte 
sedimentation rate, CRP; C-reactive protein, CCP; cyclic citrullinated peptide, DAS; disease activity score, 
VAS; visual analogue scale, HAQ; health assessment questionnaire. 
 
 
  
To determine the impact of RA factors on the likelihood that patients would not complete the 
step test, binary logistic regression analysis was performed. The model contained 10 
independent variables (age, gender, disease duration, ESR, CRP, VAS arthritis, pain, HAQ, 
tender joints, swollen joints). The model explained between 40.5% and 56.2% of the variance 
in step ability, and correctly classified 84.7% of cases. Only 3 independent variables made a 
unique significant contribution to the model. HAQ (OR = 5.65, 95% CI = 1.75-18.21; p = 
0.004), VAS arthritis (OR = 1.04, 95% CI = 1.00-1.08; p = 0.050) and Tender joints (OR = 
0.79, 95% CI = 0.64-0.98; p = 0.033). The strongest predictor of being able to complete the 
step test was the HAQ score. 
 
Step ability was not associated with DMARD group (methotrexate, other DMARD, biologic) 
(χ2 (2, n = 100) = 2.05, p = 0.358, phi = 0.14), CRP group (CRP < 5 or CRP > 5) (χ2 (1, n = 
100) = 3.03, p = 0.082, phi = 0.17), steroid exposure (χ2 (2, n = 100) = 0.35, p = 0.554, phi = 
-0.09), presence of rheumatoid factor (χ2 (4, n = 100) = 4.36, p = 0.113, phi = 2.09) or CCP 
positivity (χ2 (4, n = 100) = 5.26, p = 0.072, phi = 0.23).  
70 
 
4.3.2.2 Body Composition 
 
All body composition variables except weight were observed to be different between the two 
step ability groups when using a Bonferroni adjusted alpha level of 0.008 (adjusting for age 
and gender); Weight (F (1, 95) = 7.0, p = 0.009, partial eta squared = 0.07), BMI (F (1, 95) = 
15.4, p = 0.000, partial eta squared = 0.14), body fat percent (F (1, 95) = 12.0, p = 0.001, 
partial eta squared = 0.11), waist circumference (F (1, 95) = 15.7, p = 0.000, partial eta 
squared = 0.14), hip circumference (F (1, 95) = 8.7, p = 0.004, partial eta squared = 0.08) 
and waist:hip (F (1, 95) = 9.5, p = 0.003, partial eta squared = 0.09). Inspection of the mean 
scores indicated that patients unable to complete the step test had a less favourable body 
composition (see Table 4.9 below). When examining the groups according to gender, male 
RA patients showed no difference in body composition (See Appendix 7).  
 
 
Table 4.9 Body composition of unable and able patients.  
Body Composition 
Unable                   
(n = 35) 
Able 
(n = 65) 
P 
Weight (kg) 79.10 ± 18.23 71.50 ± 13.60 0.009 
BMI (kg·m-2) 30.40 ± 6.60 26.29 ± 4.17 0.000* 
Body Fat (%) 41.91 ± 17.60 35.30 ± 12.10 0.001* 
Waist (cm) 97.20 ± 13.13 87.44 ± 11.12 0.000* 
Hip (cm) 104.52 ± 12.14 98.06 ± 9.05 0.004* 
Waist:Hip 0.92 ± 0.07 0.88 ± 0.06 0.003* 
*Significant at Bonferroni adjusted alpha level of P < 0.008. Values are mean ± SD, N = 100, BMI; body mass 
index.  
 
 
To determine the impact of body composition variables on the likelihood that patients would 
not complete the step test binary logistic regression analysis was performed. The model 
contained 5 independent variables (weight, BMI, waist, hip and body fat percent). The model 
explained between 24.6% and 34% of the variance in step ability, and correctly classified 
74.7% of cases. Only 3 independent variables made a unique significant contribution to the 
model, BMI (OR = 1.48, 95% CI = 1.05-2.09; p = 0.024), waist circumference (OR = 1.45, 
95% CI = 1.03-1.27; p = 0.012) and weight (OR = 0.86, 95% CI = 0.78-0.95; p = 0.003). The 
strongest predictor was BMI.    
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Patients unable to complete the step test had a greater prevalence of obesity. Step ability was 
associated with BMI category (χ2 (2, n = 100) = 10.69, p = 0.005, phi = 0.33) and body fat 
percentage category (χ2 (2, n = 100) = 6.66, p = 0.036, phi = 0.26).  
 
 
4.3.2.3 CVD Risk Factors 
 
There were no significant differences in CVD risk factors (SBP, DBP, fasting lipids and 
glucose) between the two groups (F (10, 59) = 1.6, p = 0.116) as shown in Table 4.10. No 
differences were observed when the same investigation was carried out in female and male 
RA patients (See Appendix 7). 
 
 
Table 4.10 CVD risk factors and global CVD risk scores of unable and able patients.  
 CVD Risk Factors Unable (n = 35) Able (n = 65) P 
SBP (mmHg) 145.17 ± 22.78 138.34  ± 19.42 0.196 
DBP (mmHg) 82.04  ± 9.05 81.11  ± 11.79 0.738 
TC (mmol·l-1) 5.12  ± 1.24 5.40  ± 1.15 0.356 
TG (mmol·l-1) 1.76  ± 0.83 1.41  ± 0.71 0.076 
LDL-c (mmol·l-1) 2.99  ± 1.11 3.21  ± 1.05 0.417 
HDL-c (mmol·l-1) 1.31  ± 0.37 1.56  ± 0.45 0.025 
Glucose (mmol·l-1) 5.58  ± 1.41 5.16  ± 0.77 0.113 
Global CVD Risk Score 
   Framingham Risk (%) 21.28  ± 12.52 13.99  ± 9.35 0.008 
QRISK2 (%) 23.97  ± 13.92 17.64  ± 13.90 0.078 
Values are mean ± SD, N = 100. SBP; systolic blood pressure, DBP; diastolic blood pressure, TC; total 
cholesterol, TG; triglycerides, LDL-c; low density lipoprotein, HDL-c; high density lipoprotein.  
 
 
However, step ability was associated with Framingham risk score category (low, mod, high 
risk) (χ2 (2, n = 100) = 6.47, p = 0.039, phi = 0.27). There was no significant association 
between step ability and presence of hypertension (medication or high blood pressure) (χ2 (1, 
n = 100) = 0.87, p = 0.768, phi = -0.17), dyslipidemia (medication or high cholesterol) (χ2 (1, 
n = 100) = 2.26, p = 0.132, phi = 0.05), smoking status (χ2 (2, n = 100) = 4.25, p = 0.119, phi 
= 0.21), metabolic syndrome (χ2 (1, n = 100) = 2.42, p = 0.120, phi = 0.16), number of risk 
factors (χ2 (5, n = 100) = 3.43, p = 0.634, phi = 0.19) or family history of heart disease (χ2 (1, 
n = 100) = 0.067, p = 0.795, phi = -0.03).  
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To determine what factors best predict step ability in RA patients a discriminant function 
analysis was conducted. Predictor variables were selected from each of the above categories 
(RA related factors, body composition and CVD risk factors). The variables included in the 
analysis were age, CRP, HAQ, VAS arthritis, waist circumference, BMI, and Framingham 
CVD risk score. Significant mean differences were observed for all the predictors on the 
dependent variable except age. While the log determinants were quite similar, Box’s M 
indicated that the assumption of equality of covariance matrices was violated. However, 
given the large sample size, this problem was not regarded as serious. The discriminate 
function revealed a significant association between groups and all predictors, accounting for 
41.5% of between group variability, although closer analysis of the structure matrix revealed 
four significant predictors, namely HAQ (0.704), waist circumference (0.565), VAS 
arthritis (0.548) and BMI (0.543). Age and CRP were poor predictors. The cross validated 
classification showed that overall 80.9% were correctly classified. 
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4.4 Discussion 
 
This cross sectional study aimed to identify a possible relationship between cardio-respiratory 
fitness and CVD risk factors, RA disease variables and body composition in a typical RA 
population attending a routine clinic. One observation of this study was the very low cardio-
respiratory fitness levels of RA patients; they had an average predicted fitness of 22 ml·kg-
1·min-1 as assessed by the step test. This value was similar to that reported by previous RA 
studies (Minor and Hewett, 1995, Strombeck et al., 2007). However, the primary observation 
of this study was that despite the poor cardio-respiratory fitness in this current group there 
was no association with any of the RA disease activity variables, only self reported disability 
(HAQ) and two of the CVD risk factors, diastolic blood pressure and triglycerides. Cardio-
respiratory fitness was however, associated with all measures of body composition with 
central adiposity (waist circumference) being the greatest predictor of poor cardio-respiratory 
fitness.  
 
The second striking result of the current study is that 35% of patients were unable to 
complete the step test; these patients terminated the test before the end of the three minute 
stage. Despite these RA patients not being able to complete the step test and therefore not 
allowing an estimation of their cardio-respiratory fitness they have provided some significant 
findings which will be discussed further in this chapter.  
 
It may seem surprising that cardio-respiratory fitness in the current study failed to correlate 
with many of the traditional CVD risk factors that have been suggested to exist in previous 
studies in healthy populations (Carnethon et al., 2003, Gibbons et al., 1983, Sallis et al., 
1988). One explanation for lack of association in the current study may be the poor range in 
cardio-respiratory fitness level in this RA population. Eighty percent of RA patients had a 
poor cardio-respiratory fitness level. Values above 28 ml·kg-1·min-1 represent a good cardio-
respiratory fitness level for this age group and one that has been shown to provide a cardio-
protective effect (Kodama et al., 2009). However, few RA patients possessed a good cardio-
respiratory fitness level and could therefore explain why some expected associations were not 
observed. Another explanation could be that a third of RA patients were receiving medication 
to lower CVD risk either by taking anti hypertensive and/or anti hyperlipidemia medication.    
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Despite few associations between cardio-respiratory fitness and traditional CVD risk factors, 
cardio-respiratory fitness was strongly associated with body composition. Overall, patients 
who were less fit had a less favourable body composition. They were heavier, fatter and had a 
bigger waist and hips. It must be noted however, that this strong association is partly due to 
measures of body composition (weight) being included in the calculation of cardio-
respiratory fitness. However, despite this these results remain consistent with previous 
findings (Fogelholm et al., 2006, Wong et al., 2004).  
 
In order to determine why some RA patients were unable to complete the step a comparison 
was made between this group and patients who were able to complete the step test. ‘Unable’ 
patients rated their arthritis as worse (VAS arthritis), more painful and disabling (HAQ). 
Upon examination of the mean scores patients unable to complete the step were on average 
four years older and inflammation (ESR, CRP) and disease activity (DAS 28) were slightly 
higher. These differences would also have been significant if the data was analysed using 
univariate analysis only. However, further analysis was performed to determine the impact of 
all RA disease variables on step ability. Results showed that HAQ and VAS arthritis were the 
greatest predictors of step ability. Age, gender, disease duration, disease activity and 
inflammation did not have a significant impact on the RA patients step ability. This suggests 
that RA disease itself is not the primary reason that some patients are unable to complete the 
step test and that it is more likely to be due to patients’ perception of their disease and 
physical ability. It must also be noted that RA patients rated their arthritis (VAS arthritis) and 
pain whilst in the presence of their rheumatologist/nurse specialist before being approached 
by the researcher and being asked to complete the step test. A supplementary investigation 
that does not feature in the main text of this thesis but can be seen in Appendix 8 provides an 
alternative insight as to why some RA patients experience more physical limitations when 
RA disease activity is not the primary reason. Ankle brachial pressure index (ABPI), a 
measure of peripheral vascular disease was also measured in this cross sectional study. The 
majority (98%) of RA patients had a normal ABPI (> 0.9). However, RA patients unable to 
complete the step test had a significantly lower ABPI than patients who were able to 
complete the step test. A lower ABPI was also associated with higher HAQ scores. Perhaps 
patients who have a lower ABPI, which is not clinically diagnosed as peripheral vascular 
disease, experience symptoms of a vascular occlusion when performing physical tasks. This 
is an interesting observation. However, further research and additional clinical investigations 
are needed to confirm these speculations (see Appendix 8 for further details).  
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As well as perception of arthritis, physical ability and a lower ABPI, body composition had a 
major influence on step ability, especially in female RA patients. ‘Unable’ patients were 
heavier, fatter, had bigger waists and hips and had a greater prevalence of obesity. Further 
analysis of body composition variables showed that BMI was the greatest predictor of step 
ability. Despite the major differences in body composition there was no significant difference 
in CVD risk factors between ‘unable’ and ‘able’ patients. This is not surprising considering 
there were no differences in the use of anti-hypertensive or anti-hyperlipidemia medication 
between the two groups. However, ‘Unable’ patients did have a greater prevalence of having 
a high Framingham Risk score and high Qrisk2 score (> 20% risk). This could be partially 
explained by the fact that unable patients were on average four years older but perhaps this 
could also be due to the accumulated effects of individual risk factors.    
 
Discriminant function analysis confirmed the findings of the study. Patients who rated 
themselves as having more disability (HAQ), worse arthritis (VAS arthritis), those who had 
bigger waists and higher BMI were more likely to be unable to complete the step test.  
Surprisingly, disease activity, inflammation and age did not determine step ability in RA 
patients. These results verify the detrimental effects of obesity on function and perceived 
disability that is not explained by RA disease itself. There was no association between 
physical activity from the IPAQ questionnaire and cardio-respiratory fitness or step ability. 
Thus patients who were unable to complete the step test did not rate their levels of physical 
activity any differently to patients who were able to complete the step test. This perhaps 
highlights the limitations to using such a measure of self reported physical activity (Walsh et 
al., 2004). This finding is very interesting considering previous studies that have shown 
physical inactivity in RA, as measured by physical activity questionnaires was associated 
with a worse cardiovascular risk factor profile (Metsios et al., 2009), older age, obesity, more 
disability (HAQ), pain, disease activity and fatigue (Sokka and Hakkinen, 2008).  
 
Because RA is associated with increased mortality from CVD caused largely by accelerated 
atherosclerosis, the main focus of research carried out to date have been on systemic 
inflammation and its effects (Sattar et al., 2003). Less attention has been focused on the more 
traditional, modifiable risk factors of CVD because it is believed these risk factors do not 
sufficiently explain the increased mortality in RA (Del Rincon et al., 2001). Despite this, 
these risk factors are modifiable and so represent an identifiable target for intervention that 
should not be ignored (Metsios et al., 2008). The results of the present study support this 
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statement. When assessing the averages for the total group the individual CVD risk factors do 
not seem obviously elevated and are very similar to the results reported by Metsios et al. 
(Metsios et al., 2009). However, when taking into consideration patients who were receiving 
anti-hypertensive treatment and those with a high blood pressure at the time of assessment a 
very large percentage of patients were hypertensive (66%). The prevalence of hypertension 
observed in this study is very similar to that reported by Panoulas et al. (Panoulas et al., 2007) 
who found that 70.5% of RA patients were hypertensive. These results suggest that the 
prevalence of hypertension observed in RA patients is significantly higher than that reported 
for the general population in which 48% of adults aged between 55-64 years are believed to 
be hypertensive (HSE, 2010). In the present study there was a similar trend for patients with 
dyslipidemia (69%). These results show that in the current study 34% of patients were not 
being treated for hypertension while 41% of patients were not being treated for having 
abnormal lipids. Another important finding is that 41% of patients were classified as having 
metabolic syndrome. Uncontrolled blood pressure, dyslipidemia, metabolic syndrome along 
with poor cardio-respiratory fitness, physical inactivity and the level of obesity highlights the 
importance of these risk factors. It also suggests that the EULAR message about careful 
screening for and the management of CVD risk factors in RA is generally being overlooked 
(Peters et al., 2010), as the rate of potential underdiagnosed hypertension and dyslipidemia 
remains very high in the current and other RA populations (Panoulas et al., 2007).  
 
Cardiovascular co-morbidity and mortality are increased in RA (Bacon and Townend, 2001). 
Although not assessing cardiovascular events the results of the present study do highlight that 
the level of poor cardio-respiratory fitness, high physical inactivity, and obesity are a cause 
for concern in this population. All of these measures are risk factors for CVD in their own 
right but more importantly they are modifiable. Obesity seems to have a considerable impact 
on how RA patients, especially females, rate their disability and the severity of their arthritis, 
which is not fully explained by markers of inflammation or disease activity. The impact of 
obesity in the current RA group is discussed further in the next chapter. 
 
The strengths and weaknesses of this study warrant comment. The cross sectional nature of 
this study means that no conclusions can be made on the potential cause and effect of cardio-
respiratory fitness, CVD risk factors and the future cardiovascular health of RA patients. 
Because all measures are assessed at one time point this study can determine prevalence of 
disease (e.g. hypertension), however, this can also result in overestimation. Despite 
77 
 
limitations to cross sectional studies, this investigation benefits from a large sample size, in 
which participants were selected at random within a real life clinical setting. Thus, the results 
of the present study are likely representative of the general RA population.    
 
4.5 Conclusion 
 
Overall the current RA patients had very poor cardio-respiratory fitness that was below 
average when compared to the general population. This poor cardio-respiratory fitness was 
not associated with rheumatoid disease or traditional CVD risk factors in general. However, 
body composition was a major determinant. Reported measures of worse arthritis, pain and 
self reported disability (HAQ) prevented one third of RA patients from completing the step 
test, not the disease itself. It is important to note that all of these major contributing factors to 
step ability were subjective measures. Patients unable to complete the step test, in particular 
the female RA patients, also had significantly worse body composition, they were heavier, 
fatter, had bigger waists and hips and a greater prevalence of obesity. BMI, waist and weight 
seemed to have the greatest influence of all body composition variables on determining step 
ability. Being unfit and the level of obesity observed in this RA population warrants 
consideration as a risk factor, distinctly from inactivity, and worthy of screening and 
intervention. Thus, the level of obesity observed and its impact on patients with RA requires 
further analysis. This is discussed in length in Chapter 5.  
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5  Chapter 5:  
 
Impact of obesity on patients with rheumatoid arthritis 
 
 
5.1 Introduction  
 
Like poor cardio-respiratory fitness, obesity is also an independent risk factor for CVD 
(Lavie et al., 2009), yet very few studies have directed their focus on obesity in the RA 
population. Body weight is often routinely assessed when RA patients attend rheumatology 
clinics. However, this is mainly used as a demographic characteristic reported in medical 
notes and is generally excluded from further interpretation (Stavropoulos-Kalinoglou et al., 
2011). Obesity seems to have a major impact on how RA patients perceive their arthritis and 
their physical function which was evident from the findings of Chapter 4. The aim of the 
current chapter was to investigate the association between measures of obesity and RA 
disease related factors and CVD risk factors and to establish any differences in RA patients 
who had a normal BMI, were overweight or obese.  
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5.2 Methods 
 
5.2.1 Protocol  
 
The same 100 RA patients investigated in Chapter 4 were studied in order to determine the 
impact of obesity in these patients. A full description of the methodology used has been given 
in Chapters 2 and 4.  
 
5.2.2 Statistical Analysis 
 
Pearson’s correlation coefficient (parametric), Spearman’s correlation coefficient (non 
parametric) and logistic regression were used to assess the association between measures of 
obesity (BMI, body fat percent and central adiposity) and RA disease factors and CVD risk 
factors and associated variables. The group of 100 RA patients were also split according to 
their BMI – normal (BMI < 25 kg·m-2), overweight (BMI 25 – 29.9 kg·m-2) and obese (BMI 
> 30 kg·m-2) (WHO, 2000). MANOVA was used to assess the differences between these 
BMI groups for RA disease variables and CVD risk factors. If MANOVA revealed a 
significant difference the dependent variables were considered separately using a Boneferroni 
adjusted alpha level (0.05/number of dependent variables). Where necessary post–hoc 
comparisons using the Tukey HSD test was performed. Chi squared analysis was used to 
assess the association between BMI groups and all other categorical variables – RA disease, 
CVD risk and physical activity. Statistical significance was set at p < 0.05 for all analyses 
unless stated otherwise. 
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5.3 Results  
 
100 RA patients (69% female) were included in this investigation and were categorised based 
on their individual BMI: normal BMI group (27 female, 12 male; mean ± SD age, 60.4 ± 10.7 
years), overweight group (21 female, 13 male; age, 59.2 ± 10.4 years) and obese group (21 
female, 6 male; age, 59.2 ± 9.3 years). The body composition of these RA patient groups are 
outlined in detail in Table 5.1. Individual measures of obesity worsened significantly with 
increasing BMI (F (12, 182) = 17.45, p = 0.000; Wilks’ Lambda = 0.216; partial eta squared 
= 0.53). Obese patients were on average 20 kg heavier and 20% fatter than the normal BMI 
group, even when considering that the obese patients were predominantly female.  
 
Table 5.1 Body composition of the BMI groups.  
 Body Composition 
Normal 
(n = 39) 
Overweight 
(n = 34) 
Obese 
(n = 27) 
P 
Weight (kg)  62.63 ± 9.16 72.92 ± 9.24 92.96 ± 12.28 0.000* 
BMI (kg·m-2)  23.01 ± 2.48 27.57 ± 1.40 34.93 ± 4.24 0.000* 
Body Fat (%)  29.03 ±10.84 36.06 ± 9.14 52.27 ± 14.11 0.000* 
Waist (cm)  81.15 ± 9.02 92.12 ± 8.48 103.54 ± 9.73 0.000* 
Hip (cm) 93.04 ± 7.03 98.74 ± 5.79 113.18 ± 7.99 0.000* 
Waist:Hip  0.87 ± 0.06 0.93 ± 0.07 .91 ± .07 0.001# 
Values are mean ± SD, N = 100. *Significant difference between all 3 groups, #significant difference between 
normal and the other two groups using a Boneferroni adjusted alpha level of P < 0.008, BMI; body mass index.    
 
A higher BMI was associated with less favourable subjective markers of RA disease, as per 
Chapter 4. Patients with a higher BMI reported worse arthritis (VAS arthritis), more pain and 
more disability (HAQ) than patients in the normal BMI category. There was no association 
between BMI and disease duration, inflammation or disease activity (p > 0.05). Similar 
results were obtained for body fat percent. However, central adiposity which was determined 
by waist circumference was also associated with CRP. This implies that accumulation of fat 
around the trunk is associated with higher levels of inflammation (CRP), see Table 5.2. BMI, 
body fat percent and waist circumference were positively associated with triglycerides. With 
only BMI and waist circumference also being associated with HDL-c, see Table 5.3. Body 
composition did not correlate with any of the CVD global risk scores, see Table 5.4. 
However, there was a significant association between BMI and metabolic syndrome (OR = 
1.15, 95% CI = 1.05-1.25; p = 0.002), central adiposity and metabolic syndrome (OR = 1.08, 
95% CI = 1.03-1.12; p = 0.000), but not for body fat percent and metabolic syndrome (OR = 
1.02, 95% CI = 1.00-1.05; p = 0.078).   
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Table 5.2 Associations between body composition indices (BMI, body fat percent and waist circumference) and RA disease variables.  
  Disease 
Duration 
ESR CRP 
Tender 
Joints 
Swollen 
Joints 
DAS 28 
ESR 
DAS 28 
CRP 
VAS 
arthritis 
Pain HAQ 
BMI 0.121 0.009 0.155 0.042 -0.07 0.129 0.103 0.237* 0.349** 0.273** 
Body Fat % 0.141 -0.124 -0.067 0.042 -0.101 0.067 0.067 0.178 0.281** 0.221* 
Waist 0.121 0.053 0.270** 0.095 -0.088 0.152 0.143 0.224* 0.286** 0.226* 
Values are Pearson’s or Spearman’s correlation’s, N = 100.*P < 0.05, **P < 0.01, BMI; body mass index, ESR; erythrocyte sedimentation rate, CRP; C-reactive protein, 
DAS; disease activity score, VAS; visual analogue scale, HAQ; health assessment questionnaire.   
 
 
Table 5.3 Associations between body composition indices (BMI, body fat percent and waist circumference) and CVD risk factors.  
  SBP DBP TC TG LDL-c HDL-c Glucose 
BMI 0.086 -0.058 -0.042 0.299** -0.039 -0.258* 0.168 
Body Fat % -0.045 -0.102 0.135 0.360** 0.08 -0.125 0.056 
Waist  0.07 -0.038 -0.083 0.319** -0.073 -0.304** 0.162 
Values are Pearson’s or Spearman’s correlation’s, N = 100. *P < 0.05, **P < 0.01,  BMI; body mass index, SBP; systolic blood pressure, DBP; diastolic blood pressure, TC; 
total cholesterol, TG; triglycerides, LDL-c; low density lipoprotein, HDL-c; high density lipoprotein.  
 
 
Table 5.4 Associations between body composition indices (BMI, body fat percent and waist circumference) and CVD global risk.  
  Framingham CVD  Risk QRISK2 CVD Risk 
BMI 0.098 0.06 
Body Fat % -0.026 -0.097 
Waist  0.084 0.111 
Values are Pearson’s correlation’s, N = 100.BMI; body mass index. 
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5.3.1 RA Factors 
 
There was no significant difference in RA disease related factors (age, disease duration, 
inflammation, disease activity, pain, HAQ) between the three BMI groups (F (22, 170) = 
1.15, p = 0.299). Reported pain and disability (HAQ) mean scores were higher in the obese 
patients than that of overweight or normal weight patients (see Table 5.5).   
 
Table 5.5 RA related factors of the BMI groups.  
 RA Characteristic  
Normal 
(n = 39) 
Overweight 
(n = 34) 
Obese 
(n = 27) 
P 
Age (years) 60.44 ± 10.65 59.24 ± 10.44 59.23 ±  9.30 0.852 
Disease duration (years) 10.58 ± 9.02 9.05 ± 7.01 11.69 ± 11.66 0.541 
ESR (mm·hr-1) 16.92 ± 14.76 15.27 ± 12.14 16.58 ± 10.58 0.856 
CRP (mg·l-1) 14.79 ± 24.01 10.79 ± 15.42 9.85 ± 8.25 0.490 
Tender joints (n) 1.74 ± 3.63 2.30 ± 5.15 2.15 ± 3.38 0.839 
Swollen joints (n) 1.08 ± 2.62 0.63 ± 1.88 0.38 ± 1.17 0.395 
VAS arthritis (0-100) 25.89 ± 21.10 35.30 ± 26.19 36.35 ± 24.00 0.134 
Pain (0-100) 15.15 ± 22.95 21.15 ± 25.65 36.73 ± 32.05 0.007 
DAS 28 ESR 2.61 ± 1.47 2.74 ± 1.46 2.92 ± 1.24 0.677 
DAS 28 CRP 2.67 ± 1.19 2.80 ± 1.21 2.86 ± 1.05 0.793 
HAQ (0-3) 0.65 ± 0.67 0.90 ± 0.70 1.18 ± 0.88 0.022 
Values are mean ± SD, N = 100. ESR; erythrocyte sedimentation rate, CRP; C-reactive protein, DAS; disease 
activity score, VAS; visual analogue scale, HAQ; health assessment questionnaire. 
 
 
BMI category was not associated with gender (χ2 (2, n = 100) = 1.81, p = 0.405, phi = 0.13), 
DMARD group (χ2 (4, n = 100) = 0.21, p = 0.995, phi = 0.05) or steroid exposure (χ2 (2, n = 
100) = 2.53, p = 0.282, phi = 0.16).  
 
5.3.2 CVD Risk Factors and Global CVD Risk Scores 
 
There was no difference in CVD risk factors or global CVD risk scores (blood pressure, 
fasting lipids, glucose, Framingham risk score or QRISK2) between the three groups, when 
controlling for gender (F (18, 116) = 0.79, p = 0.704) (see Table 5.6).  
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Table 5.6 CVD risk factors and Global CVD risk scores of the BMI groups 
CVD Risk Factors 
Normal 
(n = 39) 
Overweight 
(n = 34) 
Obese 
(n = 27) 
P 
SBP (mmHg) 135.50 ± 19.47 141.87 ± 19.91 141.76 ± 23.57 0.806 
DBP (mmHg) 80.27 ± 11.23 80.83 ± 9.27 83.48 ± 12.32 0.648 
TC (mmol·l-1) 5.43 ± 1.28 5.03 ± 0.98 5.45 ± 1.24 0.402 
TG (mmol·l-1) 1.34 ± 0.67 1.49 ±  0.62 1.80 ± 0.94 0.083 
LDL-c (mmol·l-1) 3.28 ± 1.09 2.94 ± 0.91 3.17 ± 1.19 0.503 
HDL-c (mmol·l-1) 1.56 ± 0.50 1.39 ± 0.34 1.46 ± 0.44 0.393 
Glucose (mmol·l-1) 5.27 ± 1.08 5.19 ± 0.76 5.47 ± 1.04 0.514 
Current smoker (n) 11 8 4 ----- 
Global CVD Risk Scores 
  
  
Framingham risk (percent) 16.38 ± 11.65 15.36 ± 8.95 16.00 ± 10.49 0.596 
QRISK2 (percent)  20.43 ± 14.61 19.27 ±  13.38 19.70 ± 12.48 0.706 
Metabolic syndrome (n) 10 16 15 ----- 
Values are mean ± SD, N = 100. SBP; systolic blood pressure, DBP; diastolic blood pressure, TC; total 
cholesterol, TG; triglycerides, LDL-c; low density lipoprotein, HDL-c; high density lipoprotein.   
 
 
 
As shown in Table 5.6 the prevalence of metabolic syndrome increased with increasing BMI 
and thus BMI category was significantly associated with metabolic syndrome (χ2 (2, n = 100) 
= 6.68, p = 0.035, phi = 0.26). However, there was no association between BMI category and 
smoking status (χ2 (4, n = 100) = 6.34, p = 0.175, phi = 0.25), dyslipidemia (on medication or 
abnormal lipids) (χ2 (2, n = 100) = 1.93, p = 0.382, phi = 0.14) or hypertension (on 
medication or high blood pressure) (χ2 (2, n = 100) = 2.29, p = 0.319, phi = 0.15), family 
history of heart disease (χ2 (2, n = 100) = 0.51, p = 0.777, phi = 0.07) or number of CVD risk 
factors (χ2 (2, n = 100) = 0.51, p = 0.777, phi = 0.71).    
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5.3.3 Cardio-respiratory Fitness and “Step Ability” 
 
There was no difference in cardio-respiratory fitness between the three BMI groups (p = 
0.177). Measured cardio-respiratory fitness for normal, overweight and obese RA patients 
was 22.9 ± 6.4 ml·kg-1·min-1, 22.1 ± 6.1 ml·kg-1·min-1 and 19.13 ± 2.8 ml·kg-1·min-1, 
respectively (see Figure 5.1).  
 
 
 
Figure 5.1 Fitness level of the BMI groups, Values are mean ± SD, N = 65. 
 
 
 
There was however, a significant association between BMI category and step ability group 
(χ2 (2, n = 100) = 10.69, p = 0.005, phi = 0.33). The majority of RA patients who were obese 
were unable to complete the step, whereas the majority of RA patients with a normal BMI 
were able to complete the step test (Figure 5.2). 
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Figure 5.2 BMI category of RA patients ‘able’ and ‘unable’ to complete the step, N = 100.  
 
 
There was no association between BMI category and physical activity category (χ2 (4, n = 
100) = 2.09, p = 0.719, phi = 0.15) (Figure 5.3). MET min·week-1 for the three BMI groups 
were as follows: normal (1633 ± 2666 MET min·week-1), overweight (1119 ± 1680 MET 
min·week-1) and obese (1214 ± 2639 MET min·week-1). There was no difference in reported 
MET min·week-1 between the three BMI groups (p = 0.617). 
 
 
5.3.4 Physical Activity  
 
 
Figure 5.3 Reported physical activity and BMI category of RA patients, N = 100.   
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5.4 Discussion  
  
This is the first study of its kind to include a measurement of cardio-respiratory fitness when 
examining the impact obesity has on RA patients. In the present study it was observed that a 
less favourable body composition was associated with worse arthritis, more pain and more 
disability. CRP was also elevated in RA patients who had a bigger waist circumference. 
When examining the differences between the BMI groups, RA patients that were obese 
tended to report more pain and disability compared to their normal weight counterparts. 
However, body composition was not associated with disease duration, inflammation or 
disease activity and these were not significantly different when examining the three BMI 
groups. Body composition was however, associated with high levels of triglycerides, low 
HDL-c and presence of metabolic syndrome but not with other CVD risk factors, or global 
CVD risk scores.  
 
As expected from the results of the previous chapter (Chapter 4), RA patients who were 
obese were less likely to complete the step test. The purpose of the separate analyses 
presented in this chapter was to determine whether patients to complete the step test were 
limited by disease and/or body composition factors. The current analysis found that greater 
adiposity was associated with worse reported arthritis, more pain and more disability. Disease 
duration, ESR and disease activity were not significantly associated with body composition 
and did not differ between the three BMI groups. However, on this occasion central adiposity 
measured by waist circumference was associated with higher levels of CRP. This association 
helps to answer the above question and suggests that the inflammation (CRP) observed in this 
RA population is elevated because of excess adiposity and not necessarily because of 
increased disease activity (Festa et al., 2001). This finding is supported by Santos et al. 
(2005) who found that central obesity was a major contributing feature of high CRP and 
metabolic syndrome (Santos et al., 2005). A study by Fontana et al. (2007) helps explain this 
link; this group of researchers examined abdominal visceral fat by sampling blood from the 
hepatic portal vein of obese patients undergoing gastric bypass surgery. They found that 
abdominal visceral fat was secreting very high levels of interleukin-6 (IL-6) into portal vein 
blood. This increased level of IL-6 was in turn strongly correlated with increased levels of 
CRP (Fontana et al., 2007).   
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Body composition was also found to be associated with some measures of CVD risk in the 
present study. More specifically, a higher BMI and greater central adiposity were 
significantly associated with higher triglycerides and lower HDL-c. Similar associations were 
observed in women with the metabolic syndrome (Pimentel et al., 2010). Interestingly, 
despite these associations between markers of obesity and some CVD risk factors, there was 
no difference found in the other traditional CVD risk factors or global CVD risk scores 
between the three BMI groups in the current study. Obese patients did however have an 
increased prevalence of the metabolic syndrome, which is an established risk factor for CVD 
(Galassi et al., 2006). The obvious explanation for this is that both triglycerides and HDL-c 
are included in the criteria for the determination of metabolic syndrome and so it is 
unsurprising that BMI is associated with these specific CVD variables and not others such as 
total cholesterol or LDL-c. These results are very interesting as one would expect RA patients 
who are also obese to have a significantly worse CVD risk profile as suggested by 
Stavropoulos-Kalinoglou et al. (2009) who previously investigated the association between 
obesity and modifiable risk factors of CVD. They found a near linear relationship between 
BMI and CVD risk factors and when examining the differences in BMI subgroups, they 
found that patients who were obese also had a higher CVD risk. They also reported that RA 
patients who were obese were more likely to fulfil criteria for the metabolic syndrome, a 
finding also supported by the current investigation. However, it must be noted that the 
findings reported by Stavropoulos-Kalinoglou et al. (2009) were based on their revised RA 
specific BMI groups in which they suggest BMI should be lowered by 2 kg·m-2 and not the 
well known BMI cut offs used in the current thesis (Stavropoulos-Kalinoglou et al., 2009). 
One could argue therefore, that the lack of differences observed between the three BMI 
groups in the current study was explained by the inability of the standard BMI to correctly 
identify obesity in RA patients. However, the analysis performed using the standard BMI in 
this chapter were repeated using the results for body fat percent (F (18,116) = 1.08, p = 
0.386) and the revised BMI cut offs (F (18,116) = 1.20, p = 0.274) suggested by 
Stavropoulos-Kalinoglou et al. (2009), both of which provided very similar results (see 
Appendix 9 for further details).    
 
Another explanation for the lack of differences in CVD risk factors between the BMI groups 
could be that obesity has a protective effect against CVD in RA. Escalante et al. (2005) 
suggested that BMI had a paradoxical effect on CVD mortality in RA. They observed lower 
mortality rates amongst the heavier patients. However, they did suggest that this protective 
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effect was modified by systemic inflammation. They believed that when ESR was low, BMI 
had a protective effect, but when ESR was high this protective effect diminished (Escalante et 
al., 2005). The values for ESR reported in that study were much higher than that observed in 
the current investigation and indeed throughout this thesis. Unfortunately, Escalante et al. 
(2005) did not report any values for individual CVD risk factors and therefore more solid 
comparisons cannot be made. Perhaps the low levels of inflammation (ESR) observed in this 
RA population is having a beneficial effect on their overall cardiovascular risk factor profile.   
 
Although poor cardio-respiratory fitness was strongly associated with a less favourable body 
composition as shown in Chapter 4, there was no significant difference in cardio-respiratory 
fitness levels between the three BMI groups. Although not significant, normal weight patients 
did have a higher cardio-respiratory fitness level when compared to their overweight and 
obese counterparts. However, this data needs to be considered alongside the data for step 
ability. Obese patients were less likely to able to complete the step test (Figure 5.4) and 
therefore one could speculate that that their cardio-respiratory fitness level would have been 
much less than those who were able to complete the step test. Despite the majority of obese 
RA patients not being able to complete the step test, reporting more pain and disability; there 
was no difference in their reported physical activity. Obese patients reported the same level 
of physical activity per week as their normal weight counterparts. Perhaps, this finding 
highlights the subjective nature of assessing physical activity using a questionnaire like the 
IPAQ. Previous research has suggested that the IPAQ in particular can overestimate physical 
activity, especially moderate physical activity (Craig et al., 2003). One study reported an 
overestimation of 247% using the IPAQ when compared to physical activity measured by an 
accelerometer (Johnson-Kozlow et al., 2006). One of the main reasons for this discrepancy 
has been attributed to social desirability (Vanhees et al., 2005).  “Social desirability” has been 
explained as a defensive tendency of individuals to portray themselves in keeping with 
perceived cultural norms. It has also been suggested that people, especially women are more 
likely to underreport their fat, total energy intake and overestimate their level of physical 
activity (Adams et al., 2005, Hebert et al., 2002). With RA being a chronic disease that is 
more common in women, perhaps the use of self reported physical activity questionnaires 
should be kept to a minimum and the measurement of cardio-respiratory fitness should be 
performed instead.   
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5.5 Conclusion 
 
Assessing the impact of obesity on RA disease, CVD risk factor profile and cardio-
respiratory fitness and function has provided some novel findings. This study, the first of its 
kind, has shown that obesity heavily impacts on patients’ perception of their disease and 
physical ability. It is strongly associated with the metabolic syndrome and its individual 
components (TG, HDL-c) but not with the other traditional CVD risk factors as one might 
expect. One of the most striking findings of this study is that obesity is the main reason some 
patients are unable to complete the step and not their RA disease. Now that some key 
modifiable CVD risk factors have been highlighted including poor cardio-respiratory fitness 
and obesity, the next chapter describes an exercise intervention designed to improve upon 
these.  
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6 Chapter 6:  
 
Can a short term supervised exercise intervention improve RA patients overall 
cardiovascular health and general well being? 
 
 
6.1 Introduction  
 
Regular exercise and being physically active provides a multitude of health benefits for the 
general population and patients with chronic diseases, especially individuals with RA (discussed 
in detail in Chapter 1). Despite this knowledge, the majority of RA patients remain physically 
inactive (Sokka et al., 2008). This extreme physical inactivity plays an important role in terms of 
patient health and disease progression. It also highlights the need to encourage exercise amongst 
this population as part of routine care.  
 
Benefits of exercise in RA patients include improved cardio-respiratory fitness (Stenstrom and 
Minor, 2003), increased muscle mass (Lemmey et al., 2009), reduced adiposity (Walsmith and 
Roubenoff, 2002) and improved muscle strength and physical functioning (Hakkinen, 2004). It is 
important to note that these exercise benefits are all achieved without exacerbation of disease 
activity or joint damage (Van den Ende et al., 2000).     
 
Since RA is associated with increased morbidity and mortality from cardiovascular disease 
(CVD) a goal of any RA treatment regime should be to reduce cardiovascular co-morbidity, in 
line with the overall aim of prolonging and improving quality of life (QoL). Poor cardio-
respiratory fitness is strongly associated with cardiovascular mortality in apparently healthy men 
and women, those with co-morbid conditions (hypertension, obesity, diabetes mellitus type 2) 
and those with known coronary artery disease (Franklin and McCullough, 2009). With 
cardiovascular mortality accounting for more than 50% of deaths in the RA population (Wolfe et 
al., 1994), it is unsurprising that individuals with this chronic illness have cardio-respiratory 
fitness levels 20-30% lower than age matched healthy controls (Häkkinen et al., 2001) and 
patients who are generally physically inactive have been shown to have a significantly worse 
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cardiovascular risk factor profile (Metsios et al., 2009) in particular poor cardio-respiratory 
fitness and obesity (chapter 4).  
 
Exercise training can reduce mortality by 20-30% (Taylor et al., 2004). Thus, the probable 
cardio-protective benefit of exercise to patients with RA cannot be ignored. To date, most studies 
have focused on the improvements in functional ability and other RA related disease outcomes. 
A recent Cochrane review highlighted evidence for a positive effect of short term exercise on 
aerobic capacity (Hurkmans et al., 2009). It is worth noting that of the 8 studies included in this 
review, not one reported any cardiovascular risk factors. A more recent systematic review and 
meta-analysis of randomised controlled trials also showed that aerobic exercise improves 
important RA patient outcomes such as function, QoL and pain (Baillet et al., 2010). Again, the 
effect of exercise on cardiovascular risk factors was not included in these investigations. With a 
clear gap in research devoted to CVD and exercise in RA, the need for research investigating the 
effect of exercise training on cardio-respiratory fitness and CVD risk factors in RA is paramount.  
 
6.1.1 What Exercise Interventions Have Been Done? 
 
The beneficial effect of exercise on CVD risk factors in RA remains to be investigated. In order 
to plan an appropriate exercise intervention, a literature search of exercise interventions in other 
clinical populations (e.g. diabetes mellitus, hypertensive patients, obesity) was undertaken. 
Although many of these studies investigated long term interventions, the primary focus of the 
study described here was the beneficial effects of short term exercise interventions (see Table 
6.1). From these exercise interventions it was evident that improvements in fitness and overall 
cardiovascular health could be achieved by exercising at least 3 times per week for 8-12 weeks.  
 
It was hypothesised that 8 weeks of supervised aerobic exercise designed to increase RA patients 
cardio-respiratory fitness would also improve their cardiovascular risk factors, body composition 
and symptoms of RA disease.  
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Table 6.1 Short term exercise interventions in various non-RA clinical populations. 
Author (date) Population Exercise Duration Frequency Outcome 
Yu et al. (2003) 
Obese with 
CHD, Age 62 
yrs 
Aerobic 65-
80% MHR  
(1 hour) 
8 weeks 
2 
sessions/wk 
Improved fitness, 
HDL-c, LDL-c, 
WHR 
Lazarevic et al. (2006) 
Type 2 
diabetes, Age 
54 yrs 
Brisk walking 
50-75% MHR 
12 weeks 
3 -5 
sessions/wk 
Improved SBP, DBP 
Walker et al. (1999) 
Diabetes & 
normoglycemic 
Age 58 years 
Walking self 
paced       
 (1 hour) 
12 weeks 
5 
sessions/wk 
Improved VO2, 
weight, BMI, 
glucose, LDL-c, TG 
Maiorana et al. (2002) 
Type 2 
diabetes, Age 
52 yrs 
(excluded – TC 
> 6, BP > 160) 
Circuit training 
(aerobic and 
resistance) 
 1 hour 
8 weeks 
3 
sessions/wk 
Improved glucose, 
resting HR, WHR, 
fat percent, muscle 
strength, VO2 
Kelemen et al. (1990) 
Hypertensive 
men, Age 47 
yrs 
30 min weight 
training, 20 
mins aerobic, 
14 – 16 RPE 
10 weeks 
(reported 
differences 
after 7 
weeks) 
3 
sessions/wk 
Improved SBP, 
DBP, TC, LDL-c, 
HDL-c, Fitness 
(15%), weight 
Yeater et al. (1990) 
Type 2 
diabetes, Age 
56 yrs 
Walking/slow 
jogging  
(40–45 mins) 
8 weeks 
3 
sessions/wk 
Improved fitness, 
SBP, resting HR, TG 
CHD; coronary heart disease, TC; total cholesterol, TG; triglycerides, HDL-c; high density lipoprotein, LDL-c; low 
density lipoprotein, WHR; waist hip ratio, SBP; systolic blood pressure, DBP; diastolic blood pressure, VO2; oxygen 
consumption, BMI; body mass index, MHR; maximum heart rate, RPE; ratings of perceived exertion.  
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6.2 Methods 
 
6.2.1 Power Calculation  
 
To determine the sample size, an online power calculator was used (DSS Research, beta error 
level of 20%) utilizing data from similar exercise interventions carried out in other clinical 
populations (see Table 6.1), mainly type 2 diabetes (Lazarevic et al., 2006), obesity (Yu et al., 
2003) and hypertension (Kelemen et al., 1990). The power calculation was based on a variety of 
cardiovascular risk factors - systolic blood pressure, diastolic blood pressure, cardio-respiratory 
fitness and high density lipoprotein. These risk factors were chosen because their baseline mean 
values were similar to the mean values reported in the 100 RA patients that were tested in 
Chapter 4. The power calculations based on the above risk factors calculated a sample size 
ranging from N = 5 to N = 14.  
 
6.2.2 Participant Recruitment 
 
With ethical approval (REC reference: 11/WA/0206), thirteen RA patients were recruited into 
the study. Of these 10 patients completed the 8 week exercise programme. All patients recruited 
had a diagnosis of RA (Arnett et al., 1988). The remaining three RA patients were classed as 
drop outs for the following reasons: moved away from the area, called for surgery, decided not to 
participate after the initial assessment.    
 
6.2.3 Protocol for Baseline and Post Intervention Assessment 
 
Participation in this study comprised of three parts – baseline assessment (pre test), the 8 week 
exercise training programme and the post intervention assessment (post test). The measures 
assessed at baseline and post intervention are outlined below (full details are provided in Chapter 
2). Measures that have only been used in the current chapter are described in detail. Details of 
the exercise programme are given in Table 6.2.   
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Cardio-respiratory Fitness and Function  
 
Cardio-respiratory fitness was measured using the Siconolfi step test. Previously, we have shown 
that this simple test provides a valid and reliable estimation of VO2 max (Chapter 3), in patients 
with RA. Briefly, the test involves stepping up and down a portable 10 inch step for 3 minutes at 
a rate of 17 steps per minute. Heart rate was measured using a heart rate monitor and recorded at 
the end of the three minute stage (see Chapter 2 for a detailed description). Physical function was 
measured objectively using the 8 foot ‘Up and Go’ and 30 second sit-to-stand test.  
 
30 second Sit to Stand 
 
The 30 second sit to stand test is a measure of lower body strength. It gives an indication of an 
individual’s ability for numerous tasks such as climbing stairs, walking and getting out of a 
chair, bathtub or car (Jones and Rikli, 2002). The procedure for the test is as follows: the 
participant is seated with their feet shoulder width apart, flat on the floor. Arms must be crossed 
at the wrists and held close to the chest. From the sitting position, the participant stands 
completely up, then completely back down, and this is repeated for 30 seconds. Up and down 
equals one chair stand. If the participant has completed a full stand from the sitting position 
when the time is elapsed, the final stand is counted in the total. Recommended ranges for this test 
based on gender and age group are shown in Table 1-2 (Appendix 7), values are taken from 
(Jones and Rikli, 2002). 
 
8 foot Up and Go  
 
The 8 foot up and go test is a measure of agility, speed and balance whilst moving (Jones and 
Rikli, 2002). This test is performed with the participant seated, hands resting on the knees and 
feet flat on the floor. The participant is timed as they stand up from a seated position; walk as 
quickly as possible around a cone 8 feet away from the chair, and return to a seated position. 
Recommended ranges for this test based on gender and age group are shown in Tables 3-4 
(Appendix 7), with values taken from (Jones and Rikli, 2002). 
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Blood pressure and Fasting Lipids, Glucose 
 
After ten minutes of rest in the seated position, blood pressure was measured in duplicate using 
the auscultatory method. Each participant was required to provide a fasting blood sample within 
1 week of this testing session to assess concentrations of lipids and glucose in the blood plasma. 
 
Body Composition  
 
Height and body mass were measured by standard procedures and body mass index (BMI) was 
calculated (kg·m-2). Percentage body fat was measured using bioelectrical impedance analysis 
(Tanita corp., Tokyo, Japan). Waist and hip circumference was also measured to determine waist 
hip ratio (waist: hip). 
 
RA Disease and Related Factors 
 
Patients were asked to fill in questionnaires regarding their activities of daily living (Health 
Assessment Questionnaire), Quality of Life (SF-36) and fatigue (MAF). Patients were asked to 
rate their arthritis (global health) and current pain using a 10 cm visual analogue scale (VAS). 
An exercise physiologist examined the number of tender and swollen joints to determine disease 
activity (DAS 28). Patients were also required to have a routine blood test to assess level of 
inflammation (ESR and CRP) within one week of the testing session.  
 
Quality of Life  
 
The SF-36 Health Survey (Ware, 2000) is a questionnaire that measures eight different health 
concepts: 
 
1. Physical functioning 
2. Role limitations because of physical health problems 
3. Bodily pain 
4. Social functioning 
5. General mental health (psychological distress and psychological wellbeing) 
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6. Role limitations because of emotional problems 
7. Vitality (energy/fatigue) 
8. General health perceptions 
 
The SF-36 can also be divided into two aggregate summary measures - the physical component 
summary and the mental component summary. The SF-36 has been administered successfully in 
general population surveys all over the world (Ware et al., 1995). It has been used in young 
people, older adults and patients with chronic diseases (McHorney et al., 1994, Ware et al., 
1993). The questionnaire is regarded as a very useful measure of health status which can be 
administered in 5-10 minutes with a high degree of acceptability and data quality (Ware et al., 
1993). A copy of the SF-36 health survey can be seen in Appendix 8.  
 
Fatigue 
 
The Multidimensional Assessment of Fatigue (MAF) questionnaire was originally developed to 
evaluate self-reported fatigue in patients with RA (Belza, 1995). The MAF is a 16 item scale that 
measures fatigue according to four dimensions: degree and severity, distress that it causes, 
timing of fatigue (over the past week, when it occurred and any changes), and its impact on 
various activities of daily living (household chores, cooking, bathing, dressing, working, 
socializing, sexual activity, leisure and recreation, shopping, walking, and exercising). MAF 
scores range from 1 (no fatigue) to 50 (severe fatigue). This questionnaire has been shown to be 
reasonably valid and reliable and sensitive to change (Neuberger, 2003). A copy of this 
questionnaire can be seen in Appendix 9. 
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6.2.4 Exercise Training 
    
After baseline assessment participants trained 3 times a week for 8 weeks at the physiotherapy 
gym, Ysbyty Gwynedd. All exercise sessions were supervised by an exercise physiologist 
(myself). Each exercise training session lasted 60 minutes and consisted of three ten minute 
aerobic exercises with a short rest in between each one. Participants chose the exercise and the 
order in which they were completed (treadmill, bike, rower, stepper, cross trainer). Exercise 
intensity was increased from 55%-85% predicted heart rate maximum (220-age) during the 8 
week programme and included both continuous and interval training patterns (see Table 6.2). 
Heart rate and ratings of perceived exertion (RPE scale) were monitored individually throughout 
the exercise session. After the aerobic exercise all participants completed resistance training 
exercises (calf raises, leg raises, knee raises, squats and abdominal curls). Participants completed 
15 repetitions (reps) and 2 sets of each exercise at week 1 and this was progressed to 15 reps, 10 
pulses (fast repetitions) and 3 sets at week 8. An example of how much performance increased 
over the 8 weeks can be seen in Table 6.3. 
  
98 
 
Table 6.2 Exercise intensity progression from week 1 to week 8 
  Warm up Exercise 1 Exercise 2 Exercise 3 
Week 1 
5 min                           
50% HRM 
55% HRM 55% HRM 55% HRM 
Week 2 
5 min                           
50% HRM 
55% HRM 
65% HRM (2 min)   
55% HRM (3 min)  
55% HRM 
Week 3 
5 min                           
50% HRM 
60% HRM 
65% HRM (3 min)   
55% HRM (2 min)  
60% HRM 
Week 4 
5 min                           
55% HRM 
70% HRM (2 min)          
60% HRM (3 min)  
65% HRM 
70% HRM (2 min)              
60% HRM (3 min)  
Week 5 
5 min                           
55% HRM 
70% HRM 
80% HRM (3 min)   
65% HRM (2 min)  
70% HRM 
Week 6 
5 min                           
60% HRM 
70% HRM 
80% HRM (3 min)   
65% HRM (2 min)  
70% HRM 
Week 7 
5 min                           
60% HRM 
80% HRM (3 min)          
65% HRM (2 min)  
75% HRM 
80% HRM (3 min)              
65% HRM (2 min)   
Week 8 
5 min                           
60% HRM 
85% HRM (3 min)          
60% HRM (2 min)  
85% HRM (3 min)    
60% HRM (2 min)  
85% HRM (3 min)              
60% HRM (2 min)  
 
 
 
 
 
HRM; heart rate maximum 
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Table 6.3 Example of maximum performance increase from week 1 to week 8 on each of the 
aerobic exercise machines. Results are from a selection of participants.  
Machine Week 1 Week 8 Performance Increase (%) 
Treadmill 0.64 miles 1.08 miles 69% 
Cross Trainer 1.51 km 2.2 km 46% 
Rower 750 m 1530 m 104% 
Stepper 29 floors 50 floors 72% 
Bike 0.8 miles 1.5 miles 88% 
km; kilometres, m; metres.  
 
6.2.5 Statistical Analysis 
 
Data was analyzed using the Statistical Package for the Social Sciences, version 19 (SPSS, 
Chicago, IL, USA). Dependent t-test analysis was used to determine significant differences 
between pre and post test measures. The effect size was calculated using eta squared (t2 ÷ t2 + 
(N-1)). Significance level was set at p < 0.05 for all analyses.  
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6.3 Results  
 
Ten patients (8 female; age range 54-71 years) with established RA completed 8 weeks of 
group exercise. Patient characteristics are displayed in Table 6.4.  
 
 
Table 6.4 RA patient baseline characteristics 
Characteristic  Mean/% SD   
Age (years) 64.2 5.9 
 Disease duration (years) 10.7 11.5 
 RF positive 70% 
  CCP positive  60% 
  CRP < 5 mg·l-1 100% 
  DAS 28 < 2.6 60% 
  
    Current DMARDS 
   MTX 80% 
  SSZ 10% 
  Hydroxychloroquine 10% 
  Humira 20% 
  
    Current steroid 
   Prednisolone 10% 
  
    Other medication  
   Antihypertensive  20% 
  Antihyperlipidemia 30% 
  
    Smoking status 
   Current smoker 10% 
  Past smoker 30% 
  Never smoked 60% 
  Values are mean ± SD/%, N = 10. RF; rheumatoid factor, CCP; cyclic citrullinated peptide, CRP; C-reactive 
protein, DAS; disease activity score, MTX; methotrexate, SSZ; sulphasalazine.  
 
 
6.3.1 Compliance  
 
Compliance to training was excellent, of the 24 scheduled sessions, participants completed on 
average 22.3 sessions (range 17–24 sessions), i.e. 92.9% of the sessions.  
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6.3.2 Cardio-respiratory Fitness and Function 
 
Cardio-respiratory fitness improved significantly after the 8 week exercise programme (p = 
0.021) (see Figure 6.1 and Table 6.5). Relative to baseline, fitness improved by 13% (step 
test), lower body strength improved by 54% (sit to stand test), and agility improved by 17% 
(8ft up and go test). See Table 6.5.  
 
 
 
Figure 6.1 Predicted VO2 max as assessed by the step test before and after 8 weeks of supervised 
group exercise in patients with RA. *Significant difference between pre and post test scores, p < 
0.05. Values are mean ± SD, N = 10. 
 
 
 
 
Table 6.5 Effect of 8 weeks of supervised group exercise on fitness, lower body strength and 
agility.  
Fitness and Function PRE POST P Effect Size 
Predicted VO2 max (ml·kg-1·min-1) 21.7 ± 8.4 24.6 ± 8.4 0.021* 0.48 
30 second sit to stand (n) 11.1 ± 2.6 17.1 ± 1.7 0.000* 0.90 
8 ft Up & Go (seconds) 5.9 ± 0.4 4.9 ± 0.3 0.000* 0.91 
Values are mean ± SD, N = 10. *Significant difference between pre and post scores, P < 0.05. Effect size was 
calculated using eta squared, where 0.01 = small effect, 0.06 = moderate effect, 0.14 = large effect.   
 
 
 
 
 
 
* 
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6.3.3 CVD Risk Factors and Global CVD Risk Scores 
 
Systolic blood pressure decreased by an average of 7 mmHg after 8 weeks of group exercise 
(p = 0.021). However, there were no major changes to the fasting lipids and glucose. LDL-c 
did increase by 0.2 mmol·l-1 but remained within the normal range (see Table 6.6). 
 
Table 6.6 Effect of 8 weeks of supervised group exercise on blood pressure, fasting lipids and 
fasting glucose in patients with RA.  
CVD Risk Factors PRE POST P Effect Size 
SBP (mmHg) 133.2 ± 14.7 125.8 ± 11.9 0.021* 0.46 
DBP (mmHg) 76.2 ± 5.9 74.6 ± 7.5 0.448 0.06 
TC (mmol·l-1) 5.3 ± 0.9 5.4 ± 0.8 0.534 0.04 
TG (mmol·l-1) 1.3 ± 0.8 1.2 ± 0.7 0.785 0.01 
LDL-c (mmol·l-1) 2.9 ± 0.7 3.1 ± 0.6 0.034* 0.41 
HDL-c (mmol·l-1) 1.8 ± 0.4 1.7 ± 0.4 0.112 0.26 
Glucose (mmol·l-1) 4.9 ± 0.5 4.9 ± 0.6 0.434 0.07 
Global CVD Risk Score 
   
 
Framingham risk score (percent) 12.75 ± 7.74 11.91 ± 7.70 0.222 0.16 
QRISK2 (percent) 17.01 ± 8.30 16.87 ± 8.41 0.670 0.02 
Values are mean ± SD, N = 10. SBP; systolic blood pressure, DBP; diastolic blood pressure, TC; total 
cholesterol, TG; triglycerides, LDL-c; low density lipoprotein, HDL-c; high density lipoprotein. *Significant 
difference between pre and post scores, P < 0.05. Effect size was calculated using eta squared, where 0.01 = 
small effect, 0.06 = moderate effect, 0.14 = large effect. 
 
 
6.3.4 Body Composition  
 
There was a 9% decrease in body fat percent, 2% decrease in waist circumference and 3% 
decrease in hip circumference in this RA group following 8 weeks of exercise training. There 
was an overall reduction in total weight (1.4 kg) and BMI (0.6 kg·m-2). However, these 
changes were not significant (see Table 6.7).  
 
Table 6.7 Effect of 8 weeks of supervised group exercise on body composition.  
Body Composition  PRE POST P Effect Size 
Weight (kg) 66.8 ± 15.6 65.4 ± 14.2 0.069 0.32 
BMI (kg·m-2) 25.7 ± 4.4 25.1 ± 3.8 0.056 0.35 
Body fat (%) 34.0 ± 12.6 31.0 ± 11.9 0.018* 0.48 
Waist (cm) 82.6 ± 11.1 80.8 ± 10.3 0.035* 0.41 
Hip (cm) 98.7 ± 9.4 95.4 ± 6.9 0.016* 0.49 
Waist:Hip 0.84 ± .06 0.84 ± .07 0.226 0.16 
Values are mean ± SD, N = 10.*Significant difference between pre and post scores, P < 0.05. Effect size was 
calculated using eta squared, where 0.01 = small effect, 0.06 = moderate effect, 0.14 = large effect. 
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6.3.5 RA Disease  
 
The effects of 8 weeks of supervised exercise on inflammation, disease activity, pain, fatigue 
and QoL are presented in Table 6.8. There was no change in levels of inflammation, 
however, disease activity (DAS 28 ESR and CRP) and number of tender joints improved 
significantly. After 8 weeks of training there was a significant improvement in reported 
arthritis (VAS arthritis), pain, disability (HAQ), fatigue and QoL.  
 
 
Table 6.8 Effect of 8 weeks of supervised group exercise on specific RA factors.  
RA Characteristic  PRE POST P Effect Size 
ESR (mm·hr-1) 3.2 ± 1.9 2.3 ± 0.7 0.081 0.30 
CRP (mg·l-1) 4.0 ± 0.0 4.8 ± 2.5 0.343 0.10 
DAS 28 ESR 2.1 ± 0.7 1.2 ± 0.6 0.002* 0.66 
DAS 28 CRP 2.9 ± 0.6  2.2 ± 0.5 0.016* 0.49 
Tender joints (n) 2.9 ± 1.9 1.0 ± 1.2 0.016* 0.49 
Swollen joints (n) 0.4 ± 0.8 0.0 ± 0.0 0.168 0.20 
VAS arthritis (0-100) 27.5 ± 16.0 16.5 ± 10.0 0.040* 0.39 
Pain (0-100) 24.1 ± 17.9 12.4 ± 9.5 0.032* 0.42 
Fatigue (1-50) 18.8 ± 12.6 11.9 ± 9.2 0.019* 0.48 
HAQ (0-3) .81 ± .65 0.33 ± .29 0.007* 0.57 
SF36-Physical health 39.3 ± 9.3 48.6 ± 6.9 0.035* 0.41 
SF36-Mental health 51.5 ± 9.2 56.8 ± 4.6 0.014* 0.51 
SF36 total score 90.7 ± 11.9 105.5 ± 8.0 0.004* 0.62 
Values are mean ± SD, N = 10. ESR; erythrocyte sedimentation rate, CRP; C-reactive protein, DAS; disease 
activity score, VAS; visual analogue scale, HAQ; health assessment questionnaire. *Significant difference 
between pre and post scores, P < 0.05. Effect size was calculated using eta squared, where 0.01 = small effect, 
0.06 = moderate effect, 0.14 = large effect. 
 
 
 
The QoL measures are shown in greater detail in Figure 6.2. All QoL measures from the SF-
36 improved after the 8 week exercise programme, the greatest improvement observed was in 
physical role limitations.  
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Figure 6.2 Changes in SF-36 scores before and after the 8 week group exercise intervention in 
patients with RA. Values are mean ± SD, N = 10. *Significant difference between pre and post 
scores, P < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
* 
* 
  * 
 * 
* 
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6.4 Discussion  
 
To the best of our knowledge this is the first exercise intervention designed to improve the 
overall cardiovascular health of patients with RA. The current study has shown that 8 weeks 
of supervised group exercise increased cardio-respiratory fitness and provided improvements 
not only in cardiovascular health (systolic blood pressure) and body composition (body fat, 
waist and hip circumference) but also in RA disease symptoms (disease activity, fatigue, 
pain, disability).  
 
Cardio-respiratory fitness improved significantly by 13%. This improvement in cardio-
respiratory fitness demonstrated that the training programme performed in the current study 
was of sufficient intensity, duration and frequency to elicit such changes. In general it is 
recommended that aerobic training is performed 3 to 5 times per week, with an intensity of 
55% - 90% of HR max and with a duration of 20 to 60 minutes (ACSM, 1998). The current 
investigation has demonstrated a beneficial effect training 3 times a week, with an intensity 
of 55% - 85% HR max for 60 minutes. The increase in fitness observed in this study after 8 
weeks of exercise training is consistent with findings from previous studies also carried out in 
patients with RA (Breedland et al., 2011, Neuberger et al., 2007). The results of the present 
study confirm that a dynamic exercise programme like the one described in this chapter is 
effective in increasing cardio-respiratory fitness (Häkkinen et al., 2003, Stenstrom and Minor, 
2003, Van den Ende et al., 1998). In a systematic review carried out by Van den Ende et al. 
(1998), improvements in cardio-respiratory fitness ranged from 4 - 33%, these varying results 
were due to differences in the duration of training which ranged from 8 weeks to 2 years 
(Van den Ende et al., 1998). As well as improvements in cardio-respiratory fitness, lower 
body strength improved by 54% (sit to stand test), this finding is greater than that reported by 
Lemmey et al. (2009) who found only a 30% improvement in sit to stand after 24 weeks of 
progressive resistance training in a sample of RA patients (Lemmey et al., 2009). The 
improvements in the sit to stand test observed in the present investigation are similar to the 
improvements observed by Matsuda et al. (2010), who reported a 59% increase in a group of 
healthy older adults after a 6 week home based exercise programme. These older adults were 
on average 7 years older and had a greater BMI than the RA patients investigated in the 
current study. However, the improvements observed in the present study compare well to 
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those reported by Matsuda et al. They reported a 25% improvement in agility (Matsuda et al., 
2010), whilst in the current investigation agility improved by 17% (8 ft up and go test).  
 
The 8 week exercise programme designed to improve cardio-respiratory fitness also 
significantly reduced systolic blood pressure by 7 mmHg. The average systolic blood 
pressure at baseline was 133 mmHg which is clinically classified as within the normal range. 
However, 8 weeks of aerobic exercise reduced the number of hypertensive patients from five 
at baseline to three after the exercise intervention. No major changes to fasting lipids and 
glucose were observed. LDL cholesterol did increase by 0.2 mmol·l-1 (6.8%) after the 
exercise programme and although this was statistically significant, LDL cholesterol remained 
within the optimum range. This small change in LDL cholesterol could be explained by a 
normal physiological variation, with data suggesting that the coefficient of biological 
variation averages at 8.2% (NCEP, 1995). Despite the lack of change in fasting lipids there 
was a reduction in the Framingham 10 year risk score of 0.8%. Although not significant this 
is an encouraging finding considering the short duration of the exercise intervention and the 
fact that age and gender primarily contribute to this risk score.  
 
The literature on the benefits of exercise on cardiovascular risk factors are nonexistent in the 
RA population (Cairns and McVeigh, 2009) and so can only compare the current findings to 
those studies carried out on the general population and those on other chronic inflammatory 
diseases that are similar to RA. The lack of statistically significant improvements in lipids in 
our sample of RA patients could be due to several reasons. One could be due to the optimal 
mean baseline values of these variables, especially LDL-c, HDL-c and TG. For example, 
using the National Institute for Health and Clinical Excellence (NICE) and Department of 
Health cholesterol guidelines the average baseline values for LDL-c, HDL-c and TG would 
be classified in the normal range. However, the Joint British Societies (a group of the main 
UK expert societies involved in cardiovascular disease) recommend different cholesterol 
limits for people who have, or are at risk of, coronary heart disease. It could be argued that 
patients with RA would come under this bracket; in which case the recommended lipid levels 
are less than 4.0 mmol·l-1 for total cholesterol and less than 2.0 mmol·l-1 for LDL cholesterol. 
These guidelines match the more stringent recommendations used in the rest of Europe which 
would mean that the lipid levels observed in this investigation (TC - 5.3 mmol·l-1, LDL-c - 
2.9 mmol·l-1) are higher than the optimal. Another explanation for the lack of effect could be 
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the short duration of our exercise programme. Eight weeks is potentially not long enough to 
see a change in lipid levels from exercise alone (Kodama et al., 2007).  
 
Perhaps the lack of alteration of lipid levels is not concerning considering the notion that 
lipids have a paradoxical association with CVD risk in RA. A recent study suggested that 
lower TC and LDL-c levels were in fact associated with increased cardiovascular risk 
(Myasoedova et al., 2011). However, the relationships between lipid levels, inflammation and 
CVD are believed to be much more complex than that suggested by Myasoedova et al. (2011) 
and thus the general consensus is that traditional CVD risk management should remain high 
priority in these high risk patients (Strandberg, 2011).  
 
Previous randomised trials dealing with the effects of exercise on lipids and lipoproteins in 
adults have led to conflicting results. A meta analysis by Kelley et al. (2004) on the effects of 
walking on lipids reported significant decreases in LDL-c and TC/HDL-c. On average these 
exercise programmes lasted 23 weeks where participants walked for 40 minutes 4-5 times a 
week at an intensity of 65% VO2 max. In this meta-analysis whilst there was a significant 
improvement in cardio-respiratory fitness no change in body composition was observed 
(Kelley et al., 2004).  Many other studies however have failed to show any differences in lipid 
profiles, one home-based walking programme which did not include any direct supervision 
reported that healthy middle-aged women who walked for 30 minutes, four times a week 
improved their fitness, but showed no change in their cardiovascular risk factors (Davison 
and Grant, 1995). The authors believed the lack of effect was due to low adherence to the 
walking programme. Another similar study carried out on sedentary middle aged men also 
showed no effect on TC or HDL-c after a one-year brisk walking intervention (Stensel et al., 
1993). The lack of effect in that study was attributed to the exercise being of insufficient 
intensity. Both of the reasons outlined in these studies do not apply to the current exercise 
intervention as it is believed the exercise was of sufficient intensity and the adherence to the 
programme was excellent.   
 
As well as improvements in cardio-respiratory fitness and systolic blood pressure, 8 weeks of 
supervised aerobic exercise significantly improved RA patients’ body composition. On 
average body fat percent was reduced by 9%. This remarkable loss in fat mass was 
accompanied by a 2 cm reduction in waist circumference and 3 cm reduction in hip 
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circumference. Central adiposity (increased waist circumference) has previously been shown 
to significantly increase cardiovascular disease risk (Fanghanel et al., 2011). The reason for 
this is that excess visceral fat is metabolically active, which can cause increases in blood 
pressure, lipids and insulin resistance (Despres, 2001). Thus, reducing waist circumference 
can improve an individual’s CVD risk. There was an insignificant reduction in total body 
weight (1.4 kg) and thus little change in RA patients’ BMI, which can be partially explained 
by a 1 kg increase in lean mass (p = 0.215). However, upon further examination of BMI 
scores before and after the exercise programme the number of patients who had a normal 
BMI (< 25) increased from 5 to 6, the number of overweight (25-29.9) patients stayed the 
same (n=3), whilst the number of obese patients was reduced from 2 to 1 (≥ 30). These 
improvements in body composition are very promising considering patients were exercising 
for only 8 weeks with no change in their diet. The changes in body composition observed in 
this investigation are very similar to those reported by Lim et al. (2010). After 8 weeks of 
aquatic exercise, training 3 times a week, they observed a non significant reduction in BMI 
and a significant reduction in percent body fat, in a group of patients with knee osteoarthritis 
(Lim et al., 2010). The results of the current investigation are also supported by Dekker et al. 
(2007). They examined the beneficial effects of a 12 week aerobic exercise training 
programme in lean males, obese males and males with type 2 diabetes mellitus. There was no 
significant reduction in total mass or BMI, however, waist circumference decreased 
significantly with an average loss of 3 cm around the waist in all three groups (Dekker et al., 
2007).  
 
In support of previous literature the beneficial effects of exercise in the present study were 
achieved without any exacerbation of RA disease. In fact eight weeks of supervised aerobic 
exercise improved disease activity (DAS 28) by 42.8% (a reduction of 0.9). According to the 
EULAR response criteria this reduction represents a moderate change when the baseline DAS 
28 score is less than 3.2 (Fransen and van Riel, 2005). This reduction in disease activity was 
surprising considering the very low disease activity of this population at baseline. Disability 
measured by the HAQ score was reduced by 0.48 (59%). Not only was this statistically 
significant but this improvement in physical function was also clinically meaningful. In 
rheumatology an improvement in the HAQ disability index of at least 0.3 from baseline is 
considered a clinically significant change. Improvements in function due to exercise has 
received some debate and the beneficial effect on subjective measures of function are not 
 109 
 
universal. For example, an intensive PRT programme failed to improve modified HAQ scores 
in a group of RA patients despite significant improvements in muscle mass and strength 
(Lemmey et al., 2009). It was concluded that patients involved in that programme had 
relatively low disability and that the modified HAQ was not sensitive enough to change in a 
low disability group. Our findings contradict this statement as our group of RA patients also 
had low disability at baseline and still managed to improve their physical function. Perhaps 
this finding demonstrates that aerobic exercise is more beneficial for improving physical 
function than progressive resistance training alone, or perhaps it suggests that RA patients 
should be encouraged to engage in both aerobic and resistance training in order to experience 
maximum overall benefit.  
 
Fatigue is a common complaint in patients with RA with 40% experiencing clinically 
significant fatigue (Wolfe et al., 1996). It is often described as one of the most annoying 
problems due to the distress and disruption it can cause. Fatigue is defined as ‘extreme and 
persistent tiredness, weakness or exhaustion that can be mental, physical or both’ (Hewlett et 
al., 2005). From the RA fatigue research literature there is little known about how best to 
assess it and more importantly how to treat it (Repping-Wuts et al., 2009). In the current 
study after 8 weeks of exercise, fatigue improved by 6.9 points (36%). A change of 5 or more 
points from baseline is considered a clinically significant reduction in fatigue when using the 
MAF questionnaire (Goligher et al., 2008). The thesis’s findings are consistent with recent 
research that also suggests that fatigue can be reduced by performing regular exercise 
(Neuberger et al., 1997). One systematic review explored the effectiveness of 
nonpharmacological interventions for fatigue (Neill et al., 2006) they also concluded that 
both aerobic and resistance exercise interventions can reduce RA fatigue. 
 
As well as a clinically significant reduction in fatigue, QoL (SF-36) improved significantly 
after the 8 week exercise programme. Upon further examination of the individual items, 6 of 
8 scales improved significantly after the exercise programme (Figure 6.2). Previous literature 
on the benefits of exercise on health related QoL has reported mixed results. Bilberg et al. 
(2005) only reported improvements in physical functioning, vitality and bodily pain after 12 
weeks of pool exercise twice a week, in a sample of RA patients. They only examined heart 
rate at two of the training sessions to monitor intensity of exercise and so they concluded that 
perhaps the exercise intensity was insufficient throughout the intervention (Bilberg et al., 
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2005). It must also be noted that their sample of RA patients had a much higher baseline 
cardio-respiratory fitness than that observed in this thesis. Other studies that have found a 
significant improvement in quality of life after exercise training include patients with type 2 
diabetes mellitus (Kaplan et al., 1987) and patients with knee osteoarthritis (Rejeski et al., 
2002).  
 
The strengths and weaknesses of this pilot study warrant consideration. To the best of our 
knowledge this was the first study to investigate the beneficial effects of aerobic exercise on 
CVD risk factors in patients with RA. However, despite significant improvements to patients 
overall cardiovascular health and general well being, this study is not without limitations. 
Firstly, RA patients’ traditional CVD risk factors including body composition were not 
markedly elevated at baseline and were much lower than that of the RA patients investigated 
in Chapter 4 of this thesis. RA patients investigated in the exercise training study had a 
similar disease duration to patients investigated in the cross sectional study; however, they 
were on average 4 years older, 8 kg lighter, with smaller waists and hips. Their systolic and 
diastolic blood pressures were slightly lower whilst their fasting lipids were very similar. RA 
patients who took part in the training study also had much lower levels of inflammation and 
disease activity than patients who took part in the cross sectional study. The above 
differences indicate that the sample of RA patients included in the exercise study were not a 
true representation of the RA population. Thus, the beneficial effects of exercise on the 
cardiovascular health of RA patients with more active disease and a worse CVD risk factor 
profile remains to be determined. Secondly, the sample size in the current study was very 
small and this investigation lacked a control group, randomisation and blinding. Despite these 
limitations, this study has designed an effective group exercise intervention that can be 
carried out in a clinical setting which should be used to form the bases of future research in 
this area.     
 
6.5 Conclusion 
 
To the best of our knowledge this is the first study to investigate the effects of a short term 
group exercise programme on overall cardiovascular health and general wellbeing in RA 
patients. The results of this investigation confirm that moderate to high intensity aerobic 
exercise is a safe and effective means of improving cardio-respiratory fitness, blood pressure, 
 111 
 
body composition, function and symptoms of RA disease itself. It is becoming more evident 
that traditional risk factors cannot always be relied upon when assessing or aiming to improve 
the CVD risk of an RA patient. Therefore, factors like obesity and cardio-respiratory fitness 
become just as important. This investigation has shown that supervised group exercise can 
help patients improve their cardio-respiratory fitness, aspects of cardiovascular health and 
body composition. However, future research needs to work on how these advantages can be 
sustained, improved, including patients with a wide range of disease activity and finally, to 
determine whether or not treatment like this as part of routine care is financially viable. 
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7 Chapter 7: General Discussion  
 
The aim of the current PhD thesis was to assess cardio-respiratory fitness and the so called 
traditional CVD risk factors in patients with RA. Specifically, this project firstly aimed to 
validate a simple tool that could be used by any health professional to assess RA patient 
cardio-respiratory fitness levels in a clinical setting, secondly to investigate the association 
between cardio-respiratory fitness using the step test and CVD risk factors, body composition 
and RA disease characteristics and finally to determine whether a supervised group exercise 
programme delivered in a clinical setting could improve the overall cardiovascular health and 
general well being of these patients.   
 
Poor cardio-respiratory fitness is an acknowledged risk factor for CVD, if not a ‘traditional’ 
risk factor in the general population. RA patients’ have a greater risk of developing CVD 
when compared to individuals without RA (Bacon and Townend, 2001). However, despite 
this knowledge, the routine measurement of cardio-respiratory fitness in a clinical setting is 
generally nonexistent. The first study discussed here set out to validate a very simple tool that 
can be used by any health professional to assess RA patients’ cardio-respiratory fitness in a 
clinical setting. The Siconolfi step test is a reasonably valid and reliable measure of cardio-
respiratory fitness in these patients, but also importantly it is very simple to perform.  
 
The Siconolfi step test demonstrated that RA patient cardio-respiratory fitness levels were 
very poor. This thesis aimed to determine whether this poor cardio-respiratory fitness was 
also associated with a worse CVD risk profile, as previous research suggested that poor 
physical activity (measured subjectively using a questionnaire) was associated with a worse 
CVD profile (Metsios et al., 2009). However, despite the level of poor cardio-respiratory 
fitness observed in RA patients their so called ‘traditional’ CVD risk factors were not 
obviously elevated. Poor cardio-respiratory fitness was associated with higher triglycerides 
and a higher diastolic blood pressure but not with higher systolic blood pressure, total 
cholesterol and LDL cholesterol as one might expect from the findings of Metsios et al. 
(2009). However, poor cardio-respiratory fitness was strongly associated with a less 
favourable body composition. Perhaps the above associations with triglycerides and diastolic 
blood pressure can be partially explained by the presence of the metabolic syndrome (Lakka 
et al., 2003). Cardio-respiratory fitness did not directly correlate with the metabolic 
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syndrome, but 41% of patients were classified as having metabolic syndrome. Perhaps with 
such strong association between cardio-respiratory fitness and body composition, cardio-
respiratory fitness only associates with certain aspects of metabolic syndrome (for instance 
variables that are associated with excess body fat).  
 
One of the unexpected findings of this work was that 35% of patients with stable RA were 
unable to complete the step test. This particular test was chosen because the step test was 
reasonably tolerated by RA patients who participated in the validation study. However, on 
closer inspection these RA patients were slightly younger, weighed less and had a lower 
HAQ score. Whereas patients who took part in the cross sectional study were attending a 
routine clinical appointment. The investigation in Chapters 4 and 5 were carried out in a real 
life clinical setting and the participants studied were probably a more accurate representation 
of the RA population. Investigation of the differences between patients who were able and 
unable to complete the step test has provided some very interesting findings. RA patients 
unable to complete the step rated their arthritis as worse, more painful and disabling, yet there 
were no differences in disease duration, inflammation or disease activity between the two 
groups. In fact the only clear difference between these patients was their body composition. 
The results of this study (discussed in detail in Chapter 5) suggested that obesity has a major 
impact on RA patients’ perception of their disease and their functional ability.  
 
The prevalence of obesity in this population is concerning. Based on WHO BMI cut offs 27% 
of RA patients were obese. This is similar to the level of obesity reported in previous research 
carried out in RA (Armstrong et al., 2006) and higher than the level of obesity reported for 
the general UK population (HSE, 2009). However, the actual prevalence of obesity is likely 
to be even higher based on the potential inaccuracy of BMI as a measure of obesity in 
populations who have altered body composition. If the adapted BMI cut offs as suggested by 
Stavropoulos – Kalinoglou et al. (2007) were used then 40% of the RA patients studied in the 
cross sectional study would be classified as obese. This figure may be a more accurate 
indication of the level of obesity in the RA population as 46% of the RA patients studied in 
this thesis would be classified as obese based on their body fat percent as measured by 
bioelectrical impedance analysis. The findings of this thesis support suggestions by 
Stavropoulos – Kalinoglou et al. (2011) that BMI is likely not a very good measure of obesity 
in RA and the extent of obesity in this population is probably much worse than originally 
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perceived. The strong associations between obesity and cardio-respiratory fitness and the 
detrimental impact obesity appears to have on aspects of RA disease, cardio-respiratory 
fitness and physical function justify the use of exercise in the treatment of obesity in RA 
patients. The impact of obesity on the overall health of RA patients was highlighted by 
Stavropoulos – Kalinoglou et al. (2008). They too emphasized the need to treat obesity in RA 
and that clinical intervention involving exercise is the likely answer (Stavropoulos-
Kalinoglou et al., 2008).  
 
In terms of overall cardiovascular health, poor cardio-respiratory fitness and obesity stand  
out as two major risk factors for CVD in RA that are currently being ignored by health 
professionals. Examining the group of RA patients as a whole, their traditional CVD risk 
factors did not seem obviously elevated. This could be explained by the use of CVD risk 
lowering medication. However, in the cross sectional study 34% and 41% of RA patients 
were noted to be hypertensive and dyslipidemic, respectively and not adequately treated. 
Forty-one percent of RA patients also fulfilled the NCEP criteria for metabolic syndrome, 
another risk factor for CVD that is not routinely assessed.  
 
Despite providing some very interesting associations and differences amongst the unable and 
able groups, the cross sectional nature of the second experimental study (Chapter 4) means 
that the findings do not provide any evidence for causality. They do however; provide 
important information that may be used as the basis of future research. For instance a larger 
scale prospective study of cardiovascular health with a main focus on cardio-respiratory 
fitness and obesity is needed. Future research assessing newly diagnosed RA patients would 
help us understand whether poor cardio-respiratory fitness and obesity get progressively 
worse from diagnosis or whether these risk factors already exist at the time of diagnosis. 
Tracking these CVD risk factors as well as the more traditional risk factors would allow a 
better understanding on the importance of these factors to the overall cardiovascular health 
and wellbeing of RA patients. Also, in the cross sectional study, the step test was only 
performed once by each patient, perhaps some of the RA patients who were unable to 
complete the step test on that instance would be able to complete the step test on another 
occasion (e.g. they may feel better, more familiar with the test). Thus, the reliability of the 
step test in a typical RA population, in a clinical setting is unknown and more research using 
the step test is required to answer the above question. However, despite the limitations of this 
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cross sectional study, its findings have made an important contribution to our existing 
knowledge of RA patients’ cardiovascular health. In particular, this study has highlighted that 
even the more traditional, modifiable CVD risk factors are not being fully controlled. This is 
a very important finding if the cardiovascular health of RA patients is ever going to be 
improved.  
 
The final study in this thesis aimed to improve these so called modifiable risk factors, in 
particular cardio-respiratory fitness and obesity. Another important aspect of this pilot study 
was to design an exercise intervention that could be performed in groups in a clinical setting. 
Although only performed in a small group of patients, which was a significant limitation to 
this study, this group exercise intervention significantly improved cardio-respiratory fitness, 
aspects of cardiovascular health, body composition and even symptoms of RA disease. This 
exercise intervention was the first of its kind to investigate the beneficial effects of exercise 
on traditional CVD risk factors in patients with RA and so it could certainly be suggested that 
this short term exercise programme could help an RA patient to at least begin to improve 
their overall cardiovascular health and general well being. However, this pilot study lacked 
randomisation, blinding, a control group and a larger sample size. All of these criteria need to 
be fulfilled in future research in order to provide more sound conclusions on the beneficial 
effects exercise has on the cardiovascular health of RA patients. Future research also needs to 
include RA patients with more active disease than the patients investigated in this exercise 
intervention. Including patients with more active disease may also provide more information 
regarding their cardiovascular health that has not been shown in this thesis.  
 
Despite certain limitations, addressed in the preceding chapters, the combined studies 
discussed here have advanced our knowledge on RA patients’ cardiovascular health, by 
adding to our understanding of the factors that may contribute to the heightened CVD risk in 
this population, in particular poor cardio-respiratory fitness and obesity. The new findings 
also provide support for previous findings that have been subject to quite some debate. In 
particular this thesis supports one side of the ongoing argument about what obesity actually 
means in the RA population. Some researchers suggest that obesity is having a protective 
effect on CVD risk factors and that perhaps obesity is not even a risk factor of CVD in 
patients with RA (Peeters et al., 2003). The research by Peeters et al. (2003) along with the 
research that suggests obese patients present with less joint damage (Kaufmann et al., 2003) 
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promote the idea that obesity is not that detrimental to the RA patient. However, in the 
current thesis it has been shown that obesity significantly impacts on patients’ functional 
ability and on the perception of their arthritis. They report more pain and disability, but above 
all these obese patients have a very poor cardio-respiratory fitness. Fitness levels as low as 
10-13 ml·kg-1·min-1 were observed. This means doing very simple tasks like washing, 
dressing and grooming oneself requires 74% of their VO2 max (Tudor-Locke et al., 2009). 
Therefore, it is unsurprising that a higher HAQ score was observed in these patients. This 
serious deficiency in cardio-respiratory function illustrates the importance of interventions 
known to increase VO2 max. Exercise training is so important to delay the age at which cardio-
respiratory fitness becomes so limiting that an individual can no longer function 
independently in activities of daily living. These findings along with the findings from the 
literature discussed throughout this thesis illustrate the complex nature and importance of 
these risk factors in individuals with RA.  
 
This thesis has repeatedly demonstrated poor cardio-respiratory fitness and obesity in RA 
patients, yet these independent CVD risk factors continue to be overlooked. A recent report 
by Liao (2012) recognised that RA patients have an increased risk of CVD and in this review 
proposed three questions. How do we estimate risk of CVD in RA? Which interventions 
decrease CVD risk? And what should be the targets of the interventions? In Liao’s report the 
Framingham risk score is described as the main method for estimating CVD risk. However, it 
is also acknowledged that this method does not accurately estimate the risk of heart disease in 
RA and that it likely underestimates risk by approximately 50%. The following is an exact 
quote from the review  
 
“We have much guidance about how to prevent heart disease in RA based on the 
wealth of studies in the general population. The first, and perhaps the hardest, 
intervention is a change in habit: eating a well-balanced diet, exercising on a regular 
basis, and maintaining a healthy weight. We all know how well that works.” (Liao, 
2012).  
 
The above quote highlights the problem health professionals are faced with. Maintaining a 
healthy weight and regular exercise is recognised as a good intervention to help improve 
cardiovascular health, but because this requires too much effort, exercise is no longer 
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mentioned and the review continues with a discussion of the use of statins and screening 
lipids as a means of reducing CVD risk (Liao, 2012). The current thesis has demonstrated the 
importance of highlighting the need for lifestyle modification. Perhaps if cardio-respiratory 
fitness and body composition was measured routinely, the reality of the problem might 
encourage primary care physicians, rheumatologists and their team of health professionals to 
actually try and do something about it. However, the question arises, who should be 
responsible for addressing these issues with patients? Is this a matter for primary or 
secondary care physicians? Within secondary care, limited time means inflammatory disease 
management takes priority. This would suggest that perhaps this should be dealt with within a 
primary care setting. However, RA patients with early disease may only see their 
rheumatologist for months or even years. This “confusion” between both healthcare systems 
could explain why there are also such a large percentage of patients with untreated 
hypertension, dyslipidemia and obesity.  
 
An important novel feature of the studies reported here is the use of a submaximal step test to 
estimate cardio-respiratory fitness in patients with RA instead of the use of physical activity 
questionnaires to gage how fit and active RA patients actually are. An article by Lee et al. 
(2010) explained the importance of measuring cardio-respiratory fitness very clearly. Cardio-
respiratory fitness and physical activity are often used interchangeably (Lee et al., 2010). 
However, the measurement of both can often provide very different results (Cuperus et al., 
2012). In the cross sectional study (Chapter 4) 35% of RA patients reported having a 
moderate level of physical activity, however, no association between level of physical 
activity and cardio-respiratory fitness was observed. The measurement of physical activity 
using questionnaires relies on self reporting and has been shown to underestimate the 
association between physical activity and health outcomes (Walsh et al., 2004), whereas the 
measurement of cardio-respiratory fitness has been shown to have a much stronger 
association with all-cause mortality. Cardio-respiratory fitness is now believed to be an even 
stronger predictor of all-cause mortality in comparison to established risk factors like 
hypertension, smoking, and diabetes mellitus (Myers et al., 2002) and that an improvement in 
cardio-respiratory fitness, as small as 3.5 ml·kg-1·min-1 could reduce CVD mortality by as 
much as 16% (Blair et al., 1995). Because of this, the current thesis along with some previous 
studies (Kodama et al., 2009, Lee et al., 2010) recommend that cardio-respiratory fitness 
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should be assessed in a clinical setting and the information provided should be used to make 
clinical recommendations as part of routine care.  
 
Nonetheless, to make the assessment of cardio-respiratory fitness worthwhile, RA patients 
need to engage in regular physical activity, if they want to make changes to their overall 
cardiovascular health and well being. The issue here is that physical inactivity is not just a 
problem within rheumatology. Health surveys suggest that in the UK 71% of adult women 
and 61% of adult men do not meet the government’s recommendation for physical activity 
(HSE, 2008). This physical inactivity is thought to cost the NHS £8.2 billion per year which 
is in addition to the cost of obesity estimated at £4.2 billion per year. Despite this enormous 
burden on our health system, physical inactivity as a risk factor for many chronic diseases is 
generally ignored. More traditional risk factors like hypertension, dyslipidemia and diabetes 
mellitus are recognised as modifiable risk factors for many chronic diseases. They are 
routinely reviewed during visits to a GP because incentivised interventions are embedded 
within the primary healthcare system. GP’s are financially rewarded for meeting healthcare 
targets through the Quality and Outcomes Framework. In a recent editorial, it was proposed 
that physical activity should also be incorporated into a Quality and Outcomes Framework 
(Weiler and Stamatakis, 2010). This would quickly incorporate physical activity into GP’s 
medical systems, motivate regular follow-ups and promote physical activity within primary 
care consultations. However, there is one issue with this. GP’s are not experts in exercise 
medicine, exercise prescription and are not trained to give advice on lifestyle modification. 
Perhaps GP’s and specialist doctors who see their patients for specific medical reasons need 
to refer their patients to suitably trained allied healthcare professionals, like exercise 
physiologists, to maximise the chances of successful behaviour change. Currently the NHS 
does not employ exercise specialists; perhaps the focus should be on the employment of 
exercise physiologists as recognised healthcare professionals. This could be quite cost 
effective considering physical inactivity and obesity cost the NHS approximately £12.4 
billion a year.   
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7.1 Conclusion  
 
The work presented in the current thesis is the first to incorporate measures of cardio-
respiratory fitness, body composition and RA disease whilst investigating the traditional 
CVD risk factors of an RA population. To date no other investigation has measured all of 
these factors together in a clinical setting. In the investigated RA population there was little 
range in their cardio-respiratory fitness level, i.e. all patients had a low cardio-respiratory 
fitness and thus no outstanding associations between cardio-respiratory fitness and traditional 
CVD risk factors were observed. This could be partially explained by a large percentage of 
patients receiving CVD risk lowering medication. However, what is evident from this thesis 
is that RA patients are suffering from the effects of being unfit and overweight. Poor cardio-
respiratory fitness and obesity is having a significant impact on patients’ physical ability and 
the perception of their RA disease. The present investigation has shown that cardio-
respiratory fitness and obesity can easily be assessed in a clinical setting and should be 
incorporated as part of routine care. Based on this information RA patients should be given 
the necessary advice on how to improve their overall cardiovascular health and general well 
being. A group exercise intervention like the one outlined in this thesis could help patients 
adopt a healthier lifestyle. This along with careful management of the more traditional CVD 
risk factors could help reduce the risk of CVD mortality in this population.   
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9 Appendices  
 
Appendix 1: Normative Data on Fitness Levels (Heywood, 1998) 
 
 
Table 1 Normative data for females (values in ml·kg-1·min-1) 
 
Age Very Poor Poor Fair Good Excellent Superior 
13-19 <25.0 25.0 - 30.9 31.0 - 34.9 35.0 - 38.9 39.0 - 41.9 >41.9 
20-29 <23.6 23.6 - 28.9 29.0 - 32.9 33.0 - 36.9 37.0 - 41.0 >41.0 
30-39 <22.8 22.8 - 26.9 27.0 - 31.4 31.5 - 35.6 35.7 - 40.0 >40.0 
40-49 <21.0 21.0 - 24.4 24.5 - 28.9 29.0 - 32.8 32.9 - 36.9 >36.9 
50-59 <20.2 20.2 - 22.7 22.8 - 26.9 27.0 - 31.4 31.5 - 35.7 >35.7 
60+ <17.5 17.5 - 20.1 20.2 - 24.4 24.5 - 30.2 30.3 - 31.4 >31.4 
 
 
 
Table 2 Normative data for males (values in ml·kg-1·min-1).  
 
Age Very Poor Poor Fair Good Excellent Superior 
13-19 <35.0 35.0 - 38.3 38.4 - 45.1 45.2 - 50.9 51.0 - 55.9 >55.9 
20-29 <33.0 33.0 - 36.4 36.5 - 42.4 42.5 - 46.4 46.5 - 52.4 >52.4 
30-39 <31.5 31.5 - 35.4 35.5 - 40.9 41.0 - 44.9 45.0 - 49.4 >49.4 
40-49 <30.2 30.2 - 33.5 33.6 - 38.9 39.0 - 43.7 43.8 - 48.0 >48.0 
50-59 <26.1 26.1 - 30.9 31.0 - 35.7 35.8 - 40.9 41.0 - 45.3 >45.3 
60+ <20.5 20.5 - 26.0 26.1 - 32.2 32.3 - 36.4 36.5 - 44.2 >44.2 
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Appendix 2: Disease Activity Score 28 (DAS 28) 
 
 
 
 
 
TENDER JOINTS     SWOLLEN JOINTS 
 
 
 
 
 
     
VAS SCALE:  
 
 
(In the past week how would you rate your rheumatoid arthritis from the best it has ever been to the 
worst it has ever been?) 
 
PAIN  
 
(How would you rate your current pain?) 
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Appendix 3: Health Assessment Questionnaire (HAQ) 
 
HAQ - Please check the response which best describes your usual abilities OVER THE PAST 
 Without 
ANY 
difficulty 
With 
SOME 
difficulty 
With 
MUCH 
difficulty 
UNABLE 
To do 
SCORE 
 0 1 2 3  
Dressing and Grooming Are you able to:      
Dress yourself, including tying shoelaces and buttons?      
Shampoo your hair?      
Rising Are you able to:      
Stand up from an armless straight chair?      
Get in and out of bed?      
Eating Are you able to:      
Cut your meat?      
Lift a cup or glass to your mouth?      
Open a new carton of milk (or soap powder)?      
Walking Are you able to:      
Walk outdoors on flat ground?      
Climb up five steps?      
Hygiene  Are you able to:      
Wash and dry your body?      
Take a tub bath?      
Get on and off the toilet?      
Rising Are you able to:      
Reach and get down a 5lb object from just able your head      
Bend down to pick up clothing off the floor?      
Grip Are you able to:      
Open car doors?      
Open jars which have been previously opened?      
Turn taps on and off?      
Activities Are you able to?      
Run errands and shop?      
Get in and out of a car?      
Do chores such as vacuuming, housework, light gardening?       
 
Please tick any AIDS OR DEVICES that you usually use for any of these activities: 
 
Cane (W)        Walking frame (W)      Built up or special utensils            Crutches            Wheelchair 
 
Special chair         Raised toilet seat         Bath seat         Bath rail         Long handled appliances for reach  
 
Jar opener           Devices used for dressing (button hooks, zipper pull, shoe horn)       
 
Please tick any categories for which you usually need help from another person  
Dressing        Eating  Rising      Walking Hygiene           Reach Gripping          Housework  
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Appendix 4:  Equations to predict VO2 max 
 
Step 1: calculate VO2 
Stage 1: VO2 (litres/minute) = (16.287 x body weight in kg)/1000 
Stage 2: VO2 (litres/minute) = (24.910 x body weight in kg)/1000 
Stage 3: VO2 (litres/minute) = (33.533 x body weight in kg)/1000 
 
Step two: calculate uncorrected VO2 max 
Uncorrected VO2 max (liters/minute) = stage VO2/%VO2 max 
 
Where: 
 %VO2 max = (0.769 x stage HR) – 48.5 for men  
%VO2 max = (0.667 x stage HR) – 42 for women 
 
Step three: calculate VO2 max 
VO2 max male (liters/minute) = (0.348 x uncorrected VO2max) - (0.035 x age in years) + 3.011 
VO2 max female (liters/minute) = (0.302 x uncorrected VO2max) - (0.019 x age in years) + 
1.593 
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Appendix 5: International Physical Activity Questionnaire (IPAQ) 
 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE (IPAQ) 
 
We are interested in finding out about the kinds of physical activities that people do 
as part of their everyday lives.  The questions will ask you about the time you spent 
being physically active in the last 7 days.  Please answer each question even if you 
do not consider yourself to be an active person.  Please think about the activities you 
do at work, as part of your house and yard work, to get from place to place, and in 
your spare time for recreation, exercise or sport. 
  
Think about all the vigorous activities that you did in the last 7 days.  Vigorous 
physical activities refer to activities that take hard physical effort and make you 
breathe much harder than normal.  Think only about those physical activities that you 
did for at least 10 minutes at a time. 
 
During the last 7 days, on how many days did you do vigorous physical activities like 
heavy lifting, digging, aerobics, or fast bicycling?  
 
_____ days per week  
 
   No vigorous physical activities  Skip to question 3 
 
 
How much time did you usually spend doing vigorous physical activities on one of those 
days? 
 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
Think about all the moderate activities that you did in the last 7 days.  Moderate 
activities refer to activities that take moderate physical effort and make you breathe 
somewhat harder than normal.  Think only about those physical activities that you 
did for at least 10 minutes at a time. 
 
 
During the last 7 days, on how many days did you do moderate physical activities 
like carrying light loads, bicycling at a regular pace, or doubles tennis?  Do not 
include walking. 
 
_____ days per week 
 
   No moderate physical activities  Skip to question 5 
 
 
How much time did you usually spend doing moderate physical activities on one of those 
days? 
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_____ hours per day 
_____ minutes per day 
 
  Don’t know/Not sure  
 
 
Think about the time you spent walking in the last 7 days.  This includes at work and 
at home, walking to travel from place to place, and any other walking that you might 
do solely for recreation, sport, exercise, or leisure. 
 
5. During the last 7 days, on how many days did you walk for at least 10 minutes 
at a time?   
 
_____ days per week 
  
   No walking     Skip to question 7 
 
 
How much time did you usually spend walking on one of those days? 
 
_____ hours per day 
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
The last question is about the time you spent sitting on weekdays during the last 7 days.  
Include time spent at work, at home, while doing course work and during leisure time.  This 
may include time spent sitting at a desk, visiting friends, reading, or sitting or lying down to 
watch television. 
 
During the last 7 days, how much time did you spend sitting on a week day? 
 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
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Appendix 6: Borg RPE Scale (6-20) 
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Appendix 7: Does gender have an impact on the association between 
fitness/step ability and RA disease, body composition and CVD 
risk factors? 
 
Methods 
 
In order to determine whether gender had an impact on the associations between cardio-
respiratory fitness and RA disease, body composition and CVD risk factors or whether 
female ‘unable’ patients were any different to male ‘unable’ patients; the group of 100 RA 
patients were split into two groups – females (n=69) and males (n=31). The data analysis 
performed in chapter 4 was repeated for females and males separately.  
 
Results  
The female results will be presented first followed by the results for the male group. 
 
Fitness in Females  
 
RA Factors 
 
Fitness did not correlate with any of the RA disease variables in female patients (p > 0.05). 
 
Body Composition 
 
Fitness correlated significantly with weight (r = -0.598, p = 0.000), BMI (r = -0.620, p = 
0.000), body fat percent (r = -0.603, p = 0.000), waist circumference (r = -0.588, p = 
0.000), hip circumference (r = -0.565, p = 0.000) when adjusting for age.  
 
CVD Risk Factors  
 
Fitness only correlated significantly with glucose in female RA patients (rs = -0.376, p = 
0.034).  
 
Hierarchical multiple regression was used to assess the ability of two measures (body fat 
percent, HAQ) to predict level of fitness. HAQ was entered at step 1, explaining 0.1% of the 
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variance in fitness levels (R square change 0.001). After entry of body fat percent at step 2 
the total variance explained by the model as a whole was 19.8% (F (2,43) = 5.32, p = 0.009). 
Body fat percent explained an additional 19.7% of the variance in fitness, after controlling for 
HAQ (R square change 0.197, F change (1,43) = 10.56, p = 0.002). In the final model, only 
body fat percent was significant (beta -0.45, p = 0.002).  
 
Step Test 
 
33% (23/69) of female RA patients were unable to complete the step test. To analyse this 
population in more detail we compared this group ‘Unable group’ to those patients who 
were ‘able’ to complete the step test.  
 
RA Factors 
 
MANOVA was performed to investigate the differences in RA disease variables. There was a 
significant difference between patients able and unable to complete the step test on the 
combined variables (F (11, 55) = 4.21, p = 0.000, Wilks’ Lamda = 0.54; partial eta squared = 
0.46). When the results for the dependent variable were considered separately, the only 
differences to reach statistical significance, using a Bonferroni adjusted alpha level of 0.004, 
was VAS arthritis (F (1, 65) = 16.37, p = 0.000, partial eta squared = 0.20) and HAQ (F (1, 
65) = 28.54, p = 0.000, partial eta squared = 0.31). See Table 1.   
 
Table 1 RA characteristics of unable and able female patients.  
 RA Characteristic 
Unable                
(n = 23) 
Able                   
(n = 46) 
P 
  
Age (years) 61.3 ± 8.3 56.8 ± 11.1 0.104 
 Disease duration (years) 11.9 ± 11.9 10.1 ± 9.6 0.489 
 ESR (mm·hr-1) 21.0 ± 13.4 13.8 ± 11.9 0.029 
 CRP (mg·l-1) 18.0 ± 24.4 7.1 ± 12.7 0.019 
 Tender joints (n) 2.1 ± 3.5 2.5 ± 5.1 0.771 
 Swollen joints (n) 0.4 ± 1.4 0.5 ± 1.4 0.801 
 VAS arthritis (0-100) 48.4 ± 22.5 25.4 ± 21.2 0.000* 
 Pain (0-100) 37.5 ± 33.0 18.5 ± 26.1 0.013 
 DAS 28 ESR 3.2 ± 1.1 2.5 ± 1.5 0.060 
 DAS 28 CRP 3.1 ± 0.9 2.6 ± 1.2 0.111 
 HAQ (0-3) 1.6 ± 0.6 0.7 ± 0.7 0.000* 
 Values are mean ± SD, N = 69. ESR; erythrocyte sedimentation rate, CRP; C-reactive protein, DAS; disease 
activity score, VAS; visual analogue scale, HAQ; health assessment questionnaire.   
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Chi squared analysis revealed no significant association between step ability and DMARD 
group (χ2 (1, n = 69) = 3.45, p = 0.178, phi = 0.22), steroid exposure (χ2 (1, n = 69) = 2.30, p 
= 0.129, phi = -0.18), presence of rheumatoid factor (χ2 (2, n = 69) = 3.38, p = 0.184, phi = 
0.22) or CCP positivity (χ2 (2, n = 69) = 3.78, p = 0.151, phi = 0.23).  
 
Body Composition 
 
MANOVA was performed to investigate the differences in body composition variables 
between the step ability groups. There was a significant difference between patients able and 
unable to complete the step test on the combined variables (F (6, 61) = 3.57, p = 0.004, 
Wilks’ Lamda = 0.74; partial eta squared = 0.26). When the results for the dependent variable 
were considered separately, all body composition variables except wasit:hip reached 
statistical significance, using a Bonferroni adjusted alpha level of 0.008. (Table 5.2) Weight 
(F (1, 66) = 8.1, p = 0.006, partial eta squared = 0.11); BMI (F (1, 66) = 15.7, p = 0.000, 
partial eta squared = 0.19); body fat percent (F (1, 66) = 11.4, p = 0.001, partial eta squared 
= 0.15); waist circumference (F (1, 66) = 15.7, p = 0.000, partial eta squared = 0.19); hip 
circumference (F (1, 66) = 11.1, p = 0.001, partial eta squared = 0.14). Inspection of the 
mean scores indicated that patients unable to complete the step test had a less favourable 
body composition. Means and SD are shown below in Table 2.   
 
Table 2 Body composition of female RA patients.  
 Body Composition Unable (n = 23) Able (n = 46) P 
Weight (kg)  78.65 ± 16.90 68.08 ± 12.93 0.006 
BMI (kg·m-2)  31.56 ± 6.27 26.26 ± 4.54 0.000 
Body Fat (%)  50.72 ±14.41 40.24 ± 10.71 0.001 
Waist (cm)  94.95 ± 12.01 83.98 ± 10.03 0.000 
Hip (cm) 106.64 ± 12.61 97.38 ± 9.67 0.001 
Waist:Hip  0.89 ± 0.04 0.86 ± 0.06 0.043 
Values are mean ± SD, N = 69. BMI; body mass index  
 
 
Chi squared analysis revealed a significant association between step ability and BMI category 
(χ2 (1, n = 69) = 11.09, p = 0.001, phi = -0.40), and body fat percentage category (χ2 (2, n = 
69) = 5.92, p = 0.050, phi = 0.30). Unable patients had a greater prevalence of obesity. 
 
 158 
 
Traditional CVD risk factors  
 
MANOVA revealed no significant difference in CVD risk factors (SBP, DBP, fasting lipids 
and glucose) between the two groups (F (10, 36) = 0.83, p = 0.604). See Table 3.  
 
Table 3 CVD risk factors of female RA patients.  
 CVD Risk Factors  Unable (n = 23) Able (n = 46) P 
SBP (mmHg) 145.00 ± 19.10 137.27 ± 21.29 0.249 
DBP (mmHg) 84.21 ± 9.17 81.51 ± 11.94 0.454 
TC (mmol·l-1) 5.11 ± 1.11 5.42 ± 1.17 0.418 
TG (mmol·l-1) 1.59 ± 0.77 1.41 ±  0.79 0.475 
LDL-c (mmol·l-1) 2.92 ± 0.96 3.17 ± 1.11 0.469 
HDL-c (mmol·l-1) 1.47 ± 0.36 1.61 ± 0.47 0.320 
Glucose (mmol·l-1) 5.46 ± 1.25 5.04 ± 0.48 0.096 
Framingham risk (percent) 14.83 ± 8.63 10.14 ± 6.47 0.046 
Values are mean ± SD, N = 69. SBP; systolic blood pressure, DBP; diastolic blood pressure, TC; total 
cholesterol, TG; triglycerides, LDL-c; low density lipoprotein, HDL-c; high density lipoprotein. 
 
Chi squared analysis revealed no significant association between step ability and presence of 
hypertension (medication or high blood pressure) (χ2 (1, n = 69) = 1.96, p = 0.160, phi = -
0.17), dyslipidemia (medication or high cholesterol) (χ2 (1, n = 69) = 0.34, p = 0.561, phi = 
0.07), smoking status (χ2 (2, n = 69) = 3.46, p = 0.177, phi = 0.22), family history of heart 
disease (χ2 (1, n = 69) = 2.25, p = 0.133, phi = 0.18) or Framingham risk score category (low, 
mod, high risk) (χ2 (2, n = 69) = 5.27, p = 0.072, phi = 0.29).  
 
Summary of Female Results  
 
Poor cardio-respiratory fitness was strongly associated with a less favourable body 
composition. BMI and percent body fat had the strongest associations with fitness, the same 
finding observed in the total population. No significant associations with RA disease 
variables were observed but a poor fitness was associated with a higher glucose level. Female 
RA patients who were unable to complete the step test rated their arthritis as worse and more 
disabling, similar to that of the total group; reported pain in females was higher but not 
significantly different. Unsurprisingly, female patients unable to complete the step test had a 
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significantly worse body composition. No differences in CVD risk factors were observed 
between the step ability groups. 
 
Fitness in Males  
 
RA Factors 
 
Fitness did not correlate with any of the RA disease variables in male RA patients (p > 0.05). 
 
Body Composition 
 
Fitness correlated significantly with weight (r = -0.757, p = 0.000), BMI (r = -0.712, p = 
0.001), waist circumference (r = -0.823, p = 0.000), hip circumference (r = -0.713, p = 
0.000) and waist:hip (r = -0.488, p = 0.040) when adjusting for age. Fitness did not correlate 
significantly with body fat percent (r = -0.297, p = 0.231).  
 
CVD Risk Factors  
 
Fitness did not correlate with any of the CVD risk factors in male RA patients (p > 0.05).   
 
Because fitness did not correlate significantly with body fat percent in males the hierarchical 
multiple regression was performed using waist circumference. Hierarchical multiple 
regression was used to assess the ability of two measures (waist circumference, HAQ) to 
predict level of fitness. HAQ was entered at step 1, explaining 14.4% of the variance in 
fitness levels (R square change 0.144). After entry of waist circumference at step 2 the total 
variance explained by the model as a whole was 41.7% (F (2,16) = 5.73, p = 0.013). Waist 
circumference explained an additional 27.3% of the variance in fitness, after controlling for 
HAQ (R square change 0.273, F change (1,16) = 7.50, p = 0.015).  In the final model, only 
waist circumference was significant (beta -0.62, p = 0.015).  
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Step Test 
 
Thirty-nine percent (12/31) of male RA patients were unable to complete the step test. To 
analyse this population in more detail we compared this group ‘Unable group’ to those 
patients who were ‘able’ to complete the step test.  
 
RA Factors 
 
MANOVA was performed to investigate the differences in RA disease variables. There was 
no significant difference between patients able and unable to complete the step test on the 
combined variables (F (11, 19) = 1.41, p = 0.245, Wilks’ Lamda = 0.55; partial eta squared = 
0.45). Inspection of the mean scores suggests that patients unable to complete the step 
reported worse arthritis, more pain and more disability. See Table 4. 
 
Table 4 RA characteristics of unable and able male patients.  
 RA Characteristic  
Unable                
(n = 12) 
Able                   
(n = 19) 
P   
Age (years) 65.3 ± 6.9 61.6 ± 9.7 0.293 
 Disease duration (years) 9.1 ± 8.1 10.1 ± 4.7 0.674 
 ESR (mm·hr-1) 19.7 ± 14.2 14.9 ± 12.2 0.320 
 CRP (mg·l-1) 19.8 ± 18.1 12.9 ± 18.9 0.328 
 Tender joints (n) 1.6 ± 2.2 1.3 ± 2.5 0.732 
 Swollen joints (n) 1.1 ± 2.2 1.4 ± 3.5 0.768 
 VAS arthritis (0-100) 43.5 ± 28.3 21.7 ± 16.9 0.012 
 Pain (0-100) 30.6 ± 29.5 12.7 ± 15.1 0.033 
 DAS 28 ESR  3.1 ± 1.4 2.4 ± 1.4 0.196 
 DAS 28 CRP 3.1 ± 1.3 2.6 ± 1.1 0.215 
 HAQ (0-3) 1.2 ± 0.8 0.4 ± 0.5 0.003 
 Values are mean ± SD, N = 31. ESR; erythrocyte sedimentation rate, CRP; C-reactive protein, DAS; disease 
activity score, VAS; visual analogue scale, HAQ; health assessment questionnaire.   
 
Chi squared analysis revealed no significant association between step ability and DMARD 
group (χ2 (1, n = 31) = 0.38, p = 0.826, phi = 0.11), steroid use (χ2 (1, n = 31) = 3.45, p = 
0.776, phi = -0.16), presence of rheumatoid factor (χ2 (2, n = 31) = 1.67, p = 0.434, phi = 
0.23) or CCP positivity (χ2 (2, n = 31) = 1.61, p = 0.448, phi = 0.23).  
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Body Composition 
 
MANOVA was performed to investigate the differences in body composition variables 
between the step ability groups. There was no significant difference between patients able 
and unable to complete the step test on the combined variables (F (6, 24) = 1.43, p = 0.245, 
Wilks’ Lamda = 0.74; partial eta squared = 0.26). Inspection of the mean scores indicated 
that patients unable to complete the step test had a slightly less favourable body composition 
but this was not significant. Means and SD are shown below in Table 5.  
 
Table 5 Body composition of male RA patients.  
Body Composition Unable (n = 12) Able (n = 19) P 
Weight (kg)  80.03 ± 21.24 79.80 ± 11.94 0.969 
BMI (kg·m-2)  28.29 ± 7.16 26.39 ± 3.19 0.320 
Body Fat (%)  25.75. ± 9.77 23.21 ± 4.95 0.345 
Waist (cm)  101.33 ± 14.61 95.84 ± 9.13 0.206 
Hip (cm) 100.67 ± 10.64 99.74 ± 7.31 0.775 
Waist:Hip  1.00 ± 0.07 0.95 ± 0.05 0.030 
Values are mean ± SD, N = 31.BMI; body mass index  
 
 
Chi squared analysis revealed no significant association between step ability and BMI 
category (χ2 (1, n = 31) = 0.40, p = 0.527, phi = -0.11), or body fat percentage category (χ2 (2, 
n = 31) = 3.69, p = 0.157, phi = 0.35). Unable patients did not have a greater prevalence of 
obesity.  
 
Traditional CVD Risk Factors  
 
MANOVA revealed no significant difference in CVD risk factors (SBP, DBP, fasting lipids 
and glucose) between the two groups, F (10, 12) = 2.03, p = 0.122. See Table 6. 
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Table 6 CVD risk factors of male RA patients.  
  CVD Risk Factors Unable (n = 12) Able (n = 19) P 
SBP (mmHg) 145.44 ± 28.89 140.86 ± 14.07 0.614 
DBP (mmHg) 78.67 ± 8.23 80.14 ± 11.82 0.748 
TC (mmol·l-1) 5.12 ± 1.48 5.35 ± 1.13 0.680 
TG ( mmol·l-1) 2.02 ± 0.91 1.42 ±  0.49 0.053 
LDL-c (mmol·l-1) 3.09 ± 1.37 3.31 ± 0.91 0.657 
HDL-c (mmol·l-1) 1.06 ± 0.23 1.43 ± 0.37 0.015 
Glucose (mmol·l-1) 5.77 ± 1.49 5.46 ± 1.20 0.613 
Framingham risk (percent) 31.32 ± 11.13 23.10 ± 8.88 0.063 
Values are mean ± SD, N = 31. SBP; systolic blood pressure, DBP; diastolic blood pressure, TC; total 
cholesterol, TG; triglycerides, LDL-c; low density lipoprotein, HDL-c; high density lipoprotein. 
 
Chi squared analysis revealed no significant association between step ability and presence of 
hypertension (medication or high blood pressure) (χ2 (1, n = 31) = 0.85, p = 0.355, phi = -
0.17), dyslipidemia (medication or high cholesterol) (χ2 (1, n = 31) = 0.18, p = 0.675, phi = 
0.08), smoking status (χ2 (2, n = 31) = 1.17, p = 0.558, phi = 0.19), or family history of heart 
disease (χ2 (1, n = 31) = 0.52, p = 0.470, phi = -0.13).  
 
Chi squared analysis revealed a significant association between step ability and Framingham 
risk score category (low, mod, high risk) (χ2 (2, n = 31) = 6.29, p = 0.043, phi = 0.48).  
 
Summary of Males Results  
 
Poor fitness was strongly associated with a less favourable body composition. However, 
unlike in females, waist circumference had the strongest association in male RA patients. 
Body fat percent was not associated with fitness level. No significant associations with RA 
disease variables or CVD risk factors between the step ability groups were observed. Male 
RA patients who were unable to complete the step test did not differ significantly in terms of 
their RA disease variables. Upon further examination of their mean scores they did seem to 
rate their arthritis as worse, more painful and more disabling, however this did not reach 
statistical significance. One of the major differences observed in male RA patients was that 
there was no significant difference in body composition between patients who were unable or 
able to complete the step test. No differences in CVD risk factors were observed.  
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Discussion  
 
These results suggest that obesity may have a greater impact on physical ability and 
perception of RA disease in female RA patients than in male RA patients. BMI and body fat 
percent seem to be the greatest predictors of fitness and step ability in females whilst waist 
circumference has the most significant association with level of fitness in males. There is a 
very distinct pattern emerging from the results of chapter 4 and 5 and that is that obesity has a 
significant impact on level of fitness, step ability and how patients, especially females, 
perceive their arthritis, pain and disability. Despite obesity being a worldwide problem, 
research on obesity in RA is surprisingly very limited. But being obese has been shown to 
reduce level of physical activity and causing disability in everyday tasks (Mattsson et al., 
1997). Larsson and Mattsson (2001) investigated the perceived disability and functional 
limitations in a group of obese women. They found that obese women perceived much 
greater disability on normal activities of daily living than normal weight women. Activities 
that involved bending, kneeling and walking upstairs were perceived as being more difficult 
for obese women (Larsson and Mattsson, 2001). Previous results by Mattsson et al., (1997) 
suggested that these obese women had a lower maximum oxygen uptake, in other words they 
were more unfit. This is supported by the findings of the study.  
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Appendix 8: Ankle Brachial Pressure Index (ABPI) of RA patients  
 
 
Ankle brachial pressure index (ABPI) intra reliability  
 
To determine the intra observer reliability of JC, 7 healthy participants were recruited and 
their ABPI was measured at two time points (approximately one week apart). The mean age 
of the 7 volunteers was 22 (ranging from 18-29) years. There were 4 females and 3 males. 
Table 1 shows the raw data for the 7 volunteers where T1 and T2 represent time points one 
and two respectively.  
 
 
Table 1. Ankle brachial pressure index (ABPI) raw data for the 7 volunteers   
 
 
 
 
 
 
 
 
 
 
Table 2 demonstrates the results for the intra-observer reliability. The intraclass correlation 
coefficient (ICC) for the intra-observer reliability was high (> 0.80) for observer JC. There 
was no significant difference between ABPI results at T1 and T2 as shown by the p value in 
Table 2.  
 
 
Table 2. Results for intra-observer reliability  
  Mean SD ICC  P  
ABPI right T1 1.10 0.10 
  ABPI right T2 1.12 0.13 0.869 0.910 
ABPI left T1 1.12 0.14 
  ABPI left T2  1.11 1.13 0.914 0.461 
 
 
 
 
 
Subject ABPI right T1 ABPI left T1 ABPI right T2 ABPI left T2 
1 1.00 1.04 0.95 0.97 
2 1.12 1.16 1.21 1.13 
3 1.05 1.03 1.08 1.04 
4 1.30 1.41 1.35 1.38 
5 1.04 1.08 1.06 1.04 
6 1.10 1.00 1.00 1.10 
7 1.11 1.15 1.09 1.09 
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Ankle brachial pressure index (ABPI) in rheumatoid arthritis (RA)  
 
 
Introduction  
 
Cardiovascular disease is increased in patients with RA. ABPI is an efficient tool for 
objectively documenting the presence of lower extremity peripheral arterial disease (Allison 
et al., 2008). A fall in blood pressure in an artery at the ankle relative to the central blood 
pressure suggests a stenosis in the arterial conduits somewhere in between the aorta and the 
ankle. The aim of this investigation was to determine the prevalence of an abnormal ABPI in 
RA patients and to establish potential associations between APBI and RA disease, CVD risk 
factors and body composition.  
 
Methods  
ABPI was assessed in the 100 RA patients who took part in the cross sectional study (chapter 
4 and 5).  
 
Protocol  
The ABPI was determined by measuring the systolic blood pressure from both brachial 
arteries and from both the posterior tibial arteries after the patient had been resting in the 
supine position for 10 minutes. Systolic blood pressure was recorded using a handheld 5 mHz 
Doppler (Dopplex D900, Huntleigh, Bedfordshire, England). ABPI was calculated by 
dividing each ankle pressure by the highest brachial arterial pressure.  
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Results  
98 RA patients had a normal ABPI (0.90-1.30) with only 2 subjects having an ABPI between 
0.70 - 0.89 indicating mild disease.  
 
In relation to RA disease ABPI correlated significantly with CRP and HAQ scores, with a 
lower ABPI associated with higher levels of CRP and worse reported disability. ABPI did not 
correlate with the other RA disease related factors (see Table 3).   
 
 
Table 3. Correlations between ABPI and RA disease variables  
*p < 0.05. ESR; erythrocyte sedimentation rate, CRP; C-reactive protein, DAS; disease activity score, VAS; 
visual analogue scale, HAQ; health assessment questionnaire.   
 
 
 
 
 
ABPI correlated significantly with systolic blood pressure but did not correlate with the other 
traditional CVD risk factors (see Table 4).  
 
 
 
  ABPI ESR CRP 
Tender 
joints 
Swollen 
joints 
VAS 
arthritis 
Pain 
DAS28 
ESR 
DAS28 
CRP 
HAQ 
Disease 
duration 
Age 
ABPI x 
           
ESR -0.13 x 
          
CRP -0.23* 0.56* x 
         
Tender 
joints 
-0.06 0.30* 0.17 x 
        
Swollen 
joints 
-0.04 0.44* 0.40* 0.41* x 
       
VAS 
arthritis 
-0.15 0.33* 0.29* 0.49* 0.33* x 
      
Pain -0.09 0.16 0.10 0.38 0.19 0.65* x 
     
DAS 28 
ESR 
-0.14 0.72* 0.44* 0.75* 0.61* 0.68* 0.51* x 
    
DAS 28 
CRP 
-0.14 0.55* 0.52* 0.81* 0.64* 0.73* 0.51* 0.93* x 
   
HAQ -0.20* 0.34* 0.20* 0.32* 0.09 0.66* 0.57* 0.51* 0.50* x 
  
Disease 
duration 
0.01 -0.02 -0.11 -0.07 -0.07 0.15 0.00 -0.01 -0.02 0.14 x 
 
Age -0.09 0.08 -0.03 0.10 0.01 0.19 0.09 0.09 0.07 0.12 0.25 x 
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Table 4. Correlations between ABPI and CVD risk factors  
  ABPI  SBP DBP Framingham TC TG LDL HDL Glucose 
ABPI x 
        
SBP 0.40* x 
       
DBP -0.25 0.63* x 
      
Framingham -0.11 0.52* 0.23 x 
     
TC 0.06 -0.04 0.14 -0.01 x 
    
TG 0.02 0.15 0.14 0.13 0.04 x 
   
LDL-c 0.06 -0.02 0.13 0.07 0.92* 0.09 x 
  
HDL-c 0.01 -0.16 -0.07 -0.25 0.35* 0.37* 0.07 x 
 
Glucose -0.36 0.24 0.21 0.59* 0.03 0.05 0.09 0.17 x 
*p < 0.05. SBP; systolic blood pressure, DBP; diastolic blood pressure, TC; total cholesterol, TG; triglycerides, 
LDL-c; low density lipoprotein, HDL-c; high density lipoprotein.  
 
 
ABPI did not correlate with any of the body composition variables (see Table 5). 
 
Table 5. Correlations between ABPI and Body Composition. 
 
 
 
 
 
 
 
 
 
ABPI Weight BMI Waist Hip Waist: Hip 
Body fat 
percent 
ABPI x       
Weight 0.08 x      
BMI -0.04 0.87* x     
Waist -0.06 0.88* 0.82* x    
Hip -0.04 0.85* 0.87* 0.84* x   
Waist: hip -0.05 0.39* 0.29* 0.63* 0.13 x  
Body fat percent 0.10 0.44* 0.73* 0.33* 0.63* -0.21* x 
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Step Test and ABPI 
 
ABPI did not correlate with fitness (r = 0.104, p = 0.409).  
 
Independent samples t test illustrated a significant difference in ABPI values in patients who 
were Able and Unable to complete the step test, see Table 6.  
 
Table 6. ABPI of step ability groups, N = 100  
Step Ability Mean SD P 
Able (n=65) 1.09 0.17 
 
Unable (n=35) 0.97 0.32 0.048*  
 
 
Discussion   
 
RA patients generally had a normal ABPI indicating no clinical evidence of peripheral 
vascular disease. Only 2% of RA patients had an abnormal ABPI (< 0.9) with values 
indicating mild peripheral vascular disease. Interestingly, lower ABPI values were associated 
with higher levels of inflammation (CRP) and worse reported disability (HAQ). Also, RA 
patients unable to complete the step test had a lower ABPI when compared to patients who 
were able to complete the step test.  
 
A study by Theodoridou et al. (2003) investigated ABPI in patients with systemic lupus 
erythematosus (SLE). The prevalence of abnormal ABPI in the SLE cohort was 37%, 
however, in this study an ABPI of < 1.0 was considered abnormal based on suggestions by 
Sacks et al. (2002). In the current RA study, 17% of RA patients had an abnormal ABPI 
based on the above suggestion by Sacks et al. (2002); this is slightly lower than that reported 
by Alkaabi et al. (2003), who reported 25% of RA patients had an ABPI < 1.0. However, 
both of these values are significantly greater than the 2.5% of healthy aged matched controls 
with an ABPI < 1.0 who were also investigated by Alkaabi et al. (2003). Thus, suggesting 
that the prevalence of peripheral vascular disease is much higher in RA patients than that of 
healthy controls. Alkaabi et al. (2003) also found that patients with an ABPI < 1.0 had a 
significantly higher HAQ score compared to patients with a normal ABPI. This result is 
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supported by the present investigation in which we also found lower ABPI scores were 
significantly associated with higher HAQ scores. Patients unable to complete the step test 
also had a significantly lower ABPI than those who were able to complete the step test. 
Perhaps this increased disability and poor physical function observed in Chapter 4 can be 
partially explained by the presence of peripheral arterial obstructive disease.    
 
Despite serum lipids being strong predictors of CVD risk, no significant association between 
the lipid profile and ABPI was observed in the current study. This finding is in line with the 
results presented in Chapter 4 of this thesis and other studies (Alkaabi et al., 2003; 
Kavanaugh et al., 1994). Reduced disease activity has been shown to normalise lipid 
parameters. The RA patients studied throughout this thesis generally had well controlled 
disease and so the effects of anti-rheumatic drugs should be taken into account as certain 
second-line agents may lead to normalisation of the lipid profile (Munro et al., 1997).  
 
The current study highlights the potential increased risk of peripheral vascular disease in 
patients with RA. Research regarding peripheral vascular disease in RA is limited; however, 
the findings of this small investigation have provided us with an alternative explanation as to 
why some RA patients are unable to complete the step test and why these patients report 
more disability. Perhaps, patients with a lower ABPI genuinely experience more pain or 
difficulty doing physical tasks. Perhaps, symptoms of a lower ABPI are only experienced 
whilst doing physical activities, as this is when the muscles in the lower extremities are 
working hard and require more blood flow than when at rest. However, further work is 
needed measuring ABPI and other markers of vascular disease in RA patients in order to 
establish more concrete conclusions.  
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Appendix 9: Obesity Categories based on fat percent and revised BMI 
cut-offs  
 
 
 Table 1. RA disease characteristics of the body fat percent groups 
 RA Factors 
Normal 
(n = 32) 
Overweight 
(n = 22) 
Obese 
(n = 46) 
P 
Age (years) 60.4 ± 11.1 60.1 ± 9.2 59.0 ±  10.1 0.824 
Disease duration (years) 8.9 ± 6.9 11.2 ± 8.3 11.0 ± 10.9 0.534 
ESR (mm·hr-1) 19.5 ± 16.9 14.3 ± 11.9 14.9 ± 9.0 0.213 
CRP (mg·l-1) 14.3 ± 20.8 12.8 ± 18.8 10.2 ± 15.7 0.613 
Tender joints (n) 1.5 ± 3.5 1.6 ± 2.5 2.6 ± 5.0 0.463 
Swollen joints (n) 1.3 ± 2.9 0.9 ± 2.3 0.3 ± 0.9 0.135 
VAS arthritis (0-100) 26.7 ± 22.7 30.7 ± 19.6 35.9 ± 26.2 0.242 
Pain (0-100) 17.8 ± 23.6 19.0 ± 21.1 28.4 ± 32.2 0.196 
DAS28 ESR 2.7 ± 1.5 2.6 ± 1.4 2.8 ± 1.3 0.840 
DAS28 CRP 2.7 ± 1.2 2.8 ± 1.1 2.80 ± 1.2 0.870 
HAQ (0-3) 0.7 ± 0.7 0.8 ± 0.8 1.0 ± 0.8 0.258 
Values are mean ± SD, N = 100. ESR; erythrocyte sedimentation rate, CRP; C-reactive protein, DAS; disease 
activity score, VAS; visual analogue scale, HAQ; health assessment questionnaire.   
 
Table 2. CVD risk factors and global CVD risk scores of the body fat percent groups 
  CVD Risk Factors 
Normal 
(n = 32) 
Overweight 
(n = 22) 
Obese 
(n = 46) 
P 
SBP (mmHg) 139.1 ± 20.3 145.5 ± 19.7 139.5 ± 21.7 0.655 
DBP (mmHg) 80.7 ± 10.2 81.1 ± 12.6 82.0 ± 10.9 0.997 
TC (mmol·l-1) 5.0 ± 1.1 5.4 ± 1.4 5.5 ± 1.1 0.380 
TG (mmol·l-1) 1.34] ± 0.7 1.4 ±  0.6 1.7 ± 0.8 0.061 
LDL-c (mmol·l-1) 3.0 ± 1.0 3.3 ± 1.2 3.2 ± 1.0 0.732 
HDL-c (mmol·l-1) 1.4 ± 0.4 1.5 ± 0.4 1.5 ± 0.4 0.909 
Glucose (mmol·l-1) 5.2 ± 1.1 5.2 ± 0.4 5.4 ± 1.1 0.168 
Current smoker (n) 8 4 11 ----- 
Global CVD Risk Scores 
  
  
Framingham risk (percent) 19.4 ± 13.6 18.2 ± 7.1 13.5 ± 9.7 0.934 
QRISK2 (percent)  23.3 ± 16.5 22.7 ±  12.9 15.9 ± 12.1 0.970 
Metabolic syndrome (n) 8 10 23 ----- 
Values are mean ± SD, N = 100. SBP; systolic blood pressure, DBP; diastolic blood pressure, TC; total 
cholesterol, TG; triglycerides, LDL-c; low density lipoprotein, HDL-c; high density lipoprotein.  
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Table 3. RA characteristics of the revised BMI groups (Stavropoulos-Kalinoglou et al., 2009) 
 RA Factors 
Normal 
(n = 20) 
Overweight 
(n = 40) 
Obese 
(n = 40) 
P 
Age (years) 59.2 ± 11.3 60.3 ± 10.1 59.4 ±  9.8 0.901 
Disease duration (years) 9.9 ± 7.4 10.2 ± 8.9 10.7 ± 10.5 0.953 
ESR (mm·hr-1) 15.5 ± 14.7 16.2 ± 14.3 16.8 ± 10.3 0.936 
CRP (mg·l-1) 13.6 ± 22.4 11.8 ± 19.3 11.8 ± 14.4 0.927 
Tender joints (n) 0.7 ± 1.3 2.4 ± 5.3 2.4 ± 3.6 0.239 
Swollen joints (n) 0.8 ± 2.9 0.9 ± 2.2 0.6 ± 1.4 0.774 
VAS arthritis (0-100) 24.3 ± 15.7 31.9 ± 25.1 35.6 ± 25.8 0.229 
Pain (0-100) 13.7 ± 21.9 16.4 ± 21.4 34.1 ± 32.2 0.004 
DAS28 ESR 2.3 ± 1.2 2.7 ± 1.6 3.0 ± 1.3 0.165 
DAS28 CRP 2.3 ± 0.9 2.8 ± 1.2 2.9 ± 1.2 0.248 
HAQ (0-3) 0.7 ± 0.7 0.8 ± 0.7 1.1 ± 0.8 0.095 
Values are mean ± SD, N = 100. ESR; erythrocyte sedimentation rate, CRP; C-reactive protein, DAS; disease 
activity score, VAS; visual analogue scale, HAQ; health assessment questionnaire. 
 
 
Table 4. CVD risk factors and global CVD risk scores of the revised BMI groups (Stavropoulos-
Kalinoglou et al., 2009) 
  CVD Risk Factors 
Normal 
(n = 20) 
Overweight 
(n = 40) 
Obese 
(n = 40) 
P 
SBP (mmHg) 132.0 ± 21.8 144.7 ± 19.0 140.5 ± 21.2 0.194 
DBP (mmHg) 76.0 ± 10.3 83.4 ± 10.2 81.9 ± 11.4 0.124 
TC (mmol·l-1) 5.1 ± 1.3 5.3 ± 1.2 5.4 ± 1.1 0.761 
TG (mmol·l-1) 1.2 ± 0.8 1.4 ±  0.5 1.8 ± 0.8 0.015 
LDL-c (mmol·l-1) 2.9 ± 1.1 3.2 ± 1.1 3.1 ± 1.1 0.670 
HDL-c (mmol·l-1) 1.6 ± 0.4 1.5 ± 0.5 1.4 ± 0.4 0.229 
Glucose (mmol·l-1) 5.1 ± 0.9 5.2 ± 09 5.5 ± 1.2 0.311 
Current smoker (n) 6 10 7 ----- 
Global CVD Risk Scores 
  
  
Framingham risk (percent) 15.3 ± 12.9 18.2 ± 10.9 15.1 ± 10.1 0.646 
QRISK2 (percent)  18.9 ± 14.2 21.7 ±  15.2 18.2 ± 13.3 0.800 
Metabolic syndrome (n) 2 15 24 ----- 
Values are mean ± SD, N = 100. SBP; systolic blood pressure, DBP; diastolic blood pressure, TC; total 
cholesterol, TG; triglycerides, LDL-c; low density lipoprotein, HDL-c; high density lipoprotein.  
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Appendix 10: Fitness Test Recommendations  
 
Table 1 Recommended 30 second sit to stand ranges for males (Jones & Rikli, 2002).  
 
Age below average average above average 
60-64 < 14 14 to 19 > 19 
65-69 < 12 12 to 18 > 18 
70-74 < 12 12 to 17 > 17 
75-79 < 11 11 to 17 > 17 
80-84 < 10 10 to 15 > 15 
85-89 < 8 8 to 14 > 14 
90-94 < 7 7 to 12 > 12 
 
 
 
Table 2 Recommended 30 second sit to stand ranges for females (Jones & Rikli, 2002).  
 
Age below average average above average 
60-64 < 12 12 to 17 > 17 
65-69 < 11 11 to 16 > 16 
70-74 < 10 10 to 15 > 15 
75-79 < 10 10 to 15 > 15 
80-84 < 9 9 to 14 > 14 
85-89 < 8 8 to 13 > 13 
90-94 < 4 4 to 11 > 11 
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Table 3 Recommended 8ft up and go ranges for males (Jones & Rikli, 2002). 
 
Age below average average above average 
60-64 > 5.6 5.6 to 3.8 < 3.8 
65-69 > 5.7 5.7 to 4.3 < 4.3 
70-74 > 6.0 6.0 to 4.2 < 4.2 
75-79 > 7.2  7.2 to 4.6 < 4.6 
80-84 > 7.6 7.6 to 5.2 < 5.2 
85-89 > 8.9 8.9 to 5.3 < 5.3 
90-94 > 10.0 10.0 to 6.2 < 6.2 
 
 
Table 4 Recommended 8ft up and go ranges for females (Jones & Rikli, 2002). 
 
Age below average average above average 
60-64 > 6.0 6.0 to 4.4 < 4.4 
65-69 > 6.4 6.4 to 4.8 < 4.8 
70-74 > 7.1 7.1 to 4.9 < 4.9 
75-79 > 7.4 7.4 to 5.2 < 5.2 
80-84 > 8.7 8.7 to 5.7 < 5.7 
85-89 > 9.6 9.6 to 6.2 < 6.2 
90-94 > 11.5 11.5 to 7.3 < 7.3 
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Appendix 11: Quality of Life Questionnaire (SF-36)  
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Appendix 12:  Multidimensional Assessment of Fatigue (MAF) 
 
 
MULTIDIMENSIONAL ASSESSMENT OF FATIGUE (MAF) SCALE 
 
Instructions: These questions are about fatigue and the effect of fatigue on your activities. 
 
For each of the following questions, circle the number that most closely indicates how you 
have been feeling during the past week. 
 
For example, suppose you really like to sleep late in the mornings. You would probably circle the 
number closer to the "a great deal" end of the line. This is where I put it: 
 
Example: To what degree do you usually like to sleep late in the mornings? 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 
Now please complete the following items based on the past week. 
 
 
 
 
1. To what degree have you experienced fatigue? 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 
If no fatigue, stop here. 
 
 
2. How severe is the fatigue which you have been experiencing? 
 
 
1  2  3  4  5  6  7  8  9  10 
Mild  Severe 
 
 
3. To what degree has fatigue caused you distress? 
 
 
1  2  3  4  5  6  7  8  9  10 
No distress A great deal 
  of distress 
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MULTIDIMENSIONAL ASSESSMENT OF FATIGUE (MAF) SCALE (Continued) 
 
Circle the number that most closely indicates to what degree fatigue has interfered with your ability to 
do the following activities in the past week. For activities you don't do, for reasons other than fatigue 
(e.g. you don't work because you are retired), check the box. 
 
In the past week, to what degree has fatigue interfered with your ability to: 
 
(NOTE: Check box to the left of each number if you don't do activity) 
 
4. Do household chores 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 
5. Cook 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 
6. Bathe or wash 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 
7. Dress 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 
8. Work 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 
9. Visit or socialize with friends or family 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 180 
 
MULTIDIMENSIONAL ASSESSMENT OF FATIGUE (MAF) SCALE (Continued) 
 
(NOTE: Check box to the left of each number if you don't do activity) 
 
10. Engage in sexual activity 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 
11. Engage in leisure and recreational activities 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 
12. Shop and do errands 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 
13. Walk 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 
14. Exercise, other than walking 
 
 
1  2  3  4  5  6  7  8  9  10 
Not at all  A great deal 
 
 
15. Over the past week, how often have you been fatigued? 
 
4  Every day 
   
3  Most, but not all days 
   
2  Occasionally, but not most days 
   
1  Hardly any days 
 
 
16. To what degree has your fatigue changed during the past week? 
 
4  Increased 
   
3  Fatigue has gone up and down 
   
2  Stayed the same 
   
1  Decreased 
 
 
